annual report see good sale momentum pharmaceutical vaccine consumer healthcare pipeline progresswe global sciencele healthcare company worldleading business research deliver innovative medicine vaccine consumer healthcare product cover case study gsk innovation underpin business generation technology return rd investment accelerate develop new approach disease development new product management control addition improve patient live research development active pipeline innovative gain insight network product core area respiratory collaboration biotechs hiv infectious disease vaccine company academic institution immunoinflammation oncology enable efficient trial design rare disease great use software analytic new technology help increase productivity maximise arthur work upper providence rd lab cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result accordance legal regulatory obligation include uk list rule disclosure transparency rule financial conduct authority group undertake obligation update forwardlooke statement result new information future event reader consult additional disclosure group document publish andor file sec reader locate note disclosure accordingly assurance give particular expectation meet shareholder investor caution place undue reliance forwardlooke statement forwardlooke statement subject assumption inherent risk uncertaintie relate factor group control precise estimate group caution investor number important factor include document cause actual result differ materially express imply forwardlooke statement factor include limit discuss principal risk uncertaintie page annual report forwardlooke statement behalf group speak date base knowledge information available director date annual report expectation target future performance read assumption relate outlook inside cover document number adjust measure report performance business measure define reconciliation core result total result set gsk annual report strategic report governance remuneration financial statement investor information strategic report performance summary chairman statement ceo statement bn bn integrate approach market operate group turnover new pharmaceutical business model aer cer vaccine salesb clear strategy growth proforma cera aer cera measure success manage risk pharmaceutical bn bn vaccine consumer healthcare total operating profit core operating profit responsible business aer cerac aer cer group financial review proforma cera governance remuneration chairman governance statement p p board corporate executive team leadership effectiveness total earning share core earning share nomination committee report aer cerac aer cera accountability audit risk committee report relation shareholder bn bn corporate responsibility committee report net cash inflow free cash flowa operating activity remuneration report chairman annual statement annual report remuneration bn remuneration policy summary remuneration policy report dividend declare asset datum expect end financial statement director statement responsibility deliver sustainable performance independent auditor report financial statement note financial statement st access rd financial statement glaxosmithkline plc prepare uk gaap medicine index pharmaceutical sector investor information launch dow jones sustainability index quarterly trend year record product development pipeline product competition intellectual property principal risk uncertainty share capital share price dividend financial calendar footnote annual general meeting aer growth rate represent growth actual exchange rate use number adjust nonifrs tax information shareholder measure report performance business describe include core result shareholder service contact free cash flow cer proforma growth rate measure management law regulation planning reporting purpose directly comparable similarly describe measure company core result exclude number item present management group company believe core result allow key trend factor drive performance easily glossary term clearly identify shareholder nonifrs measure consider addition substitute superior information present accordance ifrs reconciliation total result core result set b new product define pharmaceutical relvarbreo ellipta incruse ellipta anoro ellipta arnuity ellipta eperzantanzeum nucala tivicay triumeq vaccine menveo bexsero shingrix approve c primarily reflect impact billion profit disposal oncology business gsk annual report worldleading business gsk mission improve pharmaceutical vaccine consumer healthcare quality human life business generate combined turnover billion enable people business benefit global commercial infrastructure feel well integrate supply network innovative rd live long number employee number market manufacturing site rd innovation underpin business invest billion rd business external partnership collaboration enable develop access knowledge increase understand new area science focus research core area generation technology develop new approach disease management control respiratory disease hivinfectious disease vaccine immunoinflammation oncology rare disease efficient global operating model focus optimise operation restructure investment modernisation improve profitability efficiency bn footnote use number adjust nonifrs measure report performance business describe incremental annual total operating profit core operating profit include core result free cash flow cer saving deliver margin margin proforma growth rate nonifrs measure include billion consider addition substitute superior information present accordance ifrs currency benefit gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine consumer healthcare pharmaceutical business vaccine business consumer healthcare business discover develop broad portfolio company develop market product commercialise medicine vaccine people wellness oral health nutrition treat range acute chronic age baby adolescent skin health category disease broad portfolio adult old people seven global power brand otrivin innovative establish deliver million vaccine panadol parodontax poligrip medicine respiratory hiv dose day people live sensodyne theraflu voltaren global leader country include trust focus research bestselle brand world respiratory hiv infectious read page disease immunoinflammation read page oncology rare disease read page category sale category sale sale category respiratory infanrixpediarix wellness hiv hepatitis oral health establish product meningitis nutrition skin health bn bn bn turnover turnover turnover group turnover group turnover group turnover bn bn pack medicine vaccine deliver consumer healthcare product produce produce gsk annual report chairman statement please report gsk board unanimous decision good progress appoint emma walmsley previously head operating performance significantly gsk consumer healthcare business improve business new ceo emma strong continue progress late early leadership skill clear track record stage rd pipeline important area delivery performance board believe year solid achievement emma bring new thinking group operate todays healthcare performance environment whilst time management continue strong harnessing momentum evident progress drive sale cost current performance benefit integration novartis gsk business vaccine consumer want thank sir andrew progress healthcare business dedicated service gsk transform transaction commitment leadership gsk build operating performance true global leader respective balanced set business fine market position strategically prospect deliver significant significantly improved improve financially reward shareholder substantial continue cash return lead effort pharmaceutical new product sale address press concern progress rd show good momentum industry face range reform particularly hiv respiratory new pipeline product quarter commercial model increase transparency trial result ensure medicine total pharmaceutical sale important price fairly accessible give pricing pressure face generally patient worldwide pharmaceutical company potential miss gsk wish introduction generic competition advair read future endeavour year group big single source profit board change year continue refresh board governance report group improve operational welcome new nonexecutive performance contribute markedly corporate governance report set director dr jesse goodman increase cash generation operational corporate governance practice include dr vivienne cox jesse professor report board committee cash flow benefit strongly medicine georgetown university devaluation sterling follow remuneration brexit vote june value leader public health vivienne bring year experience complex global remuneration report set nonsterle liability debt funding manufacturing organisation remuneration arrangement executive contingent consideration stacey cartwright step nonexecutive director include new increase board end december thank remuneration policy ordinary dividend p share stacey nearly year dedicated diversity statement declare level service board company expect maintain board diversity policy include gender enter critical period pipeline payment accordance set measurable objective activity reflect board statement level nomination committee monitor report creation new board science progress achievement distribution exceed free cash flow committee chair dr goodman generate business despite viability statement material improvement cash generate addition dr patrick vallance president rd joined board later year moncef viability statement set assessment refer give slaoui step board prospect group year year dividend year company moncef year commitment board scientist global repute consider appropriate dividend remarkable presence gsk particularly policy vaccine business wish course year future ceo succession closing like thank gsk key area focus board employee partner hard manage ceo work dedication business succession sir andrew step outstanding people year company successful year tenth year ceo board conduct thorough global search successor include internal external candidate philip hampton chairman gsk annual report strategic report governance remuneration financial statement ceo statement investor information group execute strongly investment rd organisation deliver sale growth continue deliver significant innovation business remain discipline example see european cost progress pipeline approval strimvelis kind innovative product gene therapy child rare condition adascid remarkable trading performance technology potential platform group sale rise actual rate number gene therapy cer proforma billion despite uncertainty volatility year exciting time experience globally total earning rd organisation key research share p actual data asset end gsk perform strongly rate cer primarily reflect good sale comparison billion profit deliver performance responsibly disposal market gsk strong commitment operating growth oncology asset core earning share responsibly play meet pa cer increase business excellent new societys big healthcare end guidance year challenge product momentum see growth take industryleade pipeline progress group business step stop payment healthcare particular contribution new professional speak medicine pharmaceutical vaccine product prescriber offer essential sale portfolio double vaccine low price organisation billion pharmaceutical support refugee acute need new product account sale introduce new approach file hiv product tivicay triumeq continue enforce patent ip base standout product sale country economic maturity work billion new respiratory partner help world well prepare product relvarbreo anoro incruse future epidemics ebola zika arnuity nucala grow strongly pleased effort meningitis vaccine bexsero operate valuesbase company menveo expect momentum recognise come group product continue access medicine index consumer healthcare business fifth consecutive time perform strongly sale outlook actual rate cer proforma progress highlight billion drive power brand investment group sensodyne voltaren panadol year build scale growth flonase sustainability develop new switch prescription product expect group overthecounter continue progress strong rd innovation pipeline enter new period leadership file asset regulator company believe gsk position approve potential deliver longterm performance drive growth business shareholder include shingrix candidate vaccine finally annual report shingle oncedaily close retire like thank triple therapy copd addition employee partner shareholder start number phase iii trial support time ceo asset hiv respiratory anaemia gsk special company touch people live world enormously privileged lead footnote sir andrew witty use number adjust nonifrs measure chief executive officer report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs ggsskk aannnnuuaall rreeppoorrtt integrate approach understand operating environment clear strategy measure performance manage risk deliver longterm value shareholder society market operate business model operate grow marketplace strategy rd underpin business prioritise investment design respond challenge opportunity potential develop innovative product sector unmet medical need demographic rd pharmaceutical change change political vaccine landscape consumer healthcare increase payer emphasis cost value access commercialisation manufacturing distribution increase expectation business technological scientific advance read read ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn clear strategy growth measure success manage risk strategic priority provide framework assess performance manage number current create longterm value shareholder set financial nonfinancial emerge risk principal risk society measure form map primary strategic basis executive remuneration priority likely impact turnover growth intellectual property grow growth earning share commercialisation grow balanced business product portfolio centre global business new pharmaceutical vaccine product quality deliver product performance research practice supply continuity crisis management deliver product value offer improve treatment patient consumer healthcare provider operate profit margin financial control reporting simplify free cash flow information protection dividend declare simplify way operate reduce net debt complexity increase efficiency free resource reinvest business return shareholder attractive return access medicine index patient safety responsible business dow jones sustainability index antibribery corruption environment health safety responsible business sustainability deliver success important result achieve read read read gsk annual report operate grow marketplace strategy design respond challenge opportunity face market operate bn world population people world population age billiona live urban area f global population access mobile phonef global middle class reside asiapacific f global youth reside develop countriesf future state global megatrend shape government kpmg gsk annual report strategic report governance remuneration financial statement investor information business model clear strategy growth measure success manage risk global global pharmaceutical sale develop economy demand billion month rolling healthcare provision continue remain healthcare market basis september high dynamic continue grow billion equivalent period complex trend high life september north america expectancy contribute backdrop remain large pharmaceutical increase proportion elderly people market share global sale improvement medical challenge global europe represent asia pacific technology put pressure economic environment include japan emerge healthcare budget market b change global political landscape global vaccine sale total billion shifting attitude globalisation expect grow free trade wage stagnation annually c concern inequality cause significant volatility uncertainty consumer healthcare market western market gsk operate account approximately billion project grow characterise political annually yearsd uncertainty exemplified vote leave eu uk societal trend support market growth result presidential election contribute challenge political uncertainty europe expect healthcare sector particularly price continue national election affordability france germany demographic change uncertainty world population continue grow new administration shape accord united nations healthcare particularly respect predict reach billion repeal replace affordable proportion elderly people grow care act prescription drug pricing number people age regulation couple question expect reach billion impact new administration e time develop economic tax trade policy country experience growth middle class expect uk remain unclear brexit world population affect countrys trading relationship middle classf corporate taxation policy movement people regulatory affair emerge market longterm economic growth increase expectation healthcare provision change diet lifestyle increase demand healthcare product especially treat chronic condition include respiratory cardiovascular disease demand expect grow significantly fast market come year mature economy footnote w orld population ageing highlight united nations b ims datum latest available time publish c nternal datum evaluatepharma world preview nternal forecast base nicholas hall euromonitor e w orld population ageing highlight united nations f f uture state global megatrend shape government kpmg gsk annual report market operate continue strategy create increase payer emphasis cost technological scientific advance value access key advance understand balanced business demographic change contribute human biology genomic lead product portfolio increase demand healthcare fundamental change research turn put pressure government disease pharmaceutical industry position budget payer lead ability develop treatment specifically continue focus public debate tackle innovative treatment change industry approach drug approach increase substantially marketplace pricing key market recent year alongside scientific advance digital technology data ultimately unsuccessful analytic enable researcher explore proposition vote call interpret large volume biological medicine price control california data genomics disease biology drug pricing ballot provide initiative expect opportunity increase speed increase use healthcare efficiency drug discovery technology assessment consider development novel therapy value money medical efficacy transform disease manage governmentappointed body like uks national institute health care increase expectation company excellence australia pharmaceutical sectorspecific context benefit advisory committee value cost affordability important society increase change demand healthcare emerge expectation company particularly market rise government continue large global company stakeholder reform healthcare system support employee consumer policy access china government continue maker influencer expect company work realise goal set behave integrity fairness operate healthy china plan significant transparently connected local measure take year reduce community play pharmaceutical price national address global challenge health price negotiation epidemic climate change respond year un highlevel panel require strong partnership access medicine report reiterate connectivity public private right country issue compulsory sector organisation licence access cheap supply generic drug expect political public scrutiny pricing continue gsk annual report strategic report governance remuneration financial statement investor information business model clear strategy growth measure success manage risk strategic response worldleading gsk position advantage demographicled demand new innovative product worldleading business pharmaceutical vaccine business consumer healthcare global presence market example underpin emerge market significant demographic change societal trend innovative rd increase demand healthcare pharmaceutical business sell volume near competitor emerge market sell vaccine region represent onethird consumer healthcare business strategy create balanced business help mitigate risk access growth opportunity world navigate change portfolio challenge face today operating environment global company global company understand benefit free trade globalisation importance company like significant local presence community significant operate large global footprint important contribution local presence market operate example tax pay job create engage government directly industry trade body abpi bia important way inform policy impact sector example uk eu life sciences steering group gsk work closely peer uk government address need industry eu exit negotiation overall continue believe brexit cause material impact financial position long term cause disruption shortterm global strategy focus pricing product level provide attractive volume expansion opportunity mean able access patient consumer world sustainable understand payer patient concern affordability healthcare pricing lead effort develop sustainable solution equitable pricing strategy medicine vaccine base country disease area product type patient ability pay launch new product price similar medicine aim replace pioneer effort impact medicine realworld clinical practice setting researchbase company rely protection patent regulatory datum exclusivity right ensure reasonable return investment recognise need flexible approach patent protection expand current approach filing enforce patent opt file patent protection leastdevelope lowincome country grant licence generic manufacturer supply version medicine low middle income country g country lead responsible responsible business fundamental gsk understand society require business behave integrity operate important financial result business approach deliver lead industry effort access medicine clinical trial datum transparency fight antimicrobial resistance evolve commercial model ensure patient interest come long pay healthcare professional speak behalf gsk annual report rd underpin business prioritise investment potential develop innovative product unmet medical need market business model operate resource create value strong rd world people culture innovation lead business employee bring expertise value rd pharmaceutical financial capital earning cash flow access capital market allow invest business vaccine collaboration partnership rd partnership consumer collaboration academic healthcare institution biotechs ngo company bring important insight innovation supplier supplier provide essential service material reinvestment gsk annual report strategic report governance remuneration financial statement investor information clear strategy growth measure success manage risk create value value create efficient global operating model shareholder aim deliver sustainable earning growth total core ep growth ep growtha dividend p primarily reflect comparison bn profit disposal market oncology asset dividend manufacture patient consumer increase access quality product enable people dose vaccine feel well live long produce commercialisation society distribution bn healthy community tax charge economic contribution job taxation donate local community product donation time cash employee country environment feel value global rollout employee family member country access groundbreake preventive healthcare programme reinvestment footnote use number adjust nonifrs measure report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report strategic priority provide framework create longterm value shareholder society market business model clear strategy growth operate strategic priority progress global sale billion p grow aer cer proforma cer total earning share new pharmaceutical vaccine aer cer product sale billion aer cer grow balanced business p product portfolio centre consumer healthcare sale core earning share global business billion aer cer aer cera proforma cer strong contribution power brand new pharmaceutical vaccine product sale filing regulator include deliver shingrix candidate vaccine close triple filing regulator eu approval strimvelis deliver product value gene therapy rare disease offer improve treatment patient adascid consumer healthcare provider consumer healthcare innovation sale product launch year improve core operate leverage simplify business total operating profit margin incremental annual cost saving billion deliver include simplify way operate reduce billion currency benefit complexity increase efficiency free core operating profit margin continue roll new global resource reinvest business system standardisation percentage point return shareholder process proforma cera attractive return expand graduated approach responsible business st patent ip widen access medicine access medicine index commit supply essential responsible business vaccine low price civil rd deliver success important society organisation refugee result achieve ema approval chlorhexedine sector dow jones sustainability index antiseptic gel newborn umbilical cord infection develop country footnote use number adjust nonifrs measure report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report strategic report governance remuneration financial statement investor information clear strategy growth measure success manage risk key challenge key priority continue pricing pressure deliver guidance europe drive sale market growth respiratory volatility slow emerge hiv meningitis vaccine power brand market economy progress regulatory filing launch successfully approve manage impact possible generic competition advair continue prioritisation deliver key data asset pipeline appropriate end manage prioritisation deployment resource capital allocation increase global demand continue improve efficiency capacity vaccine complex supply chain new exist product manufacturing process lead supply pressure integration reporting continue roll new global system system process standardisation process follow novartis transaction continue focus improve cash conversion management work capital continue optimise capital expenditure respond stakeholder ensure sustainable funding biopreparedness concern affordability organisation enhance preparedness access future epidemic continue strengthen embed flexible approach ip patent protection valuesbase culture gsk annual report assess performance set financial nonfinancial metric form basis executive remuneration market business model clear strategy growth measure operate success growth cer group turnover report proforma bn bn bn bn growth cer report proforma report proforma pharmaceutical vaccine consumer healthcare new pharmaceutical vaccine product performanceb r growth cer bn growth cer operating profit margin r total core report proforma total bn core bn growth earning share total core cer total p core p gsk annual report strategic report governance remuneration financial statement investor information measure manage risk success free cash flowd r growth e bn e na e dividend declare dividend bn c net debt bn access medicine index rank dow jones sustainability index ranking st rd pharmaceutical industry index begin th percentile th percentile th percentile information information key r remuneration executive link key indicator mark footnote exclude divestment complete b new product define pharmaceutical relvarbreo ellipta anoro ellipta incruse ellipta arnutiy ellipta eperzantanzeum nucala tivicay triumeq vaccine menveo bexsero shingrix approve c include special dividend use number adjust nonifrs measure report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs e free cash flow exclude payment legal cost restructure tax oncology disposal purchase hiv clinical asset treat intangible asset purchase gsk annual report manage current emerge risk impact strategic priority rigorous consistent risk management process market business model clear strategy growth measure success operate principal risk regularly review principal risk description assessment macro gsk exposure environment post mitigation corporate executive team assess reflective patient safety macro environment remain stable patient safety regulation standard remain consistent significant risk face organisation failure appropriately collect review follow report adverse event improve safety datum management patient communication product label improvement base evolve internal external potential source act relevant finding timely manner incorporate organisation leave gsk exposure level unchanged factor table opposite list principal risk manage intellectual property macro risk unchanged significant change affect ability secure maintain group include enforce patent failure appropriately secure maintain enforce intellectual property right definition risk assessment gsk exposure level stable base maturity risk management process general change risk year ability enforce defend patent appropriate macro level gsk mitigate activity product quality macro risk higher increase regulatory scrutiny datum integrity supply continuity drug shortage accompany new guidance revise legislation failure comply current good manufacturing practice cgmp inadequate control governance quality supply chain cover supplier standard despite challenge macro environment gsk exposure level unchanged reflect effective response manufacturing distribution product external regulatory review great focus datum integrity improve governance financial control report macro environment remain stable material change financial reporting requirement failure comply current tax law incur significant loss treasury unchanged gsk exposure level reflective significant system operating model change activity failure report accurate financial information compliance accounting implement organisation continue risk thirdparty relationship standard applicable legislation failure maintain adequate governance oversight expect system model change reduce risk future risk impact thirdparty relationship change mitigate strong risk management governance continue progress global party oversight programme antibribery corruption macro environment remain stable regulatory environment global attitude antibribery corruption remain expectation failure gsk employee consultant party comply antibribery corruption abac principle standard gsk exposure level low risk management practice gain strength embed applicable legislation deeply organisation abac programme build group value standard enable manage risk effectively commercialisation macro risk level increase great industry pricing pressure increase regulatory scrutiny respect sale promotional activity failure execute business strategy effectively manage competitive opportunity threat accordance letter spirit legal gsk exposure level unchanged implement industryleade change operating model industry group requirement particular compensation model sale representative relationship healthcare professional research practice macro risk level elevate increase regulatory scrutiny good clinical practice failure adequately conduct ethical sound preclinical clinical research gsk exposure level unchanged base mature internal control process enhance governance addition failure engage scientific activity consistent letter programme design promote good practice business unit spirit law industry group requirement environment health safety sustainability macro risk level high great focus increase regulatory activity environmental issue arrow key failure manage environment health safety sustainability ehss risk gsk exposure level unchanged control governance establish capable increase risk line objective policy relevant law regulation allow increase focus regulatory activity change risk information protection macro risk increase threat sophisticated target high volume incident risk gsk business activity information disclose decrease risk authorise information system fail available corrupt gsk exposure level unchanged effect substantial progress upgrade level protection cyber attack safeguard critical sensitive datum supply continuity crisis management macro factor regulatory focus contract manufacturer outside eu increase data integrity expectation increase supply risk failure deliver continuous supply compliant finished product inability respond extensive information gsk risk effectively crisis incident timely manner recover sustain gsk exposure level stable base significant improvement deliver ongoing supply include risk impact mitigate activity critical operation risk previously call crisis continuity management remediation programme increase monitor supervision party page viability statement gsk annual report strategic report governance remuneration financial statement investor information manage risk principal risk description assessment macro gsk exposure environment post mitigation patient safety macro environment remain stable patient safety regulation standard remain consistent failure appropriately collect review follow report adverse event improve safety datum management patient communication product label improvement potential source act relevant finding timely manner incorporate organisation leave gsk exposure level unchanged intellectual property macro risk unchanged significant change affect ability secure maintain enforce patent failure appropriately secure maintain enforce intellectual property right gsk exposure level stable base maturity risk management process general ability enforce defend patent appropriate product quality macro risk higher increase regulatory scrutiny datum integrity supply continuity drug shortage accompany new guidance revise legislation failure comply current good manufacturing practice cgmp inadequate control governance quality supply chain cover supplier standard despite challenge macro environment gsk exposure level unchanged reflect effective response manufacturing distribution product external regulatory review great focus datum integrity improve governance financial control report macro environment remain stable material change financial reporting requirement failure comply current tax law incur significant loss treasury unchanged gsk exposure level reflective significant system operating model change activity failure report accurate financial information compliance accounting implement organisation continue risk thirdparty relationship standard applicable legislation failure maintain adequate governance oversight expect system model change reduce risk future risk impact thirdparty relationship change mitigate strong risk management governance continue progress global party oversight programme antibribery corruption macro environment remain stable regulatory environment global attitude antibribery corruption remain expectation failure gsk employee consultant party comply antibribery corruption abac principle standard gsk exposure level low risk management practice gain strength embed applicable legislation deeply organisation abac programme build group value standard enable manage risk effectively commercialisation macro risk level increase great industry pricing pressure increase regulatory scrutiny respect sale promotional activity failure execute business strategy effectively manage competitive opportunity threat accordance letter spirit legal gsk exposure level unchanged implement industryleade change operating model industry group requirement particular compensation model sale representative relationship healthcare professional research practice macro risk level elevate increase regulatory scrutiny good clinical practice failure adequately conduct ethical sound preclinical clinical research gsk exposure level unchanged base mature internal control process enhance governance addition failure engage scientific activity consistent letter programme design promote good practice business unit spirit law industry group requirement environment health safety sustainability macro risk level high great focus increase regulatory activity environmental issue failure manage environment health safety sustainability ehss risk gsk exposure level unchanged control governance establish capable line objective policy relevant law regulation allow increase focus regulatory activity information protection macro risk increase threat sophisticated target high volume incident risk gsk business activity information disclose authorised information system fail available corrupt gsk exposure level unchanged effect substantial progress upgrade level protection cyber attack safeguard critical sensitive datum supply continuity crisis management macro factor regulatory focus contract manufacturer outside eu increase data integrity expectation increase supply risk failure deliver continuous supply compliant finished product inability respond effectively crisis incident timely manner recover sustain gsk exposure level stable base significant improvement deliver ongoing supply critical operation risk previously call crisis continuity management remediation programme increase monitor supervision party ggsskk aannnnuuaall rreeppoorrtt leader respiratory gsk forefront research area year pharmaceutical pharmaceutical business discover develop commercialise medicine treat broad range world common acute chronic disease ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn grow deliver simplify responsible business bn pharmaceutical filing operate profit margin launch report sale regulator new product aer cera close triple percentage point price similar proforma cer benlysta subcutaneous high aim sale new product sirukumab percentage point high replace cer proforma basis pharmaceutical sale footnote use number adjust nonifrs measure report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report pharmaceutical overview hiv improve healthcare global hiv business manage pharmaceutical business viiv healthcare company prevent disease portfolio innovative establish own gsk pfizer medicine broad range therapy treating illness shionogi shareholder area include respiratory hiv seek longlaste global leader viiv healthcare grow rapidly immunoinflammation antiinfective account pharmaceutical solution chronic urology rare disease sale lead strong demand quarter pharmaceutical sale come tivicay dolutegravir innovative integrase acute condition product launch past year strand transfer inhibitor triumeq include rare disease singlepill treatment combine dolutegravir respiratory abacavir lamivudine industrys broad range inhale respiratory product respiratory specialty product portfolio large contributor specialty product portfolio include pharmaceutical sale expectation medicine benlysta treatment product account lupus disease tanzeumeperzan approximately respiratory sale type diabete compare classic establish product past year launch classic establish product new generation respiratory product include postpatent medicine include nucala mepolizumab area antiinfective allergy ellipta portfolio neuroscience dermatology respiratory urology medicine continue topselle brand therapy area product important emerge market business sell volume near competitor leader respiratory leader respiratory gsk forefront research area year today patient clinical ensure patient benefit study investigate chronic obstructive inhalation treatment pulmonary disease copd research show patient take country believe insight medicine experience improved lung research alongside early phase scientific function high quality life few discovery help meet patient need exacerbation compare lead future twicedaily treatment new generation inhale respiratory look inhale medicine medicine clear evidence benefit tackle area high unmet research range include need respiratory disease anoro ellipta world lead longacting launch nucala muscarinic antagonistlongacting betaagonist injectable biologic treatment severe copd value give physician eosinophilic asthma study result show unprecedented choice provide right patient nucala risk treatment right patient experience asthma attack require emergency hospital care half year file regulatory approval receive current standard close triple therapy care europe approve copd treatment combine vital oncedaily treatment single inhaler gsk annual report strategic report governance remuneration financial statement investor information grow performance summary europe pharmaceutical report sale report pharmaceutical sale decline proforma respiratory million actual rate sale decline reflect sale respiratory cer adjust disposal ongoing transition new respiratory product return oncology business novartis portfolio generic competition proforma turnover cer seretide partly offset growth growth new respiratory product performance reflect return growth record sale million establish respiratory business grow product million sale new respiratory product launch year include ellipta international sale million base product breo anoro arnuity proforma sale emerge incruse biologic nucala market impact decline double million hiv sale china business primarily result increase million ongoing reshape programme broad drive primarily healthcare reform include price strong performance triumeq reduction tivicay sale million worldwide hiv sale increase million million sale new pharmaceutical product europe international million account growth primarily drive strong total pharmaceutical sale performance triumeq tivicay pharmaceutical sale continue implement new million decline report basis commercial model stop payment growth rate cer proforma respiratory sale grow hcp speak behalf january nonifrs measure describe sale new respiratory product continue drive recruit hcp state million exceeding decline internal medical expert addition advair continue roll digital tool medical education effort follow medical product information session gsk expert country hcp agree interaction help informed decision benefit patient care rate experience superior similar interaction pharmaceutical company work hard early stage research find cure hivaid form unique partnership accelerate search hiv cure million man woman child partnership recruit talent world live hiv lead world redefine researchbased pharmaceutical healthcare traditional way conduct research company legacy success hivaid approach develop treatment hiv investigate know shock kill seek reveal hide virus gsk strong pipeline new medicine persist people hiv infection hiv scientist continue work despite successful drug therapy goal day find cure augment patient immune system hivaid epidemic clear trace virus continue invest hiv cure center infect cell qura therapeutic unique jointownership collaboration create university north carolina uncchapel hill single focus find cure hivaid gsk annual report pharmaceutical continue deliver pharmaceuticals rd organisation hiv pipeline contain number drive discovery development promising medicine regimen area research include respiratory hiv innovative formulation mode action achieve infectious disease immunoinflammation delivery method announce positive accelerated file oncology rare disease result phase iii study evaluate twodrug regiman combine dolutegravir oncedaily close triple progress rilpivirine edurant janssen medicine continue progress therapy copd receive break mould conventional stage rd pipeline respiratory approval europe file oncedaily close triple therapy threedrug treatment therapy reduce streamline hiv medication gene therapy medicine copd regulatory approval future europe bring forward obtain positive datum original filing date month hiv programme support new single tablet announce positive result phase iii new attachment inhibitor pioneer copd salford lung study twodrug regimen combine twodrug hiv regiman study show compare dolutegravir lamivudine receive usual standard care copd cabotegravir oncemonthly injectable patient relvarbreo ellipta achieve therapy combine longacte superior reduction exacerbation rilpivirine hiv treatment everyday clinical practice set simple easy adhere addition announce start phase iii study strengthen prospect evaluate longacte cabotegravir wave respiratory medicine injection month prevention inlicense novel antiilr man sex man risk hiv antibody severe asthma new data infection complete acquisition support progression potential bms hiv pipeline discovery oral treatment danirixin phase iib team program clinical development potential use fully integrate viiv healthcare treat patient copd rd organisation timeline development stage pharmaceutical product industry average drug preclinical clinical trial license approval discovery testing phase phase ii phase iii candidate medicine available patient medicine candidate candidate candidate candidate year year year year year year source abpi gsk annual report strategic report governance remuneration financial statement investor information continue strengthen emerge receive positive phase ii datum immunoinflammation portfolio firstinclass antibacterial gepotidacin regulatory filing europe treat gonorrhoea food subcutaneous formulation benlysta drug administration fda grant treatment systemic lupus disease fasttrack status basis asset datum expect currently available iv formulation unmet need new medicine area end sirukumab investigational il treatment oncology asset clinical rheumatoid arthritis development see encourage codevelope janssen approve development core area immuno treatment selfadministere oncology cell therapy epigenetic home make convenient year fda grant treatment option patient breakthrough therapy status affinity gain approval enhance tcell therapy target strimvelis corrective gene therapy antigen nyeso synovial cancer child suffer rare develop adaptimmune disease adascid adenosine deaminase terminate development severe combine immunodeficiency iosmapimod copd follow analysis case study phase ii result halt development start phase ii study hiv maturation inhibitor include evaluate antigmcsf favour maturation inhibitor antigranulocyte macrophage colony pipeline well profile stimulate factor monoclonal antibody milestone inflammatory hand osteoarthritis come year significant assess oral rip kinase inhibitor pharmaceutical pipeline mark rheumatoid arthritis psoriasis patient start intense period rd activity company expect important data asset area include hiv respiratory immunoinflammation oncology approval gsk gene therapy open new chapter treatment rare disease application groundbreaking technology result world corrective gene therapy child european commission approval work take experimental strimvelis onetime treatment adascid medicine procedure develop rigorous adenosine deaminase severe combine manufacturing quality control system immunodeficiency authorisation ensure evaluate corrective stem cell gene therapy child regulator major milestone commitment survival rate year develop innovative transformative medicine treatment observe child adascid cause faulty gene pivotal study child receive inherit parent affect strimvelis contribute marketing newborn europe year child authorisation datum package alive today bear adascid healthy patient refer treatment receive fullyfunctione immune system gene therapy ospedale san raffaele consequence unable fight everyday hope strimvelis infection treatment involve correct number innovative gene therapy fatal disorder patient medicine bring patient cell year development strimvelis follow programme collaboration gsk original italian platform metachromatic leukodystropy developer san raffaele telethon institute wiskottaldrich syndrome gene therapy milan italy clinical trial gsk annual report pharmaceutical continue deliver continue pharmaceutical rd approach treatment advance medicine focus investment area development team multidisciplinary believe attractive specialist ensure progress opportunity consider patient investigational medicine later stage need market opportunity scientific development filing regulator understand concentrate ongoing evidence generation mechanism slow strategic issue overall budget reverse course disease present management oversee rd opportunity achieve remission cure management team robust governance early research effort centre board manage investment technical discovery performance unit scientific commercial decision nimble unit budget molecule lifecycle range partner include project accountability different academic institution publicprivate collaboration external partner traditional hierarchical rd model partnership pharmaceutical important approach help maintain flexibility create biotechnology company partner agility enable focus organisation world include promise early opportunity academic institution publicprivate partnership pharmaceutical biotechnology company collaborate francis crick institute gsk join force worldleade biomedical research centre landmark collaboration gsk development novel approach francis crick institute aim achieve problem pool knowledge new breakthrough understand resource hope collaboration treating disease ultimately improve success rate discover new medicine open innovation collaboration combine pharmaceutical rd expertise spirit open innovation research crick deep knowledge disease biology finding collaboration share externally joint publication mutual aim explore new avenue peerreviewe journal enable medical research drug discovery important discovery apply range disease collaboration take research community maximise linklab approach work team potential progress scientific understanding scientist organisation work accelerate development sidebyside integrate team treatment patient crick worldleade centre biomedical research heart london gsk francis crick institute charity fund global rd hub stevenage gsk medical research council cancer crick believe fluid interchange skill research uk wellcome trust university idea benefit side introduce college london imperial college london new way work stimulate king college london gsk annual report strategic report governance remuneration financial statement investor information simplify continue reshape enterprise resource planning erp pharmaceutical business reduce system enable well share datum complexity supply chain improve planning capability end supply chain maintain commitment quality system live transformation programme pharmaceutical manufacturing site cost saving generate deliver significant pharmaceutical business contribute commit quality delivery billion annual saving commit meet high reduction manufacture include billion currency benefit standard stringent quality control cost streamline group end operate quality assurance process external supply network profit margin pharmaceutical medicine vaccine manufacture percentage point higher accord current good manufacturing cer basis percentage practice cgmp regulation point high proforma cer basis internal quality management system pharmaceutical manufacturing complete threeyear site regulatory inspection transformation programme finding resolve endtoend supply chain july receive warning letter deliver improvement customer service food drug administration fda quality productivity combine relate inspection carry simplification portfolio month early gsk worthe uk deliver significant reduction primary manufacturing site respond manufacturing cost streamline promptly fda address point external supply network raise advise programme commitment create work advanced worldclass supply chain agree fiveyear global logistics contract international freight company contract key enabler reduce site cost year responsible leading fight antimicrobial resistance business demonstrate continue commitment tackle antimicrobial resistance signing landmark industry roadmap resistance antibiotic major advanced asset public health crisis people antibiotic pipeline gepotidacin die year drug resistant infection develop collaboration roadmap commit participate government biomedical pharmaceutical company advance research development authority achieve significant target barda gepotidacin include reduce environmental impact move phase iii study antibiotic production ensure follow positive phase ii result patient need global health threat antimicrobial roadmap build january commitment resistance require multistakeholder davos declaration combat antibiotic response see industry resistance collaboration year roadmap active discover work barda partner develop antibiotic year government company today pharmaceutical focus develop progress research development new new antibiotic active pipeline antibiotic new medicine addition vaccine business member innovative medicine research develop new vaccine prevent initiative newdrugsbadbug bacterial infection save life reduce longterm partner dependence antibiotic defence threat reduction agency ggsskk aannnnuuaall rreeppoorrtt follow impressive clinical trial result file candidate shingle vaccine regulator canada europe vaccine broad vaccines portfolio company vaccine people age baby adolescent adult old people ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn grow deliver simplify responsible business bn vaccine sale file operate profit margin work aer cera candidate shingles partner help world proforma cer vaccine shingrix percentage point higher well prepared growth candidate global health epidemic europe vaccine pipeline percentage point high international market range disease cer proforma basis footnote use number adjust nonifrs measure report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report vaccine vaccine business portfolio commercial portfolio vaccine business paediatric adolescent adult old robust research pipeline reflect people travel vaccine offer expertise virology bacterial large protection different disease infection different technological world deliver include bexsero meningitis b platforms vaccine menveo meningitis c w scientist dedicate discover million dose flu hepatitis synflorix pneumococcal develop vaccine vaccine day disease rotarix rotavirus gastroenteritis global rd centre europe vaccine diphtheria tetanus internal research people whoop cough infanrixpediarix rd partnership boostrix external scientist lead academic country public health institution demand vaccine continue increase world population grow help people benefit change meet demand vaccine protection use tiere deliver reliable high quality vaccine pricing approach base nation push boundary science gross national income head technology develop innovative vaccine ability pay large contributor gavi vaccine alliance publicprivate partnership aim improve access vaccine develop country candidate shingle vaccine file follow impressive clinical trial result file candidate shingle vaccine shingrix regulator canada europe seek approval shingrix time high efficacy candidate vaccine use prevent shingle demonstrate candidate vaccine common potentially condition old people weaken immune complication people shingle system leave susceptible sufferer develop painful itchy rash disease possibility get postherpetic neuralgia phn technology base open intense pain effective treatment condition month affect old adult people expect result clinical likely shingle lifetime study shingrix people individual compromise immune high risk shingle weakening system cancer patient undergo immune system patient chemotherapy especially susceptible revaccinate candidate vaccine previously receive exist vaccine study publish find shingrix efficacy people maintain year early research show efficacy gsk annual report strategic report governance remuneration financial statement investor information grow performance summary sale international market grow vaccine sale grow actual rate proforma growth primarily cer proforma cer drive synflorix market expansion vaccine sale grow million performance asia certain african country report basis drive sale new product menveo sale contribute growth include meningitis vaccine bexsero drive significant tender award proforma billion menveo contribute million argentina vaccine sale increase strong performance strong demand fluarix brazil strong demand bexsero meningitis flulaval sale million menjugate boostrix flu vaccine sale grow proforma bexsero menveo boostrix see market share growth infanrix pediarix benefit competitor supply issue market europe sale grow proforma drive primarily bexsero sale uk government immunisation programme growth rate cer private market channel nonifrs measure describe country boostrix sale europe state benefit high demand competitor supply issue uk infant benefit meningitis b vaccine number case meningitis b report uk fall significantly baby vaccinate bexsero meningococcal vaccine uk country world invasive meningococcal b disease introduce national infant immunisation leading cause meningitis programme meningitis b late industrialise world develop rapidly child vaccinate typically previously healthy child month receive booster adolescent oneyearold contract disease die suffer major physical month programme neurological disability limb launch public health england phe hearing loss figure show percent effectiveness bexsero meningitis b bexsero meningococcal b vaccine license europe past year number dose bexsero produce grow million cumulative total million gsk annual report vaccine continue deliver vaccine rd work focus follow positive scientific opinion discover develop vaccine european regulator infant help protect people broad range malaria vaccine mosquirix world health broad pipeline disease condition age organization start pilot implementation include vaccine target group pipeline candidate vaccine subsaharan africa vaccine early mid late stage country partner shingle meningitis respiratory development range disease nonprofit organisation path donate syncytial virus group b dose mosquirix pilot receive regulatory approval streptococcus new expand indication flulaval bid assist zika virus vaccine concept copd cover infant month age evaluate new vaccine technology know year obtain sam selfamplifye mrna approval europe label update national institutes health believe boostrix boostrix polio human technology potentially induce safety datum support use pregnant protective immunity zika woman launch hiberix investment governance vaccine priority meet patient need file regulatory approval address global health challenge north america europe vaccines exist candidate vaccine prevention significant improvement shingles complication case vaccine rd investment study plan file million million use japan number promise early rd complement exist asset pipeline example global hubs siena italy wavre candidate vaccines phase ii belgium opening centre meningococcal abcwy respiratory rockville maryland close major syncytial virus rsv group b streptococcus public health stakeholder exacerbation chronic obstructive global centre area pulmonary disease copd expertise vaccine discovery specific asset development benefit scientific exchange worldclass team vaccine research development cycle industry average identify produce preclinical phase phase ii proof phase iii file registration antigen antigen testing concept postmarkete surveillance research include immunology preclinical development clinical development include postmarkete surveillance transfer process manufacturing year year year year gsk annual report strategic report governance remuneration financial statement investor information simplify continue simplify commit quality operating model strengthen discovery development new manufacturing network reduce vaccine complex process vaccine continue supply cost manufacture high quality simplify operating model standard accord current good year complete majority manufacturing practice cgmp regulation realise significant saving novartis vaccine business integration regulatory inspection cost saving generate vaccine minor finding business contribute delivery case work regulator billion annual saving group address observation end include billion currency benefit saving combine strong sale growth deliver improved operate leverage profit margin percentage point high percentage point high proforma cer basis invest supply chain vaccine manufacture site country international presence enable manufacture vaccine great capacity efficiency flexibility aim critical production step inhouse possible year invest new production facility marburg site germany enable produce active component bexsero vaccine inhouse add new mump production line combine measle mump rubella varicella vaccine responsible prepare public health emergency business gsk commit help public health crisis occur ebola break west africa guidance independent expert accelerate development candidate dedicate permanent rd pilot ebola vaccine follow outbreak production facility capacity zika employ novel technology respond rapidly future global health platform start vaccine discovery programme emergencie national institutes bpo operate noprofit health noloss basis funding respond lifethreatening government nongovernmental disease surface vaccine research organisation discovery lengthy process typically take strongly support coalition year epidemic preparedness innovation cepi good chance save live global community focus vaccine development prepare advance solution protect infectious reason propose create disease outbreak stand ready partner dedicate permanent biopreparedness cepi advance epidemic organisation bpo global vaccine rd preparedness centre rockville plan facility design develop manufacture new vaccine potential public health threat target pathogen select prioritise ggsskk aannnnuuaall rreeppoorrtt consumer healthcare consumer healthcare business develop market product wellness oral health nutrition skin health portfolio include world trust bestselle brand sensodyne voltaren panadol ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn migraine headache excedrin help people manage symptom grow deliver simplify responsible business bn sale increase sale operating profit margin panadol power brand aer cera product innovation help raise awareness proforma cer launch past percentage point high dengue fever growth broadly year balanced percentage point high europe cer proforma basis international market footnote use number adjust nonifrs measure report performance business describe include core result free cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report consumer healthcare consumer healthcare business nutrition consumer healthcare split equally overthe nutrition business include horlick counter otc medicine fast move long establish wheat milk malt business world consumer good fmcg barley drink lead overthecounter category wellness oral health nutrition skin health skin health consumer healthcare sale globally wellness medicate skin health treat product company global leader wellness condition cold sore dry large category number sensitive skin abreva zovirax country retail sale lead brand hold leading position global position respiratory cold flu world large market nasal decongestant allergy smoking power brand cessation pain management prioritise seven global power brand brand panadol otrivin panadol parodontax poligrip voltaren sensodyne theraflu voltaren oral health regional core brand include flonase company globally horlick tum brand include sale toothpaste number physiogel benefit broad geographic specialist oral health globally footprint combine focus scientific country lead position expertise consumer insight sensitivity acid erosion denture care gum health sensodyne billion consumer healthcare represent consumer healthcare joint venture brand make thirdlarg product novartis gsk consumer sale gsk portfolio healthcare list business india nigeria manage migraine symptom excedrin bring home painful reality migraine recent virtual reality campaign excedrin overthecounter brand work vr expert create sale launch visual effect experience attack virtual reality vr campaign correct include blurred vision flash object misunderstanding migraine campaign aura room spin partial blindness include multichannel campaign enormous impact medium activity expert celebrity panel social medium million view discussion high profile new york event engagement launch march product sale rise share film comment retweet campaign show double digit growth year excedrin create campaign customer insight research show sufferer feel misunderstood documentarystyle film feature migraine simulator develop help migraine sufferer gsk annual report strategic report governance remuneration financial statement investor information grow performance summary europe sale grow million consumer healthcare sale grow proforma good momentum actual rate cer germany scandinavia italy partly strong growth proforma basis million offset impact challenge economic oral health wellness condition commonwealth category basis growth independent state voltaren grow power brand help wellness oral health doubledigit result continued skin health partly offset consumer healthcare success hour variant nutrition decline increase report oral health sensodyne gum health brand level sensodyne panadol portfolio record strong growth sale proforma otrivin perform strongly sale international market sale grow billion sensodyne reach billion proforma million growth time sale innovation impact sale nigerian year represent sale beverage business september particular contribution flonase effective cessation switch otc q trade venezuela end notable launch include demonetisation implement india sensodyne true white excedrin november impact indian geltab business sale middle east latin growth broadly balance america china grow particularly global geography sale strongly result well pricing grow million proforma new product introduction drive primarily sensodyne deliver doubledigit growth follow launch growth rate cer true white combine strong nonifrs measure describe momentum pronamel wellness state flonase otc grow strongly half follow line extension new overthecounter launch extend flonase brand continue success switch product prescriptiononly overthecounter fda approve flonase sensimist new product act multiple inflammatory allergy relief seasonal perennial substance additional feature allergy build success move suitable child young product prescriptiononly year old scent alcoholfree overthecounter otc usa cause little drip product launch february apply time allergy season make bring sensimist flonase product available otc meeting allergy relief umbrella aim build consumer demand great control flonase market success personal healthcare product available prescription veramyst manage switch otc draw regulatory insight pharmaceutical business help navigate highly regulate pharmaceutical environment gsk annual report consumer healthcare continue deliver success consumer healthcare continue success move business build ability understand product prescriptiononly customer need meet effective thecounter approval launch success deliver product strong research pipeline flonase sensimist allergy relief consumerdriven sciencele refocus investment case study innovation ensure achieve high return innovation enable understand consumer everyday deliver newtomarket product healthcare need view product generate bestever sale launch sale preference integral new recent launch generate innovation launch product development process digital past year high technology central life level explore way internally rd investment consumer discussion external entrepreneur healthcare million inventor harness digital million prioritise investment capability improve consumer health power core brand continue invest stateoftheart strategic focus fewer big digital real life innovation opening innovation example include new shopper sensory labs sale generate sensodyne true white excedrin geltab case study innovation launch past new eno ajwain herb flavour variant year strengthen commitment india otrivin oxy launch rd india building headcount record month conception people significant increase versus legacy organisation increase focus innovation area pay seven marketfirst innovation launch region course year rd hub base emerge market region represent business science consumer insight new innovation lab increase ability understand deliver unmet consumer need follow success uk innovation labs shopper science facility enable launch lab base work retail partner new consumer healthcare hq warren good way present product store enable integrate customer insight lab enable discover stage product development fresh insight develop tailormade original inception idea item product meet need position store shelf include consumer retailer help rd suite combine flexible work meet ambition choice space rapid prototyping capability shopper customer allow swiftly concept manufacture tablet liquids powder cream consumer sensory capability assess people use product include simulate environment product find example bathroom doctor consult room shop pharmacy gsk annual report strategic report governance remuneration financial statement investor information simplify complete majority unify branding roll integration enable increase integrate site emphasis core innovation artwork change deliver continue deliver strong growth brand streamline effort involve simplify streamline incremental annual cost saving market move standardised helped increase operate profit consumer healthcare business platform course year margin percentage point track deliver increase operate percentage point high synergy target profit margin cer basis percentage point high cer proforma basis commit quality remain track deliver annual cost consumer healthcare product saving anticipate deliver target manufacture high quality operating margin standard accord current good manufacturing practice cgmp regulation consolidation activity year regulatory inspection result reduction cost satisfactory outcome overhead establish common distribution route share enterprise resource planning platform enable access datum organisation inform decision make responsible help community well identify prevent treat dengue fever business gskle health campaign encourage well understanding manage disease mosquitoborne dengue fever cause include train trainer session million infection death refresh physicians pharmacists year endemic knowledge virus recruitment country particularly south east voluntary dengue warrior asia western pacific region spread word prevention treatment distribution dengue paracetamol panadol help treat proficiency kit healthcare professional symptom dengue fever gsk consumer healthcare launch assist wide media coverage ally dengue campaign campaign impact dramatic malaysia indonesia malaysia year rise philippine bring gsk mortality rate campaign contribute panadol power brand doctor pharmacy number death fall chain government nongovernment organisation campaign help increase campaign helped educate regional consumer healthcare product seven million people disease sale philippine net sale increase q versus period ggsskk aannnnuuaall rreeppoorrtt responsible business responsible business central strategy deliver success important result achieve ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn expand graduated approach filing enforce patent intellectual property widen access medicine poor country health behaviour people planet country partnership mandatory annual partnership cut operational save child reach training code prevention programme carbon emission scope additional million conduct complete roll child employee globally offer total value chain treatment immunisation complementary unprecedented access emission rise intervention worker preventive healthcare extend access employee medicine family member work address country footnote remain represent employee complete training require timeframe subject disciplinary action employee completion timeframe eg new starter gsk annual report responsible business commercially create value society responsible business priority develop innovative healthcare gsk responsible business priority sit successful operating product directly benefit patient context macroeconomic responsibly improve consumer equitable pricing strategy social trend affect company allow price reflect country wide society trend present people health benefit ability pay global footprint enable opportunity challenge global great access medicine vaccine healthcare company like gsk society create consumer healthcare product report progress area value shareholder deliver profitable sustainable health behaviour people business performance generate value planet identify priority return shareholder area understand issue reinvest business important business wide society benefit healthy stakeholder people essential building strong sustainable community longerterm commitment area reflect global health need significant direct indirect align gsk strategic priority economic contribution country value detail progress community operate commitment responsible tax employment people business supplement available charitable support wwwgskcomresponsibility graduate approach intellectual property expand approach filing enforce patent reflect countrys economic maturity announce adapt agreement enable dolutegravir current approach filing enforce patent available adult generic ensure balance need manufacturer royalty fee tiere protect intellectual property depend national gross domestic countrys economic maturity product follow approval regulator mean people live hiv mean long file patent develop world cover medicine leastdevelope country licence agreement lowincome country low middle income country apply patent outline intent commit think appropriate offer licence future portfolio cancer treatment allow supply generic version patent pool work medicine country g medicine patent pool explore country year help address increase burden cancer develop country line approach viiv healthcare expand licence agreement medicine patent pool adult formulation hiv drug dolutegravir include vast majority low middle income country gsk annual report strategic report governance remuneration financial statement investor information measure wellestablished longterm cite companywide ownership responsible commitment sit access key strength progress area health behaviour commitment research development people planet low middle income country measure performance access highpriority medical need medicine index dow jones beginning perform sustainability index access vaccine access medicine index index lead category gsk top access consideration medicine index fifth consecutive time dow jones sustainability index mean lead edition come sector biannual index launch dow jones sustainability index index access medicine index fund analyse economic environmental bill melinda gates foundation social performance world lead uk dutch government measure company overall percentile rank pharmaceutical company effort increase th th improve access healthcare develop meaning score country lead peer sector indexs seven category research lead industry code business development pricing manufacturing conduct climate strategy environmental distribution product donation report health outcome contribution index describes gsk strong performance corporate accessoriente company recognise governance marketing practice risk clear strategy increase access crisis management tax corporate medicine align citizenship corporate strategy progress responsible business commitment assessment show commitment complete progressing track work detail performance responsible business supplement wwwgskcomresponsibility health behaviour progress progress innovation unmet medical need complete ethical conduct progress well access medicine vaccine progress promote value sale progress marketing practice build product well meet need progress strengthen healthcare infrastructure progressing transparency clinical trial datum complete fight malaria progressing rigorous patient consumer safety progressing eliminate control neglect progressing minimise animal testing track tropical disease ensure ethical interaction progress eradicate polio progress promote human right track access antiretroviral treatment hiv progress work party track reduce child mortality progress people planet progress progress develop people inspire progressing aim carbon neutral work need healthy workplace reduce water impact progress promote inclusion diversity track reduce waste track community volunteering complete create change gsk annual report responsible business continue approach gel help prevent umbilical health tackle great cord infection newborn receive global health challenge innovate positive scientific opinion european meet unmet need make medicine medicine agency ema million commit vaccine accessible baby die year infection develop innovative strengthening healthcare system newlycut umbilical cord attract product extend innovate unmet need bacteria particular issue develop country approve local regulator access healthcare aim develop innovative product gel available notforprofit disease disproportionately affect people matter price share manufacturing knowledge world poor people widely live need great mosquirix vaccine target significant ability pay commit work health threat malaria phase iii trial government multinational organisation vaccine receive positive opinion ngo enhance preparedness ema show potential future outbreak vaccine considerable public disease ebola zika health impact combination support coalition epidemic malaria control measure preparedness innovation cepi case study propose world health organization create permanent biopreparedness confirm funding organisation bpo rockville commit enable pilot implementation maryland vaccine site mosquirix setting subsaharan africa begin early protect refugee essential vaccine supply essential vaccine low price civil society organisation use acute humanitarian situation home livelihood great humanitarian need government community refugee lose easy unable assist access healthcare leave potentially develop reliable predictable vulnerable vaccinepreventable disease supply cso step time continue work response gsk commit supply partner strengthen longterm essential vaccine internationally recognise capacity local health system support civil society organisation cso refugee host community mdecin san frontire save photo nour wahidsave child child low price use pledge come ten thousand acute humanitarian situation government refugee continue flee conflict syria unable assist south sudan build decade effort gsk work vaccine cover commitment partner increase synflorix pneumococcal vaccine access vaccine charity protect child disease respond emergency pneumonia work partner gavi vaccine alliance provide synflorix deeply discount price charity fund deliver immunisation programme refugee displace people future explore extend offer essential vaccine commitment design help maintain stable vaccination programme times gsk annual report strategic report governance remuneration financial statement investor information share expertise resource understand payer patient intellectual property external concern affordability develop researcher open innovation lab market lead effort tre canto spain build portfolio develop sustainable solution example research project look disease usa gsk pharmaceutical invest million develop world product launch similar country train frontline visit scientist result price medicine aim health worker reach million people lab lead paper supersede integrate scientific publication africa patient assistance programme noncommunicable disease open lab gsk patient assistance program currently focus cardiovascular design simplify improve disease oncology chronic respiratory programme experience eligible disease chronic kidney disease uninsured patient patient diabetes project look severe medicare prescription drug plan asthma east africa lead ugandas europe continue engage makerere university payer eu markets balance affordable extend affordability availability cost healthcare system funding commit widen access solution support ongoing charitable giving total medicine vaccine equitable innovation medicine achieve million million pricing strategy base country reimbursement ellipta portfolio disease area product type patient eu market find local solution ability pay issue affordability challenge introduction new innovation cap price patent medicine vaccine strengthen healthcare system leastdevelope country ldc reinvest profit price eu france sale pharmaceutical consumer germany italy spain uk long healthcare product ldc strengthen manufacturing cost cover healthcare infrastructure nation work amref health offer low vaccine price africa care international save organisation gavi vaccine product inkind child invest million cash alliance support country country reach million people management low gross national income train frontline health worker time pulse deliver million dose synflorix vaccine pneumoccal pioneering partnership disease million dose save child reach million rotarix vaccine rotavirus child livesaving intervention gastroenteritis bring total number million million middleincome country child screen malnutrition live poverty equitable price underfive approach enable people access immunise child product egypt offer portfolio vaccinate measle polio price meet need level treat income include price reduction diarrhoea malaria pneumonia seretide inhaler device target middle low income group gsk annual report responsible business continue approach work party behaviour aim valuesbase culture expect supplier share high training people standard ethical standard increase expect encourage reporting use preferred supplier bring value underpin concern embed value global way measure employee performance purchase order spend continue ensure rigorous safety patient consumer safety rollout global thirdparty oversight programme reach total standard manufacture medicine vaccine country latin america accord current good manufacturing interact healthcare south east asia programme aim practice regulation internal quality drive improvement supply chain professional management system distributor network ensure regulatory inspection party engage support manufacturing site value receive observation minor complete observationsa inspection party audits health safety ethic gsk value conduct food environment labour right drug administration fda conduct audits focus result form issue specifically quality process site cite deficiency current good identify area improvement manufacturing practice cgmp engage respective party observation direct impact develop improvement plan track product supply site completion overall aim enhance corrective action plan mitigate performance supply chain observation submit suspend terminate work fda case thirdparty significant issue identify transparency clinical trial datum training people gsk company sign update code conduct alltrial campaign clinical accompany annual training trial register result report people deep understanding lead industry clinical apply value everyday activity study transparency past decade publicly post b employee expect employee act line clinical study report complementary worker complete value result summarie mandatory training code code conduct training enable learner researcher submit proposal understand manage risk request access detail associate business activity clinical trial include antibribery corruption wwwclinicalstudydatarequestcom website risk maintain zero tolerance independent panel review proposal approach people work scientific merit ensure patient high risk role complete additional privacy confidentiality protect indepth antibribery corruption training proposal approve help understand manage research team grant access particular challenge face anonymise patientlevel datum daily work begin provide plain reporting investigate concern language summary clinical study centrally track misconduct allegation online clinical study register concern multiple speak channel investigation team receive report reduction footnote time await report inspection b remain represent employee complete training require time subject disciplinary action completion timeframe eg new starter gsk annual report strategic report governance remuneration financial statement investor information disciplinary action safety ensure employee discipline action employee fail act communicate consistently breakdown type policy violation line policy year revise thirdparty contract monitor employee discipline policy exist supplier screen new one violation include approach tax employee fail complete mandatory understand responsibility pay training code conduct antibribery appropriate tax fully corruption require support effort ensure company timeframe total discipline transparent manage employee receive document warning tax affair verbal warning dismiss pay significant tax uk agree leave company voluntarily global corporate function relate significant manufacturing rd attendance marketing payroll promotional activity attendance payroll include facility locate country train completion code conduct disciplinary action relate employee world substantial good manufacturing falsification absence punctuality misstate hour business employment presence distribution document work past year pay practice travel expense local work regulation environment health human right billion corporation tax globally violation safety gsk signatory un global billion nearly compact set key principle global total pay uk read business human right commit uphold universal engage artificial tax declaration human right arrangement business international labour organisation core commercial substance labour standard time responsibility focus area shareholder financially efficient operation big potential impact deliver sustainable tax rate human right manage human right detail approach tax risk supply chain reinforce tax disclosure find requirement labour right health put patient interest continue lead industry modernise way market sell medicine january stop pay sale team compensate january healthcare professional hcp speak pharmaceutical medical sale prescriber medicine representative long compensate vaccine instead strengthen individual sale target instead online resource supplement information reward technical skill scientific provide salesforce knowledge quality service broad business performance significantly expand global team inhouse medical expert provide new approach receive information medicine vaccine follow medical product information hcp way convenient session gsk expert medical expert dedicated country exclusively support hcp hcp agree interaction helped engage informed decision benefit role patient care rate experience superior similar interaction pay hcp activity pharmaceutical company clinical market research help develop see improvement customer medicine vaccine meet patient need trust transparent transaction survey hcps gsk rank disclose payment hcp customer trust fourth year market row customer value europe include russia ukraine time australia japan change way gsk gsk annual report responsible business continue approach particular emphasis leadership people need talented motivated workforce development train deliver strategy achieve people support promotion strive attract good people second line leader role continue aim create safe create environment empower evolve global leadership development inclusive environment inspire people strategy focus programme find manager reach talent leadership performance complete significant engagement improvement effectiveness base potential feedback team talent leadership talent leadership programme train leader coach focus develop employee strategic use coaching level skill need advance recognise worldclass career international coach federation prism award welcome graduate postgraduate future leader performance engagement esprit programme include global performance system centre emerge market gsk vote set clear expectation graduate employer research emphasise result people development time achieve way achieve graduate employer th line value successive year rank th overall listen people essential employee engagement respond year respond insight global employee survey employee complete member cet host listening session senior leader conduct discussion topic raise include evaluate performance future leader programme build generation leader future leader programme deliver programme rate highly participant fresh idea talent need continue drive recent survey alumnus success key market future leader programme find respondent feel rotation provide graduate breadth potential help develop relevant skill career pathway rd finance experience career gsk marketing procurement option function benefit business clear job rotation number geographical spread intake mean homegrown leader job rotation rooted market include emerge programme feedback mentoring country new recruit coach constitute formal representing nationality train remainder balance enable country graduate develop specific nation skill effective individual role business get broad grasp company learn gsk graduate join future leader distinctive global leadership approach programme gsk annual report strategic report governance remuneration financial statement investor information woman management monitor progress employee volunteering introduce pulse survey evaluate gsk employee impact engagement effort country contribute million svpvp regular interval annual survey worth skilled service nonprofit director partner country promote inclusion diversity manager diverse perspective experience pulse volunteer partnership total global workforce strengthen work assignment align worldwide healthcare challenge business help meet need un sustainable development goal employee gender number patient consumer health wellbee percentage woman management male female total healthcare company think hard rise woman board good support represent corporate executive management team cet board health patient consumer total compare average employee global energy resilience training programme ftse board accord cranfield management senior manager define innovative ambitious partnership company act strategic report director board report prevention programme pp report regulation include person responsible planning direct control woman began create strong foundation activity company strategically significant accelerate difference programme company board include director help female leader progress pp offer undertaking include consolidated account employee family member senior role programme country unprecedented access recognise good practice cranfield preventive healthcare service universitys female ftse board immunisation cancer screening report little extra cost extend global organisation want service india russia leader represent varied market commonwealth independent state gsk employee country serve nationality currently keep track achieve goal spend month nonprofit represent cet board global coverage organisation share skill effort promote protect people environment feels include want prevent incident establish lesbian gay occur global business bisexual transgender lgbt council operating markets council chair president injury occur pharmaceutical rd endorse cet reportable injury aim engage educate employee illness rate hour lgbt issue achieve work accord pharmaceutical score human right campaign safety group psg data comparable foundation corporate equality index lead company sector rate workplace lgbt equality sadly fatality sale representative die result road make gsk accessible place traffic incident india try prevent work people disability priority road incident driver safety work global programme india indonesia vietnam disability council develop online people take accessibility portal allow employee find information support adjustment work environment commit remove barrier increase understanding ensure disability opportunity gsk annual report responsible business continue approach supply chain represent large planet aim reduce environmental impact value chain footprint value chain extend follow use product access product minimise operation logistic end aim reduce carbon footprint water use life disposal remain environmental impact operational waste large value chain impact focus value chain carbon help supplier environmental extend access operational emission scope improvement example supplier total million tonne co e cover billion spend direct product broadly previous year raw material disclose information represent decrease ecodesk online platform monitor baseline reduce promote environmental improvement emission continue focus supply chain addition energy efficiency renewable energy supplier use online sustainability investment sustainable building collaboration platform gsk supplier exchange share good practice revise calculation method scope emission current certain product disproportionate ghg protocol methodology effect value chain emission include impact purchase service particularly ventolin propellantbase capital investment fuel energy relate inhaler emit greenhouse gas activity logistic upstream supply use continue research chain business travel commute solution issue include change base late methodology way manufacture reduce increase baseline figure propellant maintain million tonne co e million efficacy patient tonne co e overall carbon footprint scope increase million tonne co e million tonne co e novartis integration represent increase overall footprint versus baseline exclude novartis footprint remain flat despite volume medicine vaccine consumer footnote healthcare product ship recently available scope datum factory increase approximately publish datum online period late carbon emission plus intensity ratio regulation tonne coea b scope emission scope emission datum available scope emission intensity ratio scope emissionssales revenue tonne coem scope fte tonne coefte carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition b datum include novartis site emission headcount gsk annual report strategic report governance remuneration financial statement investor information water innovative project rajasthan arid new water stewardship policy region india replenish water reinforce commitment reduce source village sawaipura gsk water impact value chain quarter water continue look way use water horlick factory locate site successfully efficiently reduce consumption india use operation achieve zero waste landfill million water alternative development initiative indian purposing material waste wastetoenergy operation reduction ngo support community service horlick supply chain improve water management agricultural yield use aspect overall water impact value waste chain include factor local aim reduce operational waste water scarcity quality health social compare regulatory reputational risk operation produce thousand tonne waste focus effort small number previous year highimpact gsk site waterscarce baseline majority recycle region agricultural supply chain incinerate recover energy horlick product make send landfill site big portion total value chain achieve zero waste landfill water footprint repurposing material waste wastetoenergy service gsk recognise cdp leader climate change water gsk include prestigious cdp list climate water effort reduce carbon emission include reduce emission acknowledge inclusion manufacture inhaler launch cdp climate list cdp assess company complete cycle scheme globally industry sector kind work pharmacist patient company applicant recover recycle inhaler step seven healthcare company aliste help reduce operational emission high rating reflect significant step take help meet goal carbon neutral continue grow applicant company business meet healthcare need healthcare company include people water list success reflect achievement reduce water usage commitment water stewardship gsk annual report group financial review section cfos statement approach tax viability statement report framework noncontrolle interest viiv healthcare segmental review total result core result proforma growth rate reconciliation cash generation conversion financial position resource critical accounting policy treasury policy gsk annual report strategic report governance remuneration financial statement group financial review investor information continue progress item adjust total delivering strategy core result consistent year financial goal set significant financial architecture include remeasurement charge relate business contribute delivery liability future contingent broadlybased revenue growth consideration significantly continue focus execution consideration shionogi relate integration restructuring programme interest dolutegravir accelerate delivery target value future option benefit allow improve margin major restructuring charge operate leverage make continue ifrs require provide contingent substantial investment new consideration liability relate previous progress deliver product supply chain improvement business acquisition basis progress rd pipeline strategy estimate present value potential maintain focus future payment estimate financial goal financial efficiency allocation broad range outcome effect capital allow deliver core eps ifrs accounting treatment gsk set growtha ahead sale growth recognise fair value liability financial architecture end financial guidance balance sheet charge significant improvement cash measurement reflect immediately generation dividend penny operating income gsk share cash payment future discharge liability liabilitie financial architecture establish acquisition financial architecture design viability statement subsequent remeasurement charge support consistent execution viability statement set income statement payment strategy enhance return assessment prospect group charge future earning year present deliver shareholder focus deliver sustainable sale growth sale growth company improve operate business deliver leverage profitability enhance growth line medium financial efficiency objective term growth expectation lay drive growth eps ahead sale capital market day performance convert pharmaceutical sale earning cash actual rate cer proforma invest business return cer growth new product shareholder offset decline seretideadvair attractive return sale addition strong growth hiv respiratory portfolio return growth clear set priority ensure actual rate cer consistency capital allocate different business vaccine sale actual rate gsk relative return cer proforma cer driven business benchmarke relevant external strong execution business comparative cash flow return particularly flu meningitis investment cfroi base framework franchise bexsero particular metric specific capital investment consumer healthcare deliver strong benchmarke similar way performance year joint reporting framework venture sale actual rate addition total report result cer proforma cer prepare ifrs annual report growth seven power brand make reference number core offset tough comparator performance measure headwind international market management planning report operate leverage purpose nonifrs measure total operating margin adjust number item management sale compare believe useful separate movement primarily reflect key trend drive performance combination high remeasurement business clearly identify charge consumer healthcare footnote shareholder core result option viiv healthcare contingent use number adjust nonifrs measure vary significantly total result consideration liability report performance business adjustment material describe include core result free benefit profit disposal case cash flow cer proforma growth rate oncology business year nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report group financial review continue gsk financial architecture drive improve return shareholder sale growth operate leverage eps return shareholder financial efficiency free cash flow cash flow growth core operating margin improve impact decline total eps guidance drive increase leverage partly offset benefit improve expect continue progress business proforma core margina operating performance reduce business expect continue basis point total point restructuring charge year benefit recent new product launches come currency point investment core eps pa actual operational improvement drive exchange rate constant expectation core ep growth combination leverage strong exchange rate dependent number factor include growth line billion particular uncertainty relate include million currency benefit contingent consideration timing extent potential generic additional integration restructuring end gsk liability competition advair benefit continue tight cost contingent consideration payment control allow deliver margin billion billion related event generic version advair improvement continue estimate present value future payment introduce market important investment business shionogi viiv healthcare payment group expect core eps growth shionogi calculate quarter cera base expect accelerate delivery target base highteen percentage decline advair sale benefit integration restructuring revenue relevant product principally programme key objective dolutegravir discount fair value please progress year event midyear introduction total future payment reflect current sustained focus group substitutable generic competitor advair expectation total future sale execute programme end group expect fullyear product detail provide deliver annual benefit advair sale billion cer note contingent consideration liability billion exclude million core ep flat slight currency benefit target free cash flow decline percentage term cera programme year early originally net cash inflow operating activity able guidance total plan confident deliver billion free cash flow result reliably forecast certain remain million bring group billiona significantly material element total result total benefit deliver billion improve small outflow see future fair value movement annual saving constant currency basis drive improve contingent consideration option operating performance include continued financial efficiency tight control capital expenditure return shareholder continue focus improve restructuring expenditure maintain ordinary dividend financial efficiency overall funding benefit currency tail wind continue p share level pay cost protect credit profile progress objective line commitment particular shortterm target credit rebuild cash generating capacity shareholder time close rating net finance cost slightly group post completion novartis transaction early mainly currency restructure integration programme maintain dividend complete earning share integration reshape group net debt total eps p p despite shortterm pressure free cash net debt end decline primarily reflect comparison flow restructuring cost create billion billion high net debt billion profit sale end currency significant fuller review financial result set market oncology asset novartis factor adverse translation effect drive page impact charge billion increase remain arise increase valuation increase billion reflect impact liability contingent consideration dividend pay year option associate increase billion include special dividend sterling value group hiv billion declare partly consumer healthcare business offset disposal proceed approximately simon dingemans billion free cash flow billion chief financial officer gsk annual report strategic report governance remuneration financial statement investor information approach tax understand responsibility pay seek maintain open positive appropriate tax fully relationship government tax understand support effort ensure company authority worldwide welcome responsibility pay transparent tax affair constructive debate taxation policy manage tax important element appropriate tax continue significant economic contribution bring focus tax reform financially country operate include oecds base erosion engage artificial tax arrangement efficient deliver profit shift bep project business commercial european commission initiative sustainable tax rate substance seek avoid tax increase use fiscal state aid use tax haven transaction investigation oecd bep report fully disclose tax authority clarify important principle tax time responsibility pay profit shareholder financially supply chain profit make efficient deliver sustainable tax activity take place rate approach look gsk support approach particular align investment strategy implementation oecds country recommendation country country substantial economic activity report include exchange government policy promote tax regime datum tax authority key attractive business success datum validate investment transparent intent exist information hold taxpayer available relevant tax payer support ability ensure multinational uk patent box group pay right tax group corporate tax charge scope timeline million million tax reform remain uncertain present profit million gsk supportive step million represent effective simplify tax code provide tax rate clear roadmap tax system increase total tax rate primarily efficient competitive reflect high nondeductible remeasurement charge relate tax implication brexit option liability low credit dependent outcome negotiation reassessment prior year tax charge uk eu cash tax payment currently unknown continue million year million work closely abpi bia analyse implication industry addition taxis pay order highlight key focus area profit pay duty levy transactional government brexit employment taxis negotiation direct tax implication ongoing alignment group expect limited gsk structure reflect mix operation indirect tax implication geography help maintain significant include potential custom efficient effective tax rate core tax duty cost additional transaction rate administrative cost associate core tax rate expect manage import export obligation range give movement good group momentum change earning uk eu mix challenge uncertain approach tax set detail tax environment factor public policy position section describe moderate upward website detail pressure rate expect corporate tax charge year set year tax risk manage set policy procedure seek ensure consistency compliance tax legislation audit risk committee footnote board responsible use number adjust nonifrs measure report performance business approve tax policy risk describe include core result free management cash flow cer proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report group financial review continue viability statement accordance provision c revision follow hypothetical downside scenario evaluate code gsk assess prospect company scenario business performance risk include key long period month require go concern performance risk include low sale new product provision director confirm reasonable possible impact generic alternative seretideadvair expectation gsk continue operate meet liability great adverse impact generic competition gsk fall year director assessment product possible supply manufacturing challenge reference gsk current position prospect strategy board risk appetite gsk scenario external macroeconomic risk scenario reflect principal risk manage detailed page incremental risk business drive outside factor strategic report intense competition increase pricing pressure europe potential impact material negative board review internal control risk management change macroeconomic healthcare environment policy approve governance structure code conduct appraise approve major financing investment scenario principal risk scenario include severe licensing decision evaluate monitor performance assessment potential loss impact principal risk prospect gsk focus largely improve set page relate patient safety product longterm financial performance simplify operate quality supply chain continuity antibribery corruption model grow diversified global business delivering fundamentally threaten operation risk product value manage mitigating activity describe page board review gsk strategy make significant capital investment decision long term time horizon base scenario option exercise scenario evaluate multiyear assessment return capital performance additional funding requirement assume early potential business unit market opportunity pharmaceutical exercise outstanding option hold partner vaccine consumer sector approach align gsk hiv consumer business model achieve balanced growth invest high quality year review make certain assumption innovative product patient consumer healthcare normal level capital recycling likely occur consider provider internal external parameter additional financing facility require respective level increasingly unpredictable long time horizon gsk funding flexibility headroom focus detailed bottomup plan year cycle plan result stress testing certain combination review annually director approve business hypothetical scenario increase funding demand forecast show expect financial impact director believe gsk require mitigate change group fund strategy year assessment period viability statement light liquidity available group base appropriate align company establish analysis director reasonable expectation business planning process balance long term nature severe stress test company able investment pharmaceutical vaccine consumer sector continue operation meet liability fall assessment period analysis near term year period assessment business performance realistically visible plan stress test series robust operational principal risk downside scenario board review risk downside scenario consider gsk cash flow sustainability dividend fund strategy insurance provision recovery key financial ratio period metric subject sensitivity analysis involve flex number main assumption underlie forecast individually combination mitigate action realistically take avoid reduce impact occurrence underlie risk gsk annual report strategic report governance remuneration financial statement investor information report framework presentation group result pharmaceutical segment turnover operating profit group financial review discuss operate financial year end december adjusted exclude performance group cash flow financial position month sale gsk oncology business january resources compare result year primarily february result precede year reconciliation report growth rate proforma total result growth rate nonifrs measure set total report result represent group overall performance contingent consideration result contain material unusual non gsk recognise significant liability contingent consideration operational item obscure key trend factor million december fair value discount basis determine group operational performance result million represent estimate present value report core result nonifrs measure future amount payable shionogi relate viiv healthcare core result discount payment shionogi calculate core result exclude follow item total result base sale performance life relevant product amortisation impairment intangible asset exclude principally dolutegravir describe effect computer software goodwill major restructuring cost ifrs accounting treatment gsk recognise fair value include cost follow material acquisition legal charge liabilitie balance sheet remeasurement charge reflect net insurance recovery expense settlement immediately operate income charge adjust litigation government investigation transactionrelate total result present core result gsk cash accounting adjustment significant acquisition payment future discharge liability item include disposal associate product business record profit loss account future earning operating income royalty income change segment report tax effect item completion novartis transaction march item exclude core result change balance group gsk change impact significant exclusion improve segment reporting reflect effect january comparabilities consistency report majority gsk report result segment pharmaceutical peer company definition core result align include hiv pharmaceutical rd vaccine consumer group result well majority peer company healthcare addition number minor product reclassification report earning segment comparative information restate accordingly core result report utilise basis internal performance report alongside total result cash flow generation free cash flow number metric core result present free cash flow nonifrs measure net cash discuss group financial review believe core inflow operating activity capital expenditure interest result representative performance group dividend pay noncontrolle interest plus proceed operation allow key trend factor drive sale property plant equipment dividend receive performance easily clearly identify shareholder joint venture associate undertaking equity investment reason result segment management planning reporting purpose pharmaceutical pharmaceutical rd vaccine consumer discussion presentation investment analyst rating healthcare report measure basis agency free cash flow growth calculate report basis reconciliation net cash inflow operation free cash flow reconciliation total core result include detailed present breakdown key noncore item set provide shareholder ensure visibility transparency adjust free cash flow assess group performance adjust free cash flow nonifrs measure exclude payment settle legal dispute payment use number adjust nonifrs measure fluctuate significantly report period remove report performance business measure allow trend free cash flow easily identify management planning report purpose shareholder reconciliation net cash inflow operation discussion presentation investment analyst rate adjust free cash flow present agency directly comparable similarly describe measure company nonifrs measure work capital conversion cycle consider addition substitute superior working capital conversion cycle calculate number information present accordance ifrs day sale outstanding plus day inventory outstanding day purchase outstanding proforma growth rate novartis transaction complete march gsk cer growth report result include result novartis vaccine order illustrate underlying performance practice consumer healthcare business exclude result discuss result term constant exchange rate cer growth gsk oncology business march represent growth calculate exchange rate vaccine consumer healthcare segment proforma growth determine result overseas company sterling remain rate calculate compare report turnover core operate unchanged previous year cer represent profit year end december turnover growth constant exchange rate aer represent growth operating profit year end december adjust actual exchange rate include month sale novartis vaccine growth rate include report cer consumer healthcare product respectively state gsk annual report group financial review continue noncontrolle interest viiv healthcare trading profit allocation exit right viiv healthcare subsidiary group pfizer request ipo viiv healthcare time operating result turnover operate profit profit tax gsk consent ipo offering include group income statement portion complete month pfizer require gsk acquire earning allocate noncontrolle interest own shareholde original agreement gsk shareholder line respective equity unconditional right long subsequent distribution shareholding pfizer shionogi shareholder withhold consent exercise shareholder include gsk entitle preferential dividend pfizer option result accordance ifrs gsk determine performance certain product recognise liability option balance sheet shareholder contribute relative performance q gsk notify pfizer irrevocably give product change time proportion overall earning right accordingly recognise liability option viiv healthcare allocate shareholder change group balance sheet initial value million particular increase sale tivicay triumeq consistent revise treatment end q favourable impact proportion preferential dividend gsk recognise liability future preferential dividend allocate gsk gsk entitle approximately anticipate payable pfizer shionogi core earning viiv healthcare group balance sheet account cash payment shionogi viiv closing balance liability relate pfizer shareholde healthcare record earning remeasurement follow liability preferential dividend allocate pfizer shionogi include operate income acquisitionrelate arrangement pfizer option agreement reach acquire shionogis interest pfizer preferential dividend shionogiviiv healthcare joint venture viiv healthcare agree pay additional consideration shionogi original agreement shionogi request contingent performance product develop gsk acquire shareholding viiv healthcare month joint venture principally dolutegravir liability window commence gsk contingent consideration estimate recognise unconditional right long subsequent distribution group balance sheet date acquisition subsequent shareholder withhold consent exercise remeasurement reflect operate income shionogi option result gsk recognise liability cash payment shionogi viiv healthcare option balance sheet q gsk notify quarter reduce balance sheet liability contingent shionogi irrevocably give right accordingly consideration result record income recognise liability option group balance statement total cash payment shionogi sheet initial value million q shionogi respect contingent consideration amount million irrevocably agree waive option result gsk payment calculate base sale performance derecognise liability option group balance relevant product previous quarter reflect sheet directly equity value liability million cash flow statement partly operate cash flow partly derecognise purchase business investing activity tax relief gsk option shionogis shareholding viiv payment reflect group noncore total tax healthcare original agreement exercisable charge payment relate original estimate month window commencing gsk fair value contingent consideration acquisition irrevocably agree waive exercise window shionogiviiv healthcare joint venture million month window remain option report investing activity cash flow statement fair value value accounting purpose payment relate increase liability acquisition report operate cash flow movement contingent consideration payable shionogi follow contingent consideration begin year addition remeasurement income statement cash payment operate cash flow cash payment purchase business movement contingent consideration end year addition represent recognition preferential dividend payable shionogi gsk annual report strategic report governance remuneration financial statement investor information group turnover turnover bn group turnover year increase actual rate cer million pharmaceutical vaccine bn consumer healthcare growth business reflect impact novartis transaction complete march proforma basis group turnover pharmaceutical vaccine consumer healthcare sale new pharmaceutical vaccine product million sterling increase aer growth cer growth million group turnover geographic region growth growth cer group turnover europe restate growth growth cer international pharmaceutical vaccine group turnover outside europe represent consumer healthcare total group turnover segment turnover sale new pharmaceutical vaccine product corporate unallocated turnover growth growth cer group turnover respiratory relvarbreo ellipta anoro ellipta arnuity ellipta incruse ellipta nucala cvmu eperzantanzeum hiv tivicay triumeq pharmaceutical bexsero menveo vaccines identify series new pharmaceutical vaccine product expect deliver billion revenue annum cer basis product plus current clinical pipeline asset shingrix set group define new pharmaceutical vaccine product sale new pharmaceutical vaccine product expect reach billion revenue annum cer basis year early sale new pharmaceutical vaccine product million represent approximately pharmaceutical vaccine turnover gsk annual report group financial review continue pharmaceutical turnover bn pharmaceutical pharmaceutical turnover million actual rate cer adjust disposal oncology business novartis proforma hiv sale grow group turnover respiratory portfolio return growth sale continue transition globally new product respiratory sale grow international decline europe sale new pharmaceutical product million sterling aer growth cer growth increase million offset sterling decline seretideadvair sale million sale establish product decline decline region particularly international reflect loss exclusivity valtrex canada pharmaceutical turnover impact market reform continue reshape business china impact biennial price revision japan restate growth growth overall impact pricing net sale pharmaceutical cer respiratory pharmaceutical turnover million decline cardiovascular metabolic report basis grow proforma basis urology proforma performance reflect growth respiratory immunoinflammation portfolio partly offset impact generic competition pharmaceutical avodart million lovaza establish product million relenza sale million hiv follow reallocation government funding sale new respiratory product total million growth product exceed decline advair advair sale fall million represent volume decline negative impact price ventolin sale million benefit competitor supply constraint early year flovent sale decline million reflect pricing pressure ics market benlysta sale increase million ongoing demand growth europe pharmaceutical turnover declined million report basis proforma basis respiratory sale decline million reflect ongoing transition new respiratory portfolio generic competition seretide decline volume decline negative impact price million partly offset growth new respiratory product record sale million establish product sale million international pharmaceutical sale million report basis proforma basis sale emerge market decline report proforma basis impact decline china business primarily result ongoing reshape programme broad healthcare reform include price reduction recent divestment international region limitation trading venezuela japan pharmaceutical sale report basis proforma million impact biennial price revision old product supply interruption avodart early year respiratory sale japan grow strong growth new respiratory product million offset decline adoair sale gsk annual report strategic report governance remuneration financial statement investor information respiratory establish product respiratory sale increase million reflect establish product turnover fall million valtrex continue transition respiratory portfolio new sale million drive decline canada product growth new respiratory product record million follow loss exclusivity zeffix sale combine sale million include relvarbreo ellipta sale million lovaza sale fall million offset decline seretideadvair million flixotideflovent sale decrease million ventolin hiv sale grow million hiv sale increase million respiratory sale increase million europe international growth volume growth negative impact price growth region drive triumeq tivicay new respiratory product offset decline triumeq tivicay sale million million advair volume decline negative impact price respectively epzicomkivexa sale decline million new ellipta product record combine sale million selzentry sale decline million include breo ellipta sale million nucala continue decline mature portfolio mainly drive generic treatment severe asthma report sale million competition combivir million lexiva establish respiratory asset include ventolin sale million million flovent decline million ventolin sale benefit competitor supply constraint early year flovent continue impact ongoing pricing pressure ics market european respiratory sale million seretide sale million volume decline negative impact price reflect continued competition generic transition respiratory portfolio new product new respiratory product record combined sale million include relvar ellipta sale million respiratory sale international region increase million emerge market japan emerge market sale seretide million ventolin grow million japan growth new respiratory product offset adoair decline cardiovascular metabolic urology sale category million avodart franchise million primarily decline follow launch generic competition q sale eperzantanzeum million primarily prolia divest end sale record compare million immunoinflammation immunoinflammation sale grow million sale benlysta million sale million pharmaceutical sale therapy area decrease million dermatology sale decline million adversely affect supply constraint augmentin sale flat million sale product rare disease flat million include sale volibris million gsk annual report group financial review continue vaccine turnover bn vaccine sale grow actual rate cer proforma million growth benefit strong performance bexsero region high demand fluarixflulaval international tender award group turnover menveo international growth drive synflorix market expansion international tender award europe boostrix sale benefit high demand europe international growth partly offset infanrixpediarix aer growth cer growth supply constraint international unfavourable cdc stockpile movement number product portfolio sale grow proforma basis million growth drive market share growth bexsero menveo boostrix improve supply high demand restate growth growth fluarixflulaval competitor supply issue benefit cer infanrixpediarix growth partly offset adverse stockpile rotarix movement menveo unfavourable comparison synflorix benefit cdc stockpile movement infanrixpediarix fluarix flulaval boostrix rotarix bexsero europe sale grow proforma basis menveo million growth drive primarily bexsero sale boostrix private market channel country include spain infanrix pediarix italy uk follow inclusion nhs immunisation hepatitis programme boostrix sale benefit high demand priorix priorix tetra varilrix competitor supply issue sale increase germany drive cervarix improve supply hepatitis vaccine high demand encepur rabipur sale growth help tender award synflorix poland infanrixpediarix sale adversely impact mainly germany france italy competitor return market year growth partly offset unfavourable comparison menveo sales uk benefit catchup tender win international sale grow proforma basis million growth drive primarily synflorix market expansion nigeria high demand africa private market demand asia growth menveo sale drive tender award argentina rotarix sale benefit high demand brazil japan growth region drive brazil strong demand bexsero menjugate boostrix fluarixflulaval sale grow higher uptake australia growth region partly offset low sale infanrixpediarix supply constraint low hepatitis vaccine sale wholesaler destocke china follow introduction new private market distribution regulation gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare turnover bn consumer healthcare business represent consumer healthcare joint venture novartis gsk consumer healthcare list business india nigeria exclude joint venture result include group turnover trading performance nigeria beverage business q follow sale september sale grow actual rate cer million aer growth cer growth benefit significantly inclusion sale novartis product time month period proforma growth price contribute volume strong performance deliver power brand oral health wellness category region sale innovation year represent restate growth growth approximately sale particular contribution cer flonase switch otc q notable wellness launch include sensodyne true white excedrin oral health geltab nutrition sale grow proforma million sensodyne skin health deliver doubledigit growth benefit launch repair protect launch true white quarter distribution gain pronamel newly launch pronamel strong bright variant flonase otc deliver restate growth growth cer high singledigit growth strong performance half drive new format impact second half increase private label competition excedrin grow doubledigit europe drive geltab launch new digital campaign international tum deliver doubledigit growth benefit supply improvement partly offset decline aquafresh sale increase competitive pressure realignment investment power brand sales europe grow million proforma basis drive primarily performance wellness oral health category voltaren continue deliver doubledigit growth drive largely hour variant strong performance key market oral health sale grow mid singledigit strong growth sensodyne gum health portfolio partly offset flat performance aquafresh increase competitive pressure market level sale grow italy scandinavia uk germany partly offset decline sale cis impact consumer spending weak economic environment international sale million grow proforma growth growth deliver priority market primarily power brand oral health wellness category partly offset impact sale nigeria beverage business end q affect restructure activity venezuela end growth international region affect combined impact indian business demonetisation implement november general slow health food drink category impact performance nutrition category horlick particular strong growth deliver middle east latin america china growth middle east drive strong momentum power brand particularly otrivin panadol sensodyne doubledigit performance deliver brazil argentina result well price new product launch oral health china deliver high singledigit sale growth contribution portfolio sensodyne voltaren particular benefiting ecommerce retail distribution expansion gsk annual report group financial review continue total result turnover bn cost sale cost sale percentage turnover bn percentage point sterling term percentage point cer term compare reflect improved product mix particularly impact high hiv sale pharmaceutical vaccine consumer healthcare low restructuring cost increase contribution integration restructuring saving business aer growth cer growth benefit partly offset continue adverse pricing pressure pharmaceutical primarily respiratory continue investment supply chain total operating profit bn sell general administration sga cost turnover percentage point low bn percentage point low cer basis primarily reflect low restructuring cost benefit pharmaceutical restructure programme integration benefit vaccine consumer healthcare partly offset investment promotional product support particularly new aer growth cer growth launch respiratory hiv vaccine consumer healthcare research development rd expenditure million turnover high low cer basis reflect benefit cost reduction programme pharmaceutical total result group set consumer healthcare vaccine rd low restructuring cost partly offset increase investment particularly growth pharmaceutical reflect investment number new programme cost acquire bms hiv programme turnover turnover cer turnover operating incomeexpense cost sale net operating expense million million sell general income primarily reflect accounting charge relate administration remeasurement contingent consideration liability relate research shionogiviiv healthcare joint venture development remeasurement value attributable consumer healthcare royalty income joint venture option liability recognise q operating income pfizer shionogi option preferential dividend expense viiv healthcare remeasurement drive operating profit unwind discount apply future liability net finance cost update trading forecast change exchange rate profit disposal assumption update periodend rate interest associate increase estimate total sterling value gsk consumer share tax healthcare viiv healthcare business profit associate charge partly offset milestone income joint venture million relation disposal ofatumumab complete profit taxation gain number divestment taxation year include remain share hold group aspen profit taxation pharmacare net operating income million year include profit disposal oncology business profit attributable novartis million shareholder earning share p earning ad gsk annual report strategic report governance remuneration financial statement investor information total result continue operate profit profit taxation total operating profit million compare take account net finance cost share profit million benefit net disposal associate profit taxation million compare gain record follow disposal oncology business million novartis transaction taxation operating profit benefit improved operating leverage drive sale growth favourable mix business low level restructure cost uk current year charge compare accounting rest world current year charge charge relate remeasurement contingent consideration charge respect prior period liability relate shionogiviiv healthcare joint venture total current taxation remeasurement value attributable consumer total defer taxation healthcare joint venture option liability recognise q pfizer shionogi option preferential taxation total profit dividend viiv healthcare tax charge million total profit represent effective contingent consideration cash payment shionogi tax rate reflect nondeductibility company reduce balance sheet liability certain item include transactionrelated adjustment record income statement total contingent particularly remeasurement option relate viiv consideration cash payment amount million healthcare consumer healthcare joint venture million include cash payment viiv noncontrolle interest healthcare shionogi relation contingent consideration allocation earning noncontrolle interest amount liability include preferential dividend amount million million include noncontrolle million million milestone payment interest allocation consumer healthcare profit million million novartis relation vaccine million allocation viiv healthcare loss acquisition million million include impact change net finance cost proportion preferential dividend shareholder base relative performance different product year finance income allocation reflect impact contribution interest income group entity noncontrolle interest primarily fair value movement result net loss entity arise exchange earning share total earning share p compare p finance expense decrease primarily reflect benefit interest expense disposal oncology business novartis close unwind discount liability march impact charge arise remeasurement fair value movement increase valuation liabilitie contingent finance expense consideration option associate increase sterling value group hiv consumer healthcare business partly offset improve performance reduce share tax profit associate joint venture restructure cost share profit associate joint venture million dividend million board declare interim dividend result total dividend year penny line dividend declare note financial statement dividend gsk annual report group financial review continue total result continue core result reconciliation december intangible intangible total asset asset major legal transaction divestment core result amortisation impairment restructuring charge relate result turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million core result reconciliation december intangible intangible total asset asset major legal transaction divestment core result amortisation impairment restructuring charge relate result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance costs profit disposal associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million gsk annual report strategic report governance remuneration financial statement investor information total result continue item adjust total result present core result transactionrelate adjustment total result adjust number item order present transactionrelated adjustment result net charge core result explain item discuss million million primarily reflect accounting charge remeasurement liability unwind discount effect value attributable intangible asset amortisation impairment consumer healthcare joint venture option hold novartis intangible asset amortisation million compare remeasurement unwind discount effect million intangible asset impairment million contingent consideration relate acquisition million include impairment rd commercial shionogiviiv healthcare joint venture value attributable asset charge noncash item option preferential dividend payable pfizer major restructure integration shionogi major restructure integration charge million incur million reflect phase plan restructuring project follow completion chargecredit consumer healthcare joint venture option novartis transaction reduce charge pharmaceutical restructuring project programme enter contingent consideration shionogiviiv later stage cash payment million healthcare joint venture include shionogi million include settlement certain charge accrue preferential dividend previous quarter viiv healthcare option pfizer preferential dividend charge combined restructure integration programme adjustment date billion cash charge billion cash total transactionrelated charge payment date billion anticipate total cash charge combine programme expect billion aggregate impact unwind discount future noncash charge billion programme potential liability million million include deliver incremental cost saving billion include million consumer healthcare joint venture option currency benefit billion deliver approximately million contingent consideration shionogi billion annual saving include currency benefit viiv healthcare joint venture million viiv healthcare programme remain track deliver originally target total option preference dividend remain charge annual saving billion constant currency basis million drive primarily change exchange rate estimate million additional cash charge assumption update trading forecast expect residual noncash charge gsk shionogi amendment legal charge shareholder agreement viiv healthcare legal charge million million include shionogi option gsk option estimate liability benefit settlement exist matter provision shionogis option initially recognise gsk balance ongoing litigation cash payment million compare sheet end q derecognised december million directly equity stand million explanation accounting noncontrolle interest viiv healthcare set divestment item divestment item include equity investment disposal include disposal remain aspen pharmacare investment dividend impairment milestone income ofatumumab number asset disposal certain adjust item divestment item include profit disposal oncology business novartis gsk annual report group financial review continue core result turnover bn research development growth bn turnover turnover cer research development rd expenditure million turnover high aer growth cer growth high cer basis reflect increase investment particularly total pharmaceutical increase cer operation pharmaceutical rd broadly split discovery activity completion phase iia trial core operating profit bn development work phase iib onwards support specific common infrastructure share service bn appropriate phase iv cost administrative expense report sga include table growth cer discovery aer growth cer growth development facility central support function total pharmaceutical vaccine rd use core result nonifrs measure consumer healthcare rd metric include total result cash flow generation research development manage performance group nonifrs measure significant factor drive total pharmaceutical rd consider addition substitute growth progression viiv healthcare hiv portfolio superior information present accordance ifrs include programme acquire bms early year definition core result set increase discovery drive progression early cost sale stage oncology portfolio early investment bioelectronic growth development growth primarily start new phase iii programme include hiv respiratory anaemia partly offset turnover turnover cer benefit rd cost reduction programme increase cost sale facility central support function cost partly reflect investment new datum warehouse analytic transform cost sale percentage turnover way datum harness rd reallocation percentage point sterling term percentage point central support cost cer term compare proforma basis cost sale percentage decrease percentage point compare royalty income percentage point cer term royalty income million million primarily reflect improved product mix particularly impact higher reflect increase royalty income gardasil sale hiv sale pharmaceutical vaccine consumer benefit catchup adjustment prioryear estimate healthcare increase contribution integration restructuring saving business partly offset core operating profit continue adverse pricing pressure pharmaceutical primarily core operating profit million actual rate respiratory continue investment supply chain high cer term turnover increase core operate margin percentage point sell general administration high percentage point high cer growth basis proforma basis core operating profit high turnover turnover cer cer term compare turnover growth core sell general administration operating margin percentage point high percentage point high cer term proforma sga cost turnover percentage point low basis reflect improve operating leverage drive sale growth percentage point low cer basis favourable mix business proforma basis sga percentage sale reduce delivery restructuring integration benefit tight control percentage point percentage point cer primarily ongoing cost partly offset continued price pressure particularly reflect tight control ongoing cost benefit respiratory supply chain rd investment pharmaceutical restructure programme integration benefit vaccine consumer healthcare partly offset investment promotional product support particularly new launch respiratory hiv vaccine consumer healthcare gsk annual report strategic report governance remuneration financial statement investor information core result continue contingent consideration cash payment shionogi net finance cost company reduce balance sheet liability record income statement total contingent finance income consideration cash payment amount million interest income million include cash payment viiv fair value movement healthcare shionogi relation contingent consideration liability include preferential dividend amount million million milestone payment finance expense million novartis interest expense core operating profit business unwind discount liability remeasurement fair value movement restate growth finance expense margin margin cer pharmaceutical net core finance expense million compare pharmaceutical rd million reflect translation effect exchange pharmaceutical rate movement report sterling cost foreign currency vaccine denominate interestbeare instrument consumer share tax profitslosse joint venture healthcare share profit associate joint venture million million loss corporate core profit taxation unallocated cost core operate profit growth pharmaceutical turnover turnover cer pharmaceutical operate profit million high core profit tax cer term turnover increase operate taxation margin percentage point high tax core profit amount million represent percentage point high cer basis proforma basis effective core tax rate increase operating margin increase percentage point cer effective rate primarily reflect group change earning mix basis reflect favourable product mix primarily drive taxation detail growth hiv sale cost reduction benefit pharmaceutical restructuring programme partly offset increase noncontrolle interest investment new product support increase investment rd allocation earning noncontrolle interest amount number new programme continue impact low price million million include noncontrolle particularly respiratory broad transition interest allocation consumer healthcare profit million respiratory portfolio million allocation viiv healthcare profit increase million million include vaccine impact change proportion preferential dividend vaccine operate profit million high shareholder base relative performance different cer term turnover increase operating product year allocation reflect impact profit margin percentage point high contribution group entity non percentage point high cer basis control interest primarily result net loss proforma basis operating margin improve percentage entity arise exchange point point cer term primarily drive improved product mix enhance operating leverage strong sale core earning share growth restructure integration benefit cost core eps p actual rate sale sga rd high royalty income partly cer term compare cer increase operating profit offset sga investment support business growth number primarily reflect increase tax rate compare inventory adjustment additional supply chain investment great contribution growth business significant noncontrolle interest consumer healthcare consumer healthcare operate profit million high cer term turnover increase operate margin percentage point high percentage point high cer basis proforma basis consumer healthcare operate margin percentage point high cer basis improvement gross margin reflect mix benefit power brand strategy well pricing strong contribution integration synergy benefit sga rd percentage sale gsk annual report group financial review continue proforma growth rate reconciliation follow table set reconciliation report cer growth rate proforma cer growth rate state item turnover adjustment include adjustment include adjustment exclude january february january february january february turnover turnover turnover report novartis novartis consumer gsk oncology proforma growth rate vaccine product healthcare product product growth rate turnover cer cer cer cer cer group turnover europe international pharmaceuticals pharmaceuticals europe pharmaceutical international pharmaceutical emerge market pharmaceutical japan pharmaceuticals vaccine vaccines europe vaccine international vaccine menveo vaccines consumer healthcare consumer healthcare europe consumer healthcare international consumer healthcare wellness oral health nutrition skin health follow table set reconciliation report cer growth rate proforma cer growth rate state core expense heading core operating profit adjustment include adjustment include adjustment exclude january february january february january february turnover turnover turnover report novartis vaccine novartis consumer gsk oncology proforma core expense growth rate product healthcare product product growth rate operating profit cer cer cer cer cer cost sale sell general administration research development royalty income core operate profit pharmaceutical operating profit pharmaceutical operating profit exclude rd pharmaceutical rd vaccine operate profit consumer healthcare operating profit gsk annual report strategic report governance remuneration financial statement investor information cash generation conversion summary consolidate cash flow statement set reconciliation net cash inflow operating activity free cash flow adjust free cash flow reconciliation net cash inflow operating activity net cash inflow operating activity close equivalent ifrs measure free cash flow show net cash outflowinflow investing activity net cash outflow financing activity decreaseincrease cash bank overdraft net cash inflow operating activity purchase property plant equipment cash bank overdraft begin year purchase intangible asset decreaseincrease cash bank overdraft proceed sale property plant equipment exchange adjustment interest pay cash bank overdraft end year interest receive cash bank overdraft end year dividend associate joint venture comprise distribution noncontrolle interest cash cash equivalent free cash flow overdraft legal payment adjust free cash flow adjust net cash inflow operating activity future cash flow net cash inflow operating activity year long term expect future cash generate million million increase primarily operation sufficient fund operate debt servicing reflect improved operating performance segment cost normal level capital expenditure obligation positive currency benefit exclude legal settlement exist licensing agreement expenditure arise restructuring million million adjust net cash inflow programme routine outflow include tax pension operating activity million million contribution dividend subject principal risk addition payment restructure integration cost uncertainty discuss page time million million tax payment time additional demand finance acquisition million million sale oncology include potentially acquire increase ownership portion business fund divestment viiv healthcare consumer healthcare business proceed minority shareholder hold option share repurchase total cash payment viiv healthcare shionogi access multiple source liquidity short longterm relation contingent consideration liability include preferential capital market financial institution addition cash flow dividend year million million operation need million million recognise cash investment appraisal flow operating activity million million formal process assess potential investment recognise invest cash flow proposal order ensure decision align overall free cash flow strategy process include assessment cash flow free cash flow cash generate business return individual investment cfroi net present meeting obligation interest tax dividend pay value npv internal rate return irr timeline noncontrolle interest capital expenditure property project long term consider impact eps plant equipment intangible asset credit profile relevant discount rate perform financial analysis decide internally allow determination extent investment free cash inflowoutflow cover cost capital specific investment discount rate adjust free cash flow adjust account country risk weighting free cash flow million year million work capital outflow exclude legal payment adjust free cash flow work capital programme continue progress million million make improvement collection receivables restructure integration payment additional tax payment inventory management sale oncology business purchase hiv clinical asset million treat intangible asset work capital percentage turnover purchase exclude item fund divestment proceed adjust free cash flow work capital conversion cycle day million million report work capital conversion cycle day capital expenditure financial investment distort temporary favourable impact day arise cash payment tangible intangible fix asset amount novartis transaction exclude impact conversion cycle million million disposal realise day result reduction day million million cash payment acquire equity compare predominantly beneficial investment million million sale impact exchange reduce receivables day improve equity investment realise million million collection reduce inventory day gsk annual report group financial review continue financial position resource property plant equipment business sciencebase technologyintensive highly asset regulate governmental authority allocate significant noncurrent asset financial resource renewal maintenance property plant equipment minimise risk interruption production property plant equipment ensure compliance regulatory standard number goodwill process use hazardous material intangible asset investment associate joint venture total cost property plant equipment december million net book value million investment land building represent million plant defer tax asset equipment million asset construction million noncurrent asset invest million new property plant total noncurrent asset equipment mainly relate large number project renewal improvement expansion facility current asset worldwide site property mainly hold freehold new investment inventory finance liquid resource december current tax recoverable contractual commitment future capital expenditure trade receivables million operating lease commitment million believe derivative financial instrument facility adequate current need liquid investment observe stringent procedure use specialist skill cash cash equivalent manage environmental risk activity environmental issue asset hold sale date operation modify discontinue total current asset report planet note financial statement legal proceeding total asset goodwill liability goodwill increase year million current liability december million increase primarily shortterm borrowing reflect impact exchange movement contingent consideration liability intangible asset trade payable intangible asset include cost intangible acquire derivative financial instrument party computer software net book value current tax payable intangible asset december million shortterm provision million increase reflect impact exchange movement development cost capitalise total current liability year million partly offset amortisation impairment noncurrent liability exist intangible million million respectively longterm borrowing investment associate joint venture defer tax liability hold investment associate joint venture carry pension postemployment benefit value december million million provision market value december million contingent consideration liability million large investment innoviva inc book value december million noncurrent liabilitie million market value december total noncurrent liability million note financial statement investment total liability associate joint venture net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity gsk annual report strategic report governance remuneration financial statement investor information financial position resource continue investment noncurrent liability hold investment carry value december noncurrent liabilitie million december million million decrease million include million carrying value year primarily sale million relate present value estimate payable group remain stake aspen pharmacare holding limit event exercise novartis right require book value december million acquire shareholding consumer healthcare joint significant investment hold december venture detail provide note key accounting theravance biopharma inc book value judgements estimate december million million contingent consideration liability investment include equity stake company contingent consideration liability amount million research collaboration provide access biotechnology december million million development potential interest interest company million represent estimate present value arise business divestment amount payable shionogi relate viiv healthcare derivative financial instrument asset million million represent estimate present current derivative financial instrument hold fair value value contingent consideration payable novartis relate million million majority vaccine acquisition liability shionogi include related foreign exchange contract designate million respect preferential dividend million designate accounting hedge recognise directly equity year liability preferential dividend pfizer december million inventory explanation accounting treatment interest viiv inventory million increase million healthcare set increase primarily reflect impact exchange movement net debt trade receivable trade receivables million increase million primarily reflect exchange movement cash cash equivalent liquid investment derivative financial instrument liabilitie borrowing repayable year hold current derivative financial instrument fair value borrowing repayable year million million primarily relate foreign net debt exchange contract designate designate accounting hedge december net debt billion compare trade payable billion december comprise gross debt trade payable amount million increase billion cash liquid investment billion million reflect pfizer option relate increase net debt primarily reflect billion adverse viiv healthcare recognise year increase accrual exchange impact translation nonsterle denominate customer return rebate impact exchange debt exchange financing item dividend pay movement shareholder billion include special dividend billion partly offset free cash flow billion provision asset disposal billion carry defer tax provision shortterm noncurrent provision million december december cash liquid investment hold million million million follow relate legal dispute million million relate major restructure programme provision legal dispute indemnify disposal bank balance deposit liability employee relate liability cost treasury treasury repo restructure programme extent balance sheet money market fund date legal constructive obligation exist liquidity fund reliably estimate government security pension postemployment benefit account pension postemployment arrangement accordance ias deficit net surplus cash liquid investment billion billion allow deferred taxation million hold centrally december million pension arrangement million million unfunded postemployment liability increase deficit predominantly drive low discount rate discount value liability increase uk inflation rate assumption strong dollar year end partly offset special funding contribution uk scheme significant uk asset gain gsk annual report group financial review continue financial position resource continue maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bond usd bond commercial paper bank borrowing lease analysis cash gross debt effect hedge total equity follow december total equity decrease million december million primarily reflect recognition transactionrelated adjustment million impact dividend pay increase cash liquid investment pension deficit million partly offset profit gross debt fix year favourable exchange translation impact weak float sterling rate noninterest bear summary movement equity set net debt movement net debt total equity beginning year total comprehensive income year dividend shareholder net debt begin year ordinary share issue decreaseincrease cash bank overdraft gain transfer net asset increase liquid investment consumer healthcare jv net increase inrepayment shortterm loan consumer healthcare jv option exchange movement loss transfer equity investment movement investment associate net debt end year change noncontrolle interest recognition liability noncontrolle interest derecognition liability noncontrolle interest share acquire esop trust sharebase incentive plan tax sharebase incentive plan distribution noncontrolle interest total equity end year gsk annual report strategic report governance remuneration financial statement investor information financial position resource continue share purchase enter number research collaboration develop employee share ownership plan esop trust new compound pharmaceutical company term acquire million share glaxosmithkline plc arrangement include upfront fee equity investment million share hold trust satisfy future exercise loan commitment fund specify level research option award group share option award addition agree payment future scheme proportion share hold trust milestone achieve respect award rule scheme require satisfy agreement relate compound early exercise market purchase issue new stage development potential obligation milestone share share hold trust match option payment continue number year compound award grant successfully development process generally close december esop trust hold million product marketing approval great probability million gsk share future exercise share option success amount show intangible asset share award carry value million represent maximum pay milestone million deduct reserve market achieve include billion relate externalise value share million million project discovery portfolio number new commitment licensing agreement offset share repurchase december amendment exist agreement hold million share treasury share million share cost million million reach agreement trustee uk deduct retain earning pension scheme additional contribution include eliminate pension deficit identify december ordinary share purchase period january actuarial funding valuation table include commitment march company expect exclude normal ongoing annual funding requirement ordinary share repurchase remainder uk approximately million information pension commitment contingent liability obligation note financial statement pension financial commitment summarise note financial postemployment benefit statement commitment contingent liability contingent liability obligation respect short longterm debt set follow table set contingent liability comprise note financial statement contingent liability discount bill performance guarantee letter credit note financial statement net debt item arise normal course business amount provide pension postretirement benefit expect expire set note financial statement pension postemployment benefit amount provide restructure total yr yrs yrs yrs programme legal environmental dispute set note financial statement provision guarantee contingent liability contractual obligation commitment total follow table set contractual obligation commitment december fall payment normal course business provide total yr yrs yrs yrs indemnification guarantee respect business disposal legal dispute subsequently arise provision loan outflow resource consider probable interest loan reliable estimate likely outcome dispute include note financial statement finance lease obligation provision finance lease charge operate lease provide outcome tax legal dispute outflow resource consider probable reliable estimate commitment outflow december intangible asset dispute provision possible property plant equipment reliable estimate potential outflow fund investment require settle dispute possibility purchase commitment outflow remote pension ultimate liability matter vary significantly commitment amount provide dependent outcome litigation total proceeding negotiation relevant tax authority commitments respect loan future interest payable loan discuss principal risk uncertainty page disclose take account effect derivative note financial statement taxation legal proceeding gsk annual report group financial review continue critical accounting policy consolidate financial statement prepare accordance reconciliation gross turnover net turnover ifrs adopt use european union pharmaceutical business include puerto rico follow ifrs issue iasb follow accounting policy approve board describe note financial restate restate statement accounting principle policy margin margin margin require estimate assumption affect gross turnover amount asset liability revenue expense report financial statement actual amount result differ market drive estimate segment critical accounting policy relate follow area government mandate turnover state program taxation note cash discount legal dispute note customer return prior year adjustment goodwill intangible asset impairment note item total deduction business combination note net turnover pension postemployment benefit note information judgement estimate area market drive segment consist primarily manage care give note financial statement key accounting medicare plan gsk negotiate contract pricing judgement estimate honour rebate chargeback mandate segment consist primarily medicaid federal government programme turnover receive government mandate pricing rebate respect turnover accounting policy large business chargeback pharmaceutical market complex arrangement rebate discount allowance follow increase deduction market drive segment briefly describe nature arrangement existence gross turnover net turnover reconciliation primarily reflect pharmaceutical business high rebate chargeback respiratory product advair particular advair account arrangement certain indirect customer pharmaceutical turnover approximately total customer able buy product wholesaler reduce deduction rebate return respiratory portfolio price chargeback represent difference account approximately total deduction invoice price wholesaler indirect customer year advair continue suffer pricing pressure contractual discount price accrual estimate chargeback business seek transition respiratory portfolio new calculate base term agreement historical product experience product growth rate balance sheet accrual rebate discount allowance customer rebate offer key manage care group return pharmaceutical vaccine business purchase organisation gpo direct indirect manage combined basis december customer arrangement require customer achieve total accrual amount million million certain performance target relate value product purchase formulary status predetermine market share monthly process operate monitor inventory level relative competitor accrual customer rebate wholesaler abnormal movement process use estimate base specific term agreement gross sale volume prescription volume base party historical experience product growth rate datum source information receive key wholesaler medicaid programme stateadministere programme aim maintain inventory consistent level year provide assistance certain poor vulnerable patient year base pattern consumption medicaid drug rebate program establish basis pharmaceutical vaccine inventory level reduce state federal expenditure prescription drug wholesaler distribution channel december patient protection affordable care act law estimate approximately week turnover participate provide rebate state accrual medicaid calculation use party information accuracy rebate calculate base specific term relevant totally verify believe sufficiently reliable regulation patient protection affordable care act purpose cash discount offer customer encourage prompt payment accrue time invoicing adjust subsequently reflect actual experience record accrual estimate sale return apply historical experience customer return amount invoice market relate information stock level wholesaler anticipate price increase competitor activity gsk annual report strategic report governance remuneration financial statement investor information critical accounting policy continue legal dispute like pharmaceutical company face respect accounting policy legal dispute complex product liability antitrust patent litigation follow briefly describe process determine investigation operation conduct governmental level provision necessary regulatory agency year general counsel group head group legal function senior accordance requirement ias provision vice president head global litigation group contingent liability contingent asset provide responsible litigation government investigation routinely anticipate settlement cost outflow resource brief chief executive officer chief financial officer consider probable reliable estimate board director significant litigation pende likely outcome dispute legal expense arise group governmental investigation group claim group involved significant legal proceeding respect possible meeting appropriate detail status significant litigation reliable estimate expect financial effect government investigation review matter number result ultimate resolution proceeding claim notify information potential claim notify case appropriate disclosure case include assessment validity claim progress settle claim annual report provision recent settlement level potential reimbursement insurer position change time meeting include assessment assurance loss result outcome legal sufficient information available able reliable proceeding exceed material estimate potential outcome dispute external provision report group financial statement counsel assist litigation matter investigation assist briefing board senior management follow discussion matter possible reliable estimate provision require level provision legal dispute review adjust appropriate matter discuss note financial statement legal proceeding treasury policy report sterling pay dividend sterling cash flow capital management role treasury monitor manage group external financial strategy implement group financial internal funding requirement financial risk support architecture support gsk strategic priority regularly strategic objective gsk operate global basis primarily review board manage capital structure subsidiary company manage capital ensure group appropriate mix debt equity subsidiary able operate go concern gsk longterm credit rating standard poor optimise return shareholder appropriate balance stable outlook moodys investor service moodys debt equity treasury activity govern policy negative outlook shortterm credit rating approve annually board director recently p standard poor moodys respectively july treasury management group tmg meeting chair chief financial officer take place monthly liquidity risk management basis review treasury activity member receive management policy borrow centrally order meet anticipate funding information relate activity requirement cash flow forecast funding requirement monitor tmg monthly basis strategy diversify treasury operation liquidity source range facility maintain broad objective treasury activity minimise posttax net access financial market cost financial operation reduce volatility order benefit earning cash flow use variety financial instrument day sweep cash number global subsidiary finance operation derivative financial instrument manage central treasury account liquidity management purpose market risk operation derivative principally interest rate risk management comprise interest rate swap foreign exchange forward contract objective minimise effective net interest cost swap swap borrowing liquid asset balance mix debt fix float interest rate time currency require group purpose manage exposure policy interest rate risk management limit financial risk change foreign exchange rate float interest payment prescribe percentage operate interest rate profit hold issue derivative speculative purpose gsk treasury policy specifically prohibit activity transaction financial instrument undertake manage risk arise underlie business activity gsk annual report group financial review continue treasury policy continue foreign exchange risk management borrowing denominate swap foreign currency foreign currency transaction exposure arise external trade match investment overseas group asset treat flow normally hedge foreign currency transaction hedge relevant asset forward contract major exposure arise internal trade flow selectively hedge currency reduce exposure group objective minimise exposure overseas operating investment overseas group asset tmg review subsidiary transaction risk match local currency income ratio borrowing asset major currency monthly local currency cost possible gsk internal trading counterparty risk management transaction match centrally manage intercompany set global counterparty limit bank payment term reduce foreign currency risk foreign currency investment counterpartie base longterm credit rating cash flow hedge selectively management moodys standard poor treasury usage limit treasury tmg include hedge foreign monitor daily corporate compliance officer cco exchange risk arise acquisition disposal asset operate independently treasury breach limit possible manage cash surplus borrowing report cfo immediately requirement subsidiary company centrally forward contract hedge future repayment originate cco monitor credit rating counterpartie currency change rating occur notifie treasury change investment level authority limit appropriate order reduce foreign currency translation exposure seek addition relationship bank credit rating review denominate borrowing currency principal asset regularly report present annually tmg approval cash flow primarily denominate dollar euro sterling borrowing swap currency require strategic report strategic report approve board director march sign behalf simon dingemans chief financial officer march gsk annual report strategic report governance remuneration financial statement investor information corporate governance section chairmans governance statement board corporate executive team leadership effectiveness nomination committee report accountability audit risk committee report relation shareholder engagement activity corporate responsibility committee report director report gsk annual report chairman governance statement dear shareholder sir andrews leadership gsk successfully develop marketleading position vaccine consumer please present corporate healthcare provide excellent governance report platform sustainable longterm growth board remain commit highest confident emma successfully standard corporate governance build strength integrity governance structure operate strengthen pharmaceutical business board group appointment ceo designate believe critical underpinning september run ability deliver strategy create assume role ceo april year report longterm value shareholder focus completely transition step take refresh ceo executive management spending time sir andrew succession share knowledge experience nonexecutive year report step take key introduction representation refresh nonexecutive representation deepening understand board address number plan business especially rd pharmaceutical board address retirement year board primary vaccine start meet number plan focus executive succession major shareholder listen review talent leadership strategy view gsk share strategic retirement year annual item board overview vision group later nomination committee discussion year detail induction plan board primary oversight sir andrew witty indicate set focus executive march intention retire change executive board early place representation board dr succession accelerate orderly ceo succession moncef slaoui chairman global vaccine transition plan process follow indicate intention retire describe report nomination board addition dr patrick committee page vallance president rd board unanimous support appoint board appointment emma walmsley like express gratitude previously lead gsk consumer healthcare sir andrew moncef dedication business new ceo feel service gsk year leadership skill history deliver professionalism support facilitate growth drive performance fresh orderly board succession process thinking ideal choice gsk annual report strategic report governance remuneration financial statement investor information review board governance finance committee reviewing seek ensure arrangement role finance committee board board guide commitment board keep function decide specific committee value compliance governance framework regular review long require responsibility local law regulation year follow reassign board audit operate gsk code conduct enhancement risk committee code draw number key policy lie foundations science committee board decide culture value commitment provide work guide establish science committee look chairman responsible leading way apply value science pipeline rd capital ensure effective board global operation allocation priority chair dr jesse actively encourage culture goodman designate scientific environment boardroom facilitate board feel important medical expert member debate nonexecutive lead example choose background life science director able provide constructive undertake annual training specialist commercial perspective challenge management please code obligation employee matter consideration advise believe board hard late version code time timing work engage appropriate update strengthen april implementation drive balance skill experience new available governance area follow consideration appointee bring fresh insight wwwgskcom perspective improve decision science innovation underpin uk corporate governance code make recent annual board evaluation business pharmaceutical compliance exercise carry company vaccine consumer healthcare please report secretary centre identify compliance requirement rd organisation continue deliver performance improvement evaluation financial reporting council uk significant innovation group outcome set corporate governance code uk code number decision potential new board evaluation undertaken copy uk code available medicine vaccine come independent external board review wwwfrcorguk follow page outline year committee help specialist independent approach corporate governance bring great focus board evaluation carry deliberation rd critical phase commend report important set company shareholder tone organisation board look increase promote valuesbase conduct scientific capability search behaviour people flow scientific medical expert boardroom artery establish committee step business approach philip hampton chairman march gsk annual report board board composition gender diversity board date publication april male male sir philip hampton sir andrew witty female female nonexecutive chairman chief executive officer executive n date publication april nationality nationality male male british british female female appoint appoint january deputy chairman january chief executive april nonexecutive officer sir nonexecutive chairman andrew retire board date publication april march skill experience male male prior join gsk sir philip skills experience chair major ftse company sir andrew join gsk female female include royal bank work uk south scotland group plc j sainsbury africa singapore plc serve group senior role tetneurne unroen enxeocnutievexecutive finance director lloyds tsb appoint president europe group bt group plc bg group join gsk corporate executive april plc british gas plc british team andrew serve year steel plc sir philip previously numerous advisory role appoint executive director government world year lazard nonexecutive include south africa singapore years director rmc group plc guangzhou china uk years belgacom sa member prime chairman uk financial minister business advisory group investment limited manage award uk government shareholding knighthood service c oucmpop tomos ipt ioyoenasristion bank e pc ho arn mom acy e un tid c ato l inth de u su tk ry year april external appointment new year honour list year sir philip currently senior year executive independent director anglo external appointment nonexecutive american plc chairman sir andrew uk business remuneration committee ambassador serve member audit committee chinabritain business council sir philip chair advisory council edb hamptonalexander review international advisory committee ftse woman leader singapore sir andrew independent review improve cochair uk eu life science einxetceurtniveational experience gender balance ftse leadership steering group advise uk ninotnerenxaectiuotnivael experience april government life science priority context uk leave eu visiting professor institute global health innovation imperial college london global europe emap chancellor university nottingham key committee chair n nomination audit risk r remuneration c corporate responsibility science gsk annual report strategic report governance remuneration financial statement investor information emma walmsley simon dingemans dr moncef slaoui dr patrick vallance ceo designate chief financial officer chairman global vaccines president rd nationality nationality nationality nationality british british moroccan belgian american british appoint appoint appoint appoint january chief executive january chief financial moncef retire january officer april officer april board march skill experience skill experience skill experience skill experience patrick join gsk emma join gsk prior join gsk simon moncef join gsk vaccine head drug discovery responsibility consumer year experience engineer subsequently appoint senior healthcare europe investment banking sg warburg development robust vaccine vice president medicine discovery subsequently appoint president goldman sachs simon advise pipeline lead worldwide development glaxosmithkline consumer gsk decade business development member gsk corporate healthcare member appointment closely pharmaceutical product executive team gsk corporate executive team involve number gsk appointment lead rd appoint president key strategic project give overall responsibility pharmaceutical rd january appoint ceo gsk consumer gsk oncology business patrick join gsk healthcare joint venture external appointment gsk vaccines board january gsk novartis emma join simon deputy chairman global franchise prior join gsk patrick gsk board january group finance directors moncef chairman board clinical academic professor formally succeed sir andrew chairman director galvani bioelectronic medicine lead division witty gsk ceo retire early company launch november medicine university college march gsk jointly own london year verily life science prior join gsk emma work experience research clinical loreal year moncef advise medicine general internal medicine hold variety marketing president council advisor cardiovascular medicine clinical general management role paris science technology pharmacology elect london new york member board agency academy medical sciences base shanghai science technology research general manager consumer astar january products loreal china emma phrma foundation board external appointment nonexecutive director advisory patrick nonexecutive director diageo plc january committee director genome research limited september hold national institutes health uk biobank classic modern language oxford university phd molecular biology external appointment immunology universit libre de bruxelle publish scientific paper presentation prior join gsk moncef professor immunology university mon belgium external appointment moncef member biotechnology industry organization board adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef serve nonexecutive director international aids vaccine initiative iavi member board artizan biosciences inc gsk annual report board continue manvinder singh vindi banga professor sir roy anderson dr vivienne cox lynn elsenhans senior independent independent nonexecutive independent nonexecutive independent nonexecutive nonexecutive director director scientific expert director director n r n c r c c n nationality nationality nationality nationality indian british british american appoint appoint appoint appoint september senior october july july independent nonexecutive director skill experience skill experience skill experience professor sir roy world vivienne wide experience lynn wealth experience skill experience renowned medical scientist business gain energy run global business prior join gsk vindi spend advanced knowledge infectious natural resource publish significant knowledge global year unilever plc disease epidemiology sector deep market gsk operate role senior currently professor infectious understanding regulatory serve chair president chief position president disease faculty medicine government relationship executive officer sunoco inc global food home personal imperial college london work bp plc year prior join care business fellow royal society britain continental europe sunoco president member unilever executive academy medical science post include executive vice chief executive officer lynn work board vindi sit prime royal statistical society president chief executive royal dutch shell minister indias council trade honorary fellow institute bps gas power renewable join hold industry actuary foreign associate business alternative energy number senior role include board governor member national academy unit vivienne previously executive vice president global indian institute management medicine national nonexecutive director bg manufacturing iim ahmedabad vindi academy sciences french group plc rio tinto plc recipient padma bhushan academy sciences professor sir vivienne appoint commander external appointment india high civilian roy bring scientific expertise order british empire lynn nonexecutive director honour board deliberation new year honour baker hughes inc flowserve vindi nonexecutive director service uk economy corporation director thomson reuters corp external appointments sustainability texas medical center member hr committee professor sir roy member nonexecutive director international advisory board external appointment tee great houston external appointment holdingham group vivienne senior independent trustee unite way vindi partner private equity member science advisory director pearson plc non great houston investment firm clayton dubilier board natural history executive director stena rice chairman museum london international chairman supervisory board mauser member vaccine international supervisory board vallourec group chairman kalle gmbh advisory board vacciab aj supplier energy industry senior independent director pharma holding sdn bhd lead independent mark spencer group plc malaysia international director uk government member nomination alzheimers consortium harvard department international remuneration committee vindi university boston chairman development governing board scientific advisory board indian school business isb sab netherlands centre hyderabad member health ncoh indo uk ceo forum key committee chair n nomination audit risk r remuneration c corporate responsibility science gsk annual report strategic report governance remuneration financial statement investor information dr jesse goodman judy lewent urs rohner independent nonexecutive independent nonexecutive independent nonexecutive director scientific expert director director c n r r n nationality nationality nationality board member american american swiss sir deryck maughan senior independent non appoint appoint appoint executive director member january april january nominations audit risk remuneration committee skill experience skill experience skill experience retirement dr goodman previously serve judy extensive knowledge ur broad range business board senior leadership position global pharmaceutical industry legal experience serve food drug administration corporate finance join chairman number board dr stephanie burn fda include recently merck co serve recently credit suisse independent nonexecutive fda chief scientist previously chief financial officer worldleade financial service director member deputy commissioner retire judy company prior join credit remuneration corporate science public health previously nonexecutive director suisse urs serve responsibility committee director center biologics purdue pharma inc napp chairman executive board retirement board evaluation research cber pharmaceutical holding limit ceo prosieben dr goodman play leadership certain mundipharma prosiebensat media ag dr daniel podolsky role develop fda international limited company follow number year private independent nonexecutive regulatory science medical december judy practice major law firm director member countermeasure initiative previously serve non switzerland audit risk corporate work collaboratively industry executive director dell inc admit bar canton responsibility committee academia government global quaker oats company zurich state new retirement board public health regulatory partner motorola inc york prepare respond major board determine external appointment han wijer public health threat include judy recent relevant urs currently chairman independent nonexecutive emerge infectious disease financial experience agree board credit suisse group director member disaster terrorism lead appropriate ag chairmans remuneration corporate fda response west nile virus qualification background governance committee responsibility committee hn influenza audit committee financial expert chairman member retirement board pandemic serve senior board trustee credit suisse leadership team white external appointment house medical countermeasure judy nonexecutive director research institute credit suisse stacey cartwright foundation urs appoint review dr goodman bring thermo fisher scientific inc independent nonexecutive vicechairman govern scientific public health expertise motorola solutions inc director member board swiss banker board deliberation trustee rockefeller family audit risk committee association trust chairperson audit retirement board external appointment committee rockefeller financial december dr goodman currently professor service life member medicine georgetown university massachusetts institute directs georgetown university technology corporation center medical product access member american academy safety stewardship art science compass active clinician serve attend physician infectious disease serve president member board united states pharmacopeia usp member scientific advisory board sab coalition epidemic preparedness innovation cepi gsk annual report corporate executive team david redfern claire thomas chief strategy officer senior vice president human resource david join cet chief strategy officer claire appoint cet senior vice responsible corporate president human resource development strategic planning claire join company senior appoint chairman board manager human resource sale viiv healthcare ltd april marketing group uk pharmaceuticals nonexecutive director aspen director human resource pharmacare ltd uk pharmaceutical appoint previously senior vice president senior vice president human resources northern europe responsibility gsk pharmaceutical europe senior vice pharmaceutical business region president human resource pharmaceutical prior senior vice president international central eastern europe david join prior gsk work ford motor gsk company hold position human david bachelor science degree resource bristol university uk claire bachelor science degree charter accountant economic management industrial relation university wale sir andrew witty chief executive officer emma walmsley ceo designate simon dingemans abbas hussain dan troy chief financial officer president global pharmaceuticals senior vice president general counsel patrick vallance president rd abbas join cet appoint dan joined gsk cet senior vice president global pharmaceuticals president general counsel biographical detail page join company president emerge previously partner washington markets asia pacific join law firm sidley austin llp principally viiv healthcare ltd board october represent pharmaceutical company trade previously spend year eli lilly association matter relate food hold position include president europe drug administration fda government work eli lilly australia regulations dan chief counsel india turkey germany role fda include business development sale dan hold bs industrial labor relation marketing management cornell university jd columbia degree medicinal chemistry university school law chair pharmacology loughborough university chamber commerce litigation center bear madras india january gsk announce abbas decision leave company late year gsk annual report strategic report governance remuneration financial statement investor information phil thomson roger connor nick hiron senior vice president communications president global manufacturing senior vice president global ethic government affair supply compliance phil join cet appoint roger join cet appoint nick appoint cet senior senior vice president communications president global manufacturing supply gms vice president global ethic compliance government affair responsibility working year president responsible compliance risk management medium relation investor relation corporate designate gms roger join gsk corporate security investigation responsibility internal communication product astrazeneca work number nick join gsk international communication government affair gsk finance manufacturing strategy role auditor later head audit assurance global brand community partnership prior current position vice combine audit function president office ceo corporate joined company commercial trainee independent team common riskbase strategy february move pharmaceutical brand methodology nick relocate china marketing product communication hold degree mechanical establish governance model china director medium relation manufacturing engineering queen business create consistent approach director investor relation university belfast masters compliance return corporate medium manufacturing leadership cambridge nick fellow chartered institute relations vice president university charter accountant management accountant july coopte member chinabritain business council phil earn degree english history durham university luc debruyne brian mcnamara president global vaccines ceo gsk consumer healthcare luc join cet president global brian join cet appoint information vaccine role hold join ceo gsk consumer healthcare brian join year dr moncef slaoui gsk work commercial gsk march head europe member cet stand strategy director rd lead america gsk consumer healthcare december european commercial centre excellence follow creation joint venture luc general manager gsk novartis previously head january luke miel appoint netherlands senior vice novartiss otc division brian begin career president global pharmaceutical start president general manager italy procter gamble board member date gsk confirm appoint senior vice president pharma world selfmedication industry association europe prior current role luc member earn undergraduate degree electrical international federation pharmaceutical engineering union college new york manufacturers association ifpma vaccine mba finance university ceo roundtable management cincinnati committee belgian federation enterprise hold master degree physical education university leuven gsk annual report corporate governance continue leadership effectiveness corporate governance framework board coherent corporate governance framework clearly define responsibility accountability framework design safeguard enhance longterm shareholder value provide robust platform realise group strategy grow deliver simplify internal control risk management arrangement describe page integral gsk governance framework board operate effectively consideration key matter board committee establish set board chief audit risk remuneration nomination corporate science executive committee committee committee responsibility committee officer committee read read read read read corporate executive team wwwgskcom wwwgskcom wwwgskcom wwwgskcom wwwgskcom term reference term reference term reference term reference term reference board committee meeting attendance board audit risk remuneration nomination corporate responsibility maximum maximum maximum maximum maximum member attend possible attend possible attend possible attend possible attend possible sir philip hampton sir andrew witty simon dingemans dr moncef slaoui professor sir roy anderson vindi banga dr vivienne cox appoint july lynn elsenhans dr jesse goodman judy lewent urs rohner stacey cartwright retire december dr stephanie burn retire sir deryck maughan retire dr daniel podolsky retire han wijer retire etail regular attendee committee meeting chairman ceo executive director set report committee report include later corporate governance report gsk annual report strategic report governance remuneration financial statement investor information board programme area focus strategic priority link strategy board oversight execution strategy include report principal business rd gms organisation discussion approval strategic combination verily life science develop bioelectronic medicine result galvani joint venture hold joint board cet strategy day discuss evolution strategy external landscape change competitor advantage governance arrangement report pension insurance tax treasury strategy review rd pipeline new product review viiv healthcare joint venture performance year board regularly discuss report ceo head principal business rd gms organisation group financial performance annual budget forward look year plan progress finance transformation programme enhance process service capability brexit impact plan governance board undertake follow corporate governance duty receive report board committee approve annual report agm preparation consider observation action internal evaluation board performance receive report corporate governance regulatory development train corporate integrity agreement cia new market abuse regulation mar update code conduct approve appointment new ceo director approve appointment new auditor effect talent succession head hr briefed board talent leadership development strategy strategy key grow deliver simplify gsk annual report corporate governance continue leadership effectiveness continue key board role responsibilitie strong leadership ndependent oversight rigorous challenge chairman philip hampton nonexecutive director lead manage business board provide strong independent element board provide direction focus constructively support challenge management ensure clear structure effective operation board scrutinise performance meeting agree deliverable committee shape proposal strategy management set board agenda ensure sufficient time allocate letter appointment set term promote effective debate support sound decision make condition directorship ensure board receive precise timely clear devote time necessary proper performance information duty meet nonexecutive director annual basis expect attend board meeting additional discuss individual contribution performance meeting require training development need independence statement share peer feedback provide board evaluation process board consider nonexecutive director meet nonexecutive director independently identify page include professor sir roy anderson executive director tenure year demonstrate appropriate lead discussion shareholder degree independence character judgement responsible group performance free business relationship materially satisfied financial reporting council uk corporate interfere exercise judgement independence governance code independence test appointment commitment nonexecutive director serve board year subject rigorous chairman role description available wwwgskcom review chief executive officer senior independent nonexecutive director sir andrew witty vindi banga responsible management business act sound board chairman trust develop group strategic direction consideration intermediary director approval board lead review annually chairman performance implement agree strategy canvassing view nonexecutive director collectively support member corporate executive team discuss result chairmans effectiveness review chief executive officer role description chairman available wwwgskcom lead search appointment process recommendation board new chairman act additional point contact shareholder maintain understand issue concern major shareholder briefing investor relation team company secretary senior independent nonexecutive director role description available wwwgskcom timely support advice company secretary act secretary board board committee victoria whyte supports board committee chairman annual agenda plan set ensure information available board member timely fashion facilitates flow information board committee nonexecutive director management support chairman designing deliver board induction coordinate ongoing business awareness training requirement nonexecutive director undertake internal board committee evaluation request chairman advise director board practice procedure corporate governance matter chair group disclosure committee act point contact shareholder corporate governance gsk annual report strategic report governance remuneration financial statement investor information board induction company secretary assist chairman individually new director receive general induction personalise designing facilitate induction programme new director induction devise individually tailor new design purpose orientate familiarise director background education experience role new director industry organisation governance strategy grow deliver simplify year emma walmsley ceo designate dr jesse goodman new usbased science medical expert dr vivienne cox highly experienced ukbased nonexecutive director appoint board general board induction executive nonexecutive director emma walmsley dr jesse goodman director dutie role executive dr vivienne cox responsibility director gsk corporate role nonexecutive build relationship governance structure director chairman gsk corporate integrity gsk strategy board agreement cia training competitor fill capability gap gsk code conduct external environment training meet cet member gsk financial structure customise executive director induction customise nonexecutive director induction emma walmsley dr jesse goodman dr vivienne cox ceo designate scientific medical expert maximise handover opportunity ceo rd vaccine brief business continue build knowledge business external deep dive commercial model environment site visit ware site visit ware engage broadly business externally stevenage wavre stevenage wavre listen mode corporate responsibility remuneration define leadership brand ceo committee induction corporate responsibility committee induction finalise strategy narrative financial plan define cultureway work cet wide gsk group legal responsibility duty ceo board business awareness training chairman meet director annually onetoone ensure nonexecutive director develop maintain basis discuss ongoing training development great insight understanding business invite requirement board keep uptodate legal regulatory attend internal management meeting include meeting governance matter regular paper briefing cet research advisory board research development company secretary presentation internal management team rdmt portfolio discovery investment external adviser board global pharma operation committee board member undertake specific refresher commercial leadership team risk oversight training gsk cia new mar regulations compliance council rocc meet employee agree undertake training gsk code conduct informally visit group operation reception hold board meeting gsk annual report corporate governance continue leadership effectiveness continue internal evaluation board internally facilitate company secretary draw company secretary response chairman request information gathering stage evaluation prepare online survey process discuss comprise small number chairman focus question phase phase phase phase preparation interview review outcomes company secretary company secretary followup facetoface prepare board paper telephone interview january meeting board member discuss form basis response invite discussion board member provide learn pointssuccesse clarification area focus board insight perspective identify set performance board success area focus ceo succession process create opportunity deep strategic comprehensive reflective informative process discussion particularly evolution conclude successfully schedule pharmaceutical industry competitive landscape therapy area gsk culture performance work increase board visibility understand pipeline rd organisation identify way improve board appreciate decision make creation establishment science increase board oversight science committee enhance board innovation collaboration new science committee oversight group rd consider datum new system new board member settle quickly contribute great understanding help immediate positive contribution follow evolve business strategy comprehensive inductions board successfully create increase opportunity strategic debate gsk annual report strategic report governance remuneration financial statement investor information board performance action point progress conclusion board evaluation review internally facilitate company secretary set action point progressachievement strategy assist new director additional background briefing material additional material provide ahead debate strategy company board portal arrange regular discussion medium long term strategy board agenda compile include fresh insight different perspective opportunity consider strategy different perspective implement suggestion enhance effectiveness board provide positive feedback annual board cet strategy meeting meeting hold newly acquire siena site executive increase focus executive succession plan ensure board position operate succession effectiveness disaster recovery plan executive succession plan result ned refreshment appointment board cet describe detail report nomination committee page consider alternative suggestion nonexecutive director refreshment new approach identify potential scientific medical expert utilise support external recruitment expert deep dive consider deep dive particularly board meet programme adjust site visit rd strategy pipeline product launch price joint venture consider matter year new business model gms consider hold site visit operational site year joint board cet strategy meeting september hold siena italy manufacturing rd facility acquire result novartis transaction board opportunity meet employee able learn firsthand facility people process integrate wide group shareholder review look enhance company communicate year board audit risk shareholder committee continue enhance quarterly reporting assist shareholder understand company performance standing board material continue drive boardcommittee material concise logistic effective highlight issue concern chairman committee chairman aim presentation time time discussion company secretary focus issue debate meeting preparation chair meeting allow social time board member know well give number new board member gsk annual report corporate governance continue leadership effectiveness continue nomination committee report dear shareholder philip hampton busy year committee nomination committee ceo sir andrew witty indicate march intention chairman retire board early nearly year ceo year gsk principal focus ceo succession process relate executive management succession planning ceo executive management succession committee year annually scrutinise robustness succession planning arrangement executive role director executive management role annual review committee review recommend board talent leadership strategy key regular item structure size composition board board committee discussion oversight overall aim appointment director members board process board committee seek assurance committee cet continuous adequate supply highquality internal succession board cet candidate potentially step board cet require membership committee engage egon zehnder korn ferry committee member committee member specialise recruitment high calibre board director philip hampton january firm ensure review process truly global chairman company inaccessible professor sir roy anderson october committee participation nonexecutive vindi banga january director spend time consider future strategic direction lynn elsenhans january company input executive recruitment firm judy lewent compile ceo role profile profile contain brief urs rohner january requirement desire skillset potential successor sir deryck maughan july sir andrew need brief draft emphasise importance board committee placed ceo etail committee member skills experience great business leader team builder give biography board page executive recruitment firm initiate global search committee member attendance agree profile large global pharmaceutical level healthcare company yield pool internal external company secretary secretary committee candidate reduce shortlist potential candidate attend meeting attendees committee meeting firm report regularly committee process include progress regular attend shortlist internal external candidate meet key attendee attendee require board member subject interview continuous chief executive officer assessment review extend period non head human resource executive director meet shortlist candidate appropriate external adviser culminate onetoone discussion nonexecutive director seek view candidate please nonexecutive director clear consider right candidate succeed sir andrew emma walmsley ceo gsk consumer healthcare division committee meet agree proposal board recommend emmas appointment ceo designate recommendation receive unanimous board approval september announce emma join board executive director effect january ceo effect april gsk annual report strategic report governance remuneration financial statement investor information nomination committee report continued committee wellpositione appoint emmas successor new nonexecutive director appointment brian mcnamara head americas europe gsk addition search new executive consumer healthcare succeed end september director usbase sme committee search brian cet member immediate effect join nonexecutive director egon zehnder engage gsk march completion novartis transaction conduct search broad selection criterion dossier potential nonexecutive appointee consider october emma focus attention completely committee candidate shortlist interview merit transition role gsk ceo detail assess relevant qualification time commitment transition induction arrangement find interview select candidate committee pleased year committee conduct search recommend board dr vivienne cox nonexecutive appointment process new executive director dr moncef director appoint board effect july slaoui chairman global vaccine indicate june board consider year international intention retire company year business experience global manufacturing organisation board year gsk moncef step challenge technology bring fresh insight board board march retire company deliberation june board appointment retirement committee recommend dr patrick vallances appointment ongoing refreshment board lead follow board december board approve patrick plan change appointment join board executive director january director appointment date retirement date dr jesse goodman january addition luc debruyne president global vaccine appoint cet member september dr vivienne cox july anticipation dr slaouis retirement cet december emma walmsley january dr patrick vallance january stephanie burn luke miel appoint president global pharmaceuticals join gsk cet later year astrazeneca sir deryck maughan executive vice president european business dr daniel podolsky han wijer abbas hussain president global pharmaceuticals decide leave company serve year cet stacey cartwright december agree leave gsk late year sir andrew witty march dr moncef slaoui march enhancing board scientific capability board scientific capability recently refresh egon zehnder korn ferry provide recruitment consultancy appointment dr jesse goodman chief scientist services committee addition recruitment hr fda appoint board january service provide company succeed dr daniel podolsky retire plan year service agm designate usbased scientific medical expert sme committee currently seek enhance board science capability engage korn ferry conduct global search nonexecutive director sme addition new wholly independent board committee science committee establish december provide oversight gsk rd pipeline scientific research strategy committee recommend board science committee chair dr jesse goodman nonexecutive director appoint science committee include ukbased sme professor sir roy anderson judy lewent sme currently recruit appoint science committee light new board committee ensure effective continuity professor sir roy anderson join board agree stand reelection shareholder stepping board agm board confirm professor sir roy continue demonstrate characteristic independence carry role board gsk annual report corporate governance continue leadership effectiveness continue nomination committee report continued board committee chairman membership change year committee approve follow change membership board committee director committee membership appointment date retirement date vindi banga nomination audit risk remuneration january committees member professor sir roy anderson dr jesse goodman corporate responsibility committee member dr vivienne cox corporate responsibility committee member july dr jesse goodman science committee chairman january professor sir roy anderson judy lewent science committee member january dr vivienne cox remuneration committee member january urs rohner nominations committee member january stephanie burn remuneration corporate responsibility committee member sir deryck maughan nomination audit risk remuneration committee member dr daniel podolsky remuneration corporate responsibility committee member han wijer remuneration corporate responsibility committee member stacey cartwright audit risk committee member december board composition diversity representation woman management position gsk committee seek balance composition board illustrate gender diversity gsk global committee refresh progressively time workforce alongside initiative promote diversity inclusion draw experience long serve director organisation support engagement benefit new external perspective insight executive search firm egon zehnder korn ferry recent appointee bring board deliberation sign voluntary code conduct gender diversity good practice nonexecutive director draw wide range industry background include pharmaceutical rd vaccine note recommendation set parker consumer product healthcare medical research academia review committee report publish financial service wealth experience complex november ftse board organisation global reach majority board director colour adjust diversity policy scientific mathematical background attune industry accordingly reflect new target operate committee evaluation commit diversity boardroom gsk committees annual evaluation internally facilitate committed equal opportunity employee level company secretary behalf committee chairman organisation board management seek encourage supplement questionnaire circulate committee member diverse inclusive culture gsk conclude committee continue operate effectively key requirement effective board comprise range balance skill experience knowledge gender agreed committee seek identify independence individual prepare challenge experience scientific medical expert additional work team need back diversity consideration give ongoing basis performance personal attribute include character intellect sound judgement succession plan cet talent gsk honesty courage performance culture committee continue plan nonexecutive director retirement base evolution committee responsible develop measurable objective group strategy support implementation board diversity policy include gender monitor progress achievement objective diversity policy line lord davy new voluntary target female board level representation currently woman philip hampton board corporate executive team closing nomination committee chairman gap board cet gender representation march increase pipeline female direct report cet particular area attention female pipeline development central theme review dame alexander ftse continue develop valuable work lord davy initiate gsk annual report strategic report governance remuneration financial statement accountability investor information audit risk committee report dear shareholder judy lewent follow page report aim share insight audit risk committee activity undertake oversee audit risk committee chairman committee year committee work largely recur structured programme activity devise programme company secretary agree content management external auditor start year adapt appropriate year progress run conclude successful tender external audit contract significant undertaking committee support role management year exercise committee review responsible committee scrutiny enhancement simplification financial internal reporting process internal control risk management financial reporting integrity financial statement include system process cover annual report quarterly result announcement external auditor system internal control conclusion audit tender year advise shareholder identification management risk external committee put external audit contract internal audit process competitive tender process committee initiate july initiate audit tender selection appointment process conclude december board external auditor remuneration oversight appoint committee prefer choice deloitte llp work deloitte company new auditor current external membership auditor pricewaterhousecooper llp pwc invite committee member committee member participate tender prevail rule audit firm judy lewent april rotation continue office subject chairman reappointment shareholder agm retire vindi banga january complete audit lynn elsenhans january gsk financial year onwards deloitte appoint stacey cartwright april december pwcs place subject shareholder approval wish thank sir deryck maughan january firm participate tender professionalism commitment demonstrate process dr daniel podolsky january report key step governance arrangement output etail committee member financial accounting audit tender process give committee scientific experience expertise give judgement deloitte well place succeed pwc biography board page deliver high quality audit gsk committee member attendance level committee currently oversee transition pwc company secretary secretary committee deloitte ensure attend meeting entire board invite attend pwc continue discharge auditing responsibility effectively committee meeting attendee include end time office regular attend deloitte take necessary step ensure independent attendee attendee require gsk time begin observe pwc appropriate general counsel juncture financial controller look forward report shareholder discharge head audit assurance activity associate transition gsk annual head global ethic compliance report chief medical officer chief product quality officer external auditor accordance frc code board determine judy lewent recent relevant financial experience board agree judy lewent appropriate qualification background audit committee financial expert define sarbane oxley act determine independent mean securities exchange act amend addition judy lewent vindi banga member remuneration committee allow provide input committee review group performance oversight risk factor relevant remuneration matter gsk annual report corporate governance continue accountability continue audit risk committee report continue financial reporting council audit quality review sec settlement gsk enter settlement committee confidence external auditor delivery securities exchange commission sec relation high quality effective audit gsk reinforce inquiry past sale marketing practice china outcome frc audit quality review team aqr review settlement company obligation provide sec pwcs audit gsk financial statement gsk audit information framework evolution ongoing abac select aqrs annual inspection audit programme monitoring purpose committee review quality large audit firm uk committee discuss consider update provide sec agree result outcome review aqrs finding settlement corroborate result committee independent infoprotect reflect fast evolve landscape potential evaluation pwc conclude external auditor impact key enterprise risk multiyear infoprotect effective committee receive report pwc detail programme refresh heighten attention audit address small number finding identify pay area business high risk aqr team satisfy pwcs plan response exposure improvement prioritise delivery achieve competition market authority compliance statement great risk reduction improve maturity information committee consider company security privacy process chief information security comply mandatory audit process audit committee officer ciso cfo boardlevel responsibility responsibility provision competition market authority enterprise risk continue ensure cyber security defence statutory audit service order report describe work remain strong effective cfo ciso brief committee committee discharge responsibility regularly development preapproval nonaudit services committee review enhance governance report committee risk discuss adapt company approach exist nonaudit oversight compliance council rocc receive internal control service policy comply new requirement set frc risk management report year base revise ethical standard implementation eu audit respective governance responsibility wide regulation gsk financial year particular agree organisational internal risk governance framework efficiency change nonaudit service preapproval process line quality upward reporting mechanism crucial assist new restriction auditor supply nonaudit service uk committee properly monitor gsk internal framework list company change outline control risk management global risk office implement follow committee rocc report internal framework control risk management improvement business unit risk enterprise development exposure core discipline committee follow development business unit enterprise committee reporting schedule improve risk area communication report training analytic help management report business unit present strengthen culture compliance risk management rocc submit committee mean committee feedback properly incorporate anti bribery corruption abac party oversight management deliberation rocc addition business tpo programme high priority committee unit provide monthly update rocc concentrate oversee follow area progress year progress risk management commitment abac global risk assessment new programme simplification helped foster focus discussion launch significantly enhance way abac risk rocc business unit risk management priority identify prioritise group exist abac help committee improve understand enterprise datum centrally pool global risk office help risk strategy gsk enterprise risk owner encourage abac risk exposure measure enable provide commentary organisation risk tolerance respect management target risk mitigation technique company specific risk responsible mitigating addition high risk activity business unit region development risk performance dashboard abac tpo programme provide standard framework product quality research practice enhance govern party relationship move design committee ability understand monitor risk exposure deployment phase supplier assessment programme level ongoing basis operate large majority latin america south east compliance activity asia market apply range party build trust embed value global ethic particular assess supplier deem gsk high compliance gec function continue embe live risk risk level corrective preventative action track value build trust strategy help motivate employee manage easytouse reporting system company core value heart decision employee enrol programme particular gec deploy enterprisewide training employee tpo programme expect cover coincide release april gsk update code global operation ensure continue risk management conduct heart compliance programme improvement respect party relationship focuses gsk core value patient focus integrity embed basic tpo capability supplier lifecycle respect people transparency management software introduce buy experience simplification gsk annual report strategic report governance remuneration financial statement investor information audit risk committee report continue addition deliver training employee global reporting system platform enterprise gec introduce follow training tool committee please oversee significant progress specifically aim team leader help reinforce value base move standardise global system conduct team support endtoend process management continue deploy upgrade plan major system deployment leader lead discussion toolkit launch enable complete half schedule budget leader team meaningful discussion remain deployment multiyear programme importance gsk value right time culture complete early increase discussion informal short length provide opportunity focus capture benefit new standardised system explore gsk value leader team think process generate gsk quality mean company business toolkit use combination external event research role academic study good employee finally role chair committee continue busy poor decision varied year significant interaction key senior executive auditor attend range management value maturity assessment leadership team self meeting include rocc consumer healthcare assessment tool allow team assess value finance gec global manufacturing supply leadership team embed business establishe value lead audit tender process meet bidding firm audit improvement plan base outcome assessment partner team familiarise quality value maturity assessment vma capability gain impression like undertaken gec gsk business unit line work value objective set corporate executive team vma roll continue business unit board colleague please visit manufacturing rd facility siena italy gm certifications general manager gm confirmation process acquire novartis transaction meet local pharmaceutical vaccine continue senior executive employee able learn firsthand require gms confirm adherence gsk internal facility people process integrate control framework revise confirmation process launch wide group please learn gsk internal september focus specific risk area include control risk management practice translate tpo health care professional government official interaction embed business embed abac risk associate pricing commercial term consumer healthcare implement personal note like acknowledge sir andrew similar process gms confirm operation internal contribution company visionary leader drive control framework key risk minimum control gsk value term ceo lead positive change establish industry way work like wish corporate integrity agreement committee oversight endeavour look forward work company responsibilitie corporate integrity successor emma walmsley succeed ceo agreement cia sign department health april human services final year commitment certain state salesforce compensation extend committee continue receive quarterly cia compliance assurance update head gec review recommend board adoption judy lewent annual resolution confirm adherence term audit risk committee chairman cia inclusion certification report company provide march appropriate regulatory authority year give success gm confirmation cia certification process far cia end committee keen retain good practice compliance discipline cia result assess gec proposal rollout tailor business unit confirmation combine principle process propose simplification design provide committee consolidated assurance internal control framework requirement identify understand possible gap identify address business unit gsk annual report corporate governance continue accountability continue committee area committee focus item discuss frequency financial reporting review integrity draft financial statement appropriateness accounting policy go concern assumption consider approval process confirm recommend annual report fair balance understandable review recommend approval annual report form f review approve director expense review recommend approval quarterly preliminary result announcement dividend q review significant issue relation quarterly preliminary result q consider evolve market practice viability statement requirement review recommend inclusion viability statement annual report p review accounting development impact key accounting issue p review gaap vs nongaap report p global internal control review global pharmaceutical vaccine rd gms consumer healthcare business unit assurance compliance report review gsk internal control framework confirm compliance sarbanesoxley act review audit assurance work approve plan work undertake corporate integrity agreement cia training undertake new market abuse regulation training receive renew cia compliance assurance report q review report operational excellence programme q review implementation new system group support function p receive litigation report update receive abac investigation status report external auditor review approve auditnonaudit expenditure incur consider auditor report annual result perform evidencebase assessment external auditor effectiveness external audit consider qualification expertise independence external auditor recommend reappointment external auditor committee agree auditor remuneration approve audit plan audit fee proposal set performance expectation auditor consider initial result audit p review agree preapproval budget auditor provide nonaudit service q undertake competitive audit tender process recommend board audit firm include preferred firm appoint audit financial statement risk review risk management framework compliance review risk element group treasury pension risk insurance tax policy receive status report follow enterprise risk abac commercialisation crisis continuity ehss p information protection management financial control report product quality research practice receive update integration follow novartis transaction p receive terrorism risk assessment report p receive update brexit implication p receive risk oversight compliance council meeting update consider emerge risk governance confirm compliance uk corporate governance code matter discuss evaluation exercise committee agree action plan improve operation committee review committee term reference meet privately separately head global ethic compliance audit assurance confirm committee term reference adhere receive corporate governance update p review approve approach modern slavery act p meet privately external auditor end meeting committee activity key annually q quarterly p periodically stand gsk annual report strategic report governance remuneration financial statement investor information significant issue relate financial statement consider quarterly financial result announcement financial result contain annual report committee review significant issue judgement management determine result committee review paper prepare management set key area risk action undertake quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider relation financial statement year end december set follow table summary financial outcome appropriate addition committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly review current forecast net financial statement debt position financing facility option available group follow review risk potential impact unforeseen event committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition revenue accrual rebate rar accrual customer return rebate pharmaceutical vaccine accrual return rebate billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter include committee receive detailed report actual potential litigation internal external investigation group legal counsel number detail update investigation group commercial commercial practice practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion set note financial statement provision provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december group balance sheet include tax payable liability billion impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement follow improve sale relation viiv healthcare performance tivicay triumeq significant weakening sterling year necessary increase liability pay contingent consideration acquisition shionogiviiv healthcare joint venture december group balance sheet include contingent consideration liability billion relation viiv healthcare note financial statement contingent consideration liability detail consumer healthcare option committee consider management judgement valuation liability recognise respect novartis option shareholde consumer healthcare joint venture include review unwind impact discount liability increase liability cause significant weakening sterling year viiv healthcare option committee consider amendment viiv healthcare shareholder agreement year result recognition option hold shionogi pfizer q subsequent derecognition shionogi option q committee review agree accounting option concur management judgement valuation pfizer option million december gsk annual report corporate governance continue accountability continue audit tender pwc auditor company group detailed market assessment number audit firm inception performance review include firm outside big approach annually audit partner rotation requirement observe participate process judy lewent final pre selection audit lead partner request proposal indicate year annual report gsk decide undertake data room issue open bidding firm july external audit tender view replace pwc site meeting take place gsk house day financial year onwards good interest september opportunity finance shareholder comply audit firm rotation requirement functional leader meet bidding firm team facetoface robust governance structure implement head meeting judy lewent oversaw esc audit risk committee arc manage support deliver colleague mean discuss gsk audit requirement successful audit tender process firm help develop proposal evaluate judy lewent chair executive steering committee esc technical knowledge strength weakness feel overseen audit tender process evaluate audit firm like work feedback gsk liaise arc member esc cfo participant discuss committee shared group financial controller company secretary group audit partner prior submission audit tender proposal financial controller chair operation steering committee october finance head coordinate audit bidding firm proposal subject detailed evaluation tender process crossfunctional planning team provide key area probe identify discussion audit daytoday support advice level governance partner team oral presentation committee purpose illustrate year annual report gsk attendee take place november key objective arc deliver fair transparent information evaluation stage process site meeting successful audit contract tender process minimum disruption write proposal submission oral presentation share business endorse weight selection criterion discuss arc conclusion process evaluation methodology base gsk expectation enable arc recommend board appointment external auditor equally divide audit quality deloitte prefer new auditor shortlist bidding service audit team capability competence firm recommendation board subsequently endorse addition critical success factor prioritise guide gsk enter transition phase process lead committee board make final recommendation deloitte take external audit contract effect decision comprise january update activity disclose audit approach strategy annual report high quality independent audit effective partnership risk transition auditor value money external audit tender process governance oversight key step pretender evaluation decision make key step invitation rfp issue site write oral arc board participate datum meeting proposal presentation recommendation decision interview lead room evaluation arc panel partner open july september october november december governance arc chair executive executive arc executive arc arc board cfo operation operation operation executive group financial steering co steer co steer co steer co controller outputs short list knowledge initial feedback proposal debrief recommend successful firm preselection building firm share lead evaluation final evaluation firm appoint lead partner partner input exam question firm appointment effect development oral preference january proposal presentation express firm gsk annual report strategic report governance remuneration financial statement investor information auditor appointment ongoing effectiveness quality external audit process committee commit ensure ongoing basis gsk receive high quality effective audit evaluate effectiveness audit process prior make recommendation reappointment external auditor committee review effectiveness performance criterion agree conjunction management begin year audit activity committee typically undertake year satisfy external audit quality effectiveness timeline set auditor appointment auditor expectation formal auditor appointment committee evaluation process set audit plan budget setting matter address matter address matter address matter address review effectiveness external agree performance shareholder vote agm review feedback committee auditor expectation set expectation auditor resolution appoint auditor member independently previous year upcoming audit determine remuneration annual committee evaluation review auditor independence review agree audit plan cover appropriate level qualification upcoming audit relationship auditor expertise resource consider auditor quality control quality insight provide consider auditor procedure committee work exhibit appropriate level agree set statutory audit fee sufficient challengescepticism receive management feedback access auditor work prior year audit process management consider initiate survey cover preapprove budget nonaudit defer audit contract tender robustness audit process service ideally satisfied recommend statutory audit fee follow quality delivery people board auditor reappointment year service agm january march december detailed criterion committee use judge effectiveness external auditor override responsibility deliver smooth run thorough efficiently execute audit set performance expectation gsk external auditor specific auditor discuss approach area focus advance early engagement understanding implication gsk new operating model responsibility ensure sarbanesoxley scope additional procedure discuss endorse management communicate timely basis gsk pwc avoid surprise timely reporting issue level group ensure clarity role responsibilitie auditor local management respond issue raise management timely basis meet agree deadline provide continuity succession planning key employee auditor provide sufficient time management consider draft auditor report respond request query employ consistent communication local central audit team wide auditor provide uptodate advice new viability statement requirement responsibility provide uptodate knowledge technical governance issue include evolve market practice viability statement requirement serve industry resource communicate good practice industry trend report integrate reporting adhere independence policy include gsk policy financial reporting council isa applicable security exchange commission standard deliver focus consistent audit approach globally reflect local risk materiality liaise gsk audit assurance team avoid duplication work global ethic compliance team ensure common understanding audit outcome provide consistency advice level organisation ultimately provide high quality service board scrupulous scrutiny group act utmost integrity gsk annual report corporate governance continue accountability continue nonaudit services sarbanesoxley act prohibit engagement prohibition gsk policy update black list external auditor provision certain service legal prohibit nonaudit service new regulation apply actuarial internal audit outsource financial information system group gsk financial year onwards design external auditor permit provide nonaudit subject exception outside eu committee service auditrelate tax service approve committee ensure auditor objectivity independence preapproval frc new guidance audit committee restricts safeguard policy require preapproval committee categorywide preapproval process gsk policy service contractual similar obligation policy update nonaudit service restrict group choice external auditor preapprove committee chairman nonaudit service competitive cfo delegate committee tender financial service provider external auditor line group procurement process skill preapprove experience external auditor suitable group financial controller supplier nonaudit service consideration case approve designate group request proposal submit relevant cet member financial controller cfo approval nonaudit service spending monitor fee pay company auditor associate set committee quarterly basis discuss committee detail give note financial chairman statement operating profit follow policy guideline engage external auditor possible accounting firm engage undertake provide nonaudit service observe nonaudit service ascertain skill experience external auditor suitable supplier nonaudit service ensure adequate safeguard place objectivity auditnonaudit service year comparison graph independence group audit threaten compromise ensure total fee level exceed annual audit fee special circumstance clear advantage company auditor undertake additional work policy maintain number year committee review december compliance financial reporting council frc revise ethical standard eu audit regulation new regulation follow audit assurance service key policy guideline consider committee fee audit assurance service include million arise review novartis transaction subsequent increase complexity group approximately half expect recur fee cap gsk exist nonaudit service fee cap service include tax regulatory compliance treasuryrelate annual audit fee gsk policy stringent frcs service new fee cap set average audit fee service relate novartis transaction precede year period gsk exist policy cap retain fair balanced understandable assessment key compliance requirement group financial committee evaluation statement annual report fair balanced committee annual evaluation internally facilitate understandable coordination review groupwide company secretary supplement questionnaire contribution annual report follow establish circulate committee member behalf committee document process perform parallel chairman conclude committee continue formal process undertake external auditor operate effectively term enhancement committee deliberation follow improvement point agree committee receive summary approach take management preparation gsk annual report committee focus way improve ensure meet requirement frcs code transparency company report reflect good practice enable committee board confirm committee consider way work agree gsk annual report take fair enhancement reflect committee change agenda balanced understandable committee ask management continue improve code conduct report line crispness report receive number establish policy include code conduct available governance section committee keen continue receive regular update website confidential speak reporting line cyber security understand datum analytic technology report investigation unlawful conduct update help monitor employee supplier behaviour version code conduct publish april company value gsk annual report strategic report governance remuneration financial statement investor information internal control framework board recognise obligation present fair balanced ensure effective governance promote ethical culture understandable assessment gsk current position group place risk oversight compliance council prospect board accountable evaluate approve rocc team senior leader authorise board effectiveness internal control include financial assist audit risk committee committee oversee operational compliance control risk management risk management internal control activity provide process operate group business unit framework risk management upward escalation significant risk business unit risk board internal control framework framework mean structure report rocc business unit risk group ensure compliance law regulation management compliance board rmcbs responsible reliability financial report comprehensive risk management promote local tone risk culture framework support continuous process board ensure effective oversight internal control risk identification evaluation management group principal management process risk require financial reporting council frc uk corporate governance code uk code design principal risk assign risk owner member manage eliminate risk achieve business senior management risk owner responsible reporting objective risk management strategy respective principal risk rocc committee year fit purpose framework conjunction value speak process ensure risk associate rocc rmcbs assist global ethic business activity actively effectively control line compliance division gec responsible advance risk agree risk appetite believe framework provide management development practice drive compliance reasonable absolute assurance material policy support riskbase decision make gec actively misstatement loss promote ethical behaviour enable member organisation operate accordance value comply applicable law regulation enterprise oversight audit assurance assurance ness monitor discb eu p nl fs ii onl rn e cne ees mn em da nna tan ga eg m ne dm e b n v iat dn ua ss ut c aka sc lec ac icu cnu ot en ub et n sa n tlb ait st bi yli l w iy ty itw h ch mc cwo op rm nili ta ttp ren ol nc li sa e sn tc ne rd n e p e n e n b e p e n e nt e n e p e n usi b tn e n e p e ni p ro b le ser p n di n g mom na toa rg ine gma ec not tiv e cs omm u nication training gnirotinom sseu nis ecnarussn gsk value gsk annual report audit assurance division aa line agree board review focus company subsidiary assurance plan provide independent assurance senior extend material associate undertaking joint management board risk manage venture investment consider risk group assurance help senior management board company participation activity establish meet oversight advisory responsibility fulfil procedure control place identify entity result group strategic objective build trust patient consolidated group result stakeholder aa dual reporting line chief believe process follow board financial officer committee committee review regularly system internal control committee receive regular report business unit risk management process accordance guidance principal risk owner gec aa area significant risk risk management internal control relate financial group relate internal control report provide business reporting issue frc assessment internal control environment review group risk management approach principal risk area include enhancement strengthen discuss manage risk section strategic control environment follow consideration report report page management principal risk committee conclude effectiveness control explain principal risk uncertaintie page environment report board annually group viability discuss group financial review accordance frc uk code provision board section strategic report authority delegate committee conduct robust assessment group principal risk include consideration nature extent risk willing achieve group strategic objective board committee maintain oversight ensure effectiveness internal control environment risk management process operation group year date approval annual report governance structure risk management gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser corporate governance continue accountability continue internal control framework continue board director responsible system corporate governance strategy risk management financial performance audit risk committee responsible reviewing approve adequacy effectiveness risk management internal control corporate executive team support ceo manage business activity risk oversight authorise board assist audit risk committee oversee compliance council risk management internal control activity group business unit responsible system corporate governance strategy risk management financial performance risk management ensure appropriate internal control effective risk management compliance board implement complement country executive risk board ensure consistent approach risk management local geography level gsk annual report strategic report governance remuneration corporate governance continue financial statement relation shareholder investor information engagement activity work engage effectively shareholder regular communication agm investor relation activity governance remuneration meeting announce financial result quarterly basis annual result include annual report shareholder receive cornerstone investor calendar annual meeting annual summary advise annual report hold shareholder key investment notice annual general meeting available website industry body influential proxy advisory firm discuss corporate governance remuneration matter year sir andrew witty simon dingemans give session december attend presentation institutional investor analyst medium chairman sid committee chair cover year result available webcast broad range governance issue hold morning teleconference second quarter result afternoon allow uk overseas investor hold webcast teleconference audience convenient opportunity participate discussion result available website philip hampton chairman share update key area investor relation ir department office london focus board include philadelphia act focal point communication investor ceo cfo chairman maintain active dialogue oversight management execution strategy institutional shareholder performance plan objective performance programme regular meeting year hold rd delivery assessment pipeline individual meeting investor host ceo executive team succession include ceo approximately group meeting investor potential transition activity investor wide evolution refreshment board company secretary act focal point communication corporate governance matter small central urs rohner remuneration committee chairman take corporate responsibility cr team coordinate strategy opportunity discuss progress remuneration policy development report specifically respect cr committees review executive remuneration ahead matter ir department communicate socially remuneration policy vote agm responsible investor stakeholder addition judy lewent chair audit risk committee lynn elsenhans chair corporate chairman meet regularly institutional shareholder responsibility committee provide overview work hear view discuss issue mutual importance respective committee communicate view member board senior independent nonexecutive director sid finally vindi banga sid provide insight nonexecutive director available meet shareholder perspective board culture dynamic impression gsk senior team people business listen view shareholder receive feedback session hold run corporate reporting agm season help shape key area corporate governance remuneration disclosure annual general meeting shareholder invite attend annual general meeting year like hold qeii centre london provide opportunity question board chairman board committees formal agm proceeding provide shareholder chance meet informally board director available meeting gsk annual report corporate governance continue corporate responsibility committee report dear shareholder lynn elsenhans committee act custodian policy practice corporate responsibility define safeguard reputation company committee chairman chair committee continue fellow committee member challenge shape company responsible business agenda committee member bring wide range experience insight different sector provide oversight company responsible business opportunity risk year long serve committee member dr stephanie burn role dr daniel podolsky stand committee committee review retired board han wijer serve external issue potential impact committee year stand time gsk business retire board greatly appreciate reputation management knowledge insight bring work annual governance oversight gsk responsible business committee time commitment please welcome professor sir roy anderson membership dr jesse goodman dr vivienne cox new members committee roy jesse worldrenowne medical scientist committee member committee member researcher helped maintain continuity scientific lynn elsenhans october advice committee deliberation vivienne bring chairman deep knowledge sustainable business practice develop professor sir roy anderson year service predominantly energy natural dr vivienne cox july resources sectors dr jesse goodman work committee year focus issue dr stephanie burn december material gsk mission strategy value dr daniel podolsky july discussion include explore company seek han wijer october balance need return investment innovation need price product appropriately drive access broad ee committee member attendance level range patient addition consider way company secretary secretary committee gsk seek operate transparency integrity attend meeting attendees committee meeting approach rd commercial selling model include relationship party regular attend year continue enjoy positive engagement attendee attendee require investor responsible business approach performance chief executive officer particular focus integrate group company chairman business model strategy help enhance investment value chairman global vaccine create business opportunity mitigate risk create general counsel broad social environmental value head communication government affair head pharmaceutical lynn elsenhans head pharmaceutical rd corporate responsibility committee chairman head human resource head external market communication march head global corporate responsibility executive independent external corporate responsibility adviser augment engagement stakeholder opinion sophia tickell appoint independent external adviser committee position previously hold march july ms tickell extensive experience pharmaceutical industry improve health system productivity sustainability energy supply distribution climate change policy shorttermism financial market cofounder director meteo direct pharma future series aim align well societal shareholder value hold number board advisory role ms tickell attend meeting committee provide independent advice guidance corporate social responsibility matter chairman ceo gsk annual report strategic report governance remuneration financial statement investor information corporate responsibility committee report continue main responsibility people enable people thrive develop committee rolling agenda receive report individual deliver mission member cet senior manager ensure progress planet grow business reduce meet responsible business commitment area environmental impact value chain focus review annual basis addition meeting committee consider possible health innovate address currently unmet health need emerge issue bear company improve access product irrespective people reputation interaction stakeholder committee live ability pay control eliminate disease review approve responsible business supplement affect world vulnerable people available reference wwwgskcomresponsibility behaviour put interest patient consumer drive value back robust policy strong compliance process work committee committee focus primarily matter set area committee focus item discuss health flexible open rd approach disease develop world area great medical need antibiotic dementia gsk approach price particular balance return investment innovation alongside need support access medicine vaccine strategy support global public health priority include pricing model malaria vaccine ebola response behaviour change gsk engage healthcare professional global incentive compensation program sell competency model embed valuesbase decision make organisation include training compliance progress work align party gsk standard expectation conduct public disclosure clinical research transparency detail datum trial result patient safety replacement refinement reduction use animal research development people organisational change employee relation inclusion diversity leadership development approach performance management employee health safety wellbeing insight staff survey planet environmental performance carbon water waste impact committee evaluation committee annual evaluation internally facilitate company secretary supplement questionnaire circulate committee member committee adviser behalf committee chairman conclude committee continue operate effectively term enhancement committee deliberation follow point agree committee programme meeting agenda devise ensure additional time allow full discussion issue consideration give monitor group cr work scorecard approach director director power determine uk legislation director cease director article association contain rule appointment bankrupt replacement director provide director appoint ordinary resolution member resolution cease director virtue company act director provide instance director article appoint way retire agm follow suffer mental physical ill health board resolve appointment shall cease director article provide director normally subject miss director meeting continuous period reelection agm interval year annually month permission board resolve hold office continuous period year shall cease director board agree director wish prohibit director law continue member board seek reelection annually accordance uk corporate governance code resign offer resign board accept offer require resign board gsk annual report corporate governance continue director continue director conflict interest director report director duty company act avoid purpose uk company act director situation direct indirect conflict report glaxosmithkline plc year end december interest possible conflict company article provide comprise page corporate governance general power board authorise conflict report director statement responsibility page page investor information nomination committee authorise board strategic report set matter require disclose grant regularly review potential actual conflict director report consider strategic authorisation record company secretary importance company follows note board director count quorum authorisation actual potential conflict risk management objective policy page ongoing basis director responsible inform company secretary new actual potential conflict likely future development company arise change circumstance strategic report affect authorisation previously give provide research development activity page authorisation director absolve statutory duty promote success company actual conflict arise diversity inclusion postauthorisation board choose exclude director provision information consultation employee receipt relevant information participation debate suspend director board resort carbon emission require director resign follow information incorporate nomination committee review register potential director report conflict authorisation january report board conflict appropriately authorise location annual report process authorisation continue operate effectively interest capitalise financial statement describe note financial statement relate party note transaction end financial year director publication unaudite financial information group financial review person closely associate material interest contract significance group company detail longterm incentive scheme remuneration report waiver emolument director applicable independent advice waiver future emolument director applicable company agree procedure director independent legal andor financial advice company expense non preemptive issue equity cash applicable deem necessary non preemptive issue equity cash applicable unlisted major subsidiary undertaking indemnification director parent company participation place applicable qualifying party indemnity provision define list subsidiary company act force benefit director provision service control applicable director hold office signing shareholder annual report shareholder waiver dividend financial statement change control essential contract note contract arrangement individually shareholder waiver future dividend financial statement fundamental ability business operate effectively note company party material agreement agreement control shareholder applicable effect alter terminate change control follow takeover bid agreement director director report draw present provide compensation loss office employment accordance reliance english company law result takeover provision company liabilitie director connection report shall share plan cause option award grant subject limitation restriction provide law plan vest takeover detail termination provision director report approve board director company framework contract executive director march sign behalf give version company remuneration policy report available wwwgskcom investor section philip hampton chairman march gsk annual report strategic report governance remuneration financial statement investor information remuneration section chairman annual statement annual report remuneration remuneration policy summary remuneration policy report gsk annual report remuneration report chairman annual statement dear shareholder remuneration outcome behalf board director award relation pleased present accordance remuneration policy remuneration report approve shareholder include annual statement annual key decision remuneration report remuneration summary committee committee follow remuneration policy bonus outcome executive remuneration policy report director determine reference provide detail new policy performance agree annual report remuneration financial measure develop new annual statement subject committee assessment advisory vote annual general individual level performance gsk remuneration policy meeting agm achieve performance excess spend considerable remuneration policy report relevant financial target year subject bind vote conjunction assessment individual time listening performance result bonus context executive remuneration payment target shareholder gsk maximum opportunity see gsk perform strongly propose approach detail bonus outcome year good sale growth provide include provide well pharmaceutical vaccine consumer enhance disclosure bonus target healthcare business excellent new alignment reduce product momentum discipline cost control year detail individual performance multiplier ipm pipeline progress result maximum pay level apply executive director key financial measure great simplicity target core earning share vest performance share growth end guidance plan psp award match addition total shareholder return award defer annual bonus tsr growth achieve plan dabp base agree outperform ftse index measure relative tsr adjust year free cash flow rd new product performance equal weighting performance measure year december threshold target tsr cash flow measure meet maximum rd target achieve result overall vest level detail vest outcome psp dabp matching award provide gsk annual report strategic report governance remuneration financial statement investor information review remuneration policy finalising proposal respond change annual bonus structure committee review number point raise remuneration policy objective shareholder consultation committee remuneration policy review maintain alignment strategic particularly thoughtful committee decide simplify goal align policy quantum incentive structure annual bonus individual good practice revise remuneration new policy implement performance multipli remove policy design emma walmsley detail annual bonus operate final change policy set additive basis bonus drive success company remuneration policy report page opportunity subject single profit delivery business strategy metric core group pbit instead create shareholder value separate measure profit apply executive director change previous year remain simplify pay arrangement implementation remuneration policy subject scorecard individual deliver appropriately competitive objective ensure maximum package attract retain motivate new appointment board bonus opportunity deliver executive talent discuss annual maximum target achieve respect align remuneration arrangement report sir andrew witty stepping financial individual element senior layer ceo effect march plan succeed emma organisation walmsley note committee depart executive remuneration policy review give careful detailed consideration note sir andrew witty include review package emma remuneration package stepping ceo effect new ceo president rd take account relevant factor march dr moncef slaoui committee carry extensive include constructive feedback leave board march consultation process significant receive shareholder result remain company number major shareholder number refinement original june feedback receive shareholder proposal termination payment greatly value give careful take account fact executive outstanding incentive consideration committee emmas ceo role reduction award treat accordance key change propose element remuneration remuneration policy detailed remuneration policy focus package comparison sir andrews summary treatment award increase alignment shareholder current arrangement overall package provide detail reduce maximum incentive c payment include future opportunity include receive sir andrew committees annual report remuneration removal bonus matching plan intention emmas package agm review come year subject reduction maximum potential pay development performance role finally like thank shareholder level engage shareholder input engagement remuneration policy review welcome simplification annual bonus change limit shareholder feedback report scheme set remuneration policy look forward receive support increase ceo share ownership summary emma walmsley new new remuneration policy annual requirement package set end letter report remuneration agm detail provide annual report remuneration dr patrick vallance join board role president rd january receive base salary pension arrangement urs rohner annual bonus psp opportunity remuneration committee chairman accordance set remuneration policy march gsk annual report remuneration report chairmans annual statement continue key change remuneration policy increase level mandatory deferral annual bonus alignment shareholder significant increase share ownership requirement ceo x salary x salary reduction overall maximum overall maximum incentive opportunity executive director reduce opportunity eg total remuneration package new ceo c receive current ceo removal matching awards dabp plan simplification alignment executive director ontarget maximum bonus opportunity change multiplicative additive bonus structure overview new ceo remuneration package overview comparison previous ceo rationale reduction low salary award base salary initial appointment salary significantly low increase level bpeanssei osnalary contribution define pension benefit pension contribution contribution plan previous ceo define provide ms walmsley match benefit arrangement prior join contribution salary board remain align ie pension contribution provide executive immediately board target opportunity reduction target align annual bonus annual bonus salary bonus opportunity opportunity structure maximum opportunity salary executive director salary maximum opportunity reduction removal match ltis salary total longterm incentive award dabp opportunity simplifie remuneration maximum package reduce salary include overall incentive opportunity award psp psp opportunity matching award low dabp previously award sir andrew witty salary significantly align share share ownership requirement current requirement ownership requirement salary maximum psp opportunity remuneration policy align interest ceo shareholder total reduction package c gsk annual report strategic report governance remuneration financial statement annual report remuneration investor information glance pay performance objective kpi incentive scheme outcome financial annual bonus financial performance grow balanced business core group operating profit core group pbit maximum vaccine performance target nonfinancial health increase access healthcare target behaviour put patient consumer people talent development diversity planet reduce environmental impact threshold target core group core group vaccine operate profit pbit performance maximum performance target performance achieve longterm strategic objective lti outcome performance period end december strong rd innovation rd new product relative rd efficient global adjust free cash flow tsr new product operating model rd rd worldleade relative tsr business adjust award lapse free cash flow award vest rd highlight summary follow show breakdown total remuneration pay executive director respect sir andrew witty ceo simon dingemans cfo dr moncef slaoui chairman global vaccine fix pay salary benefit pension performance pay annual bonus ltis earn executive director shareholding audit share ownership vs sor align interest executive director shareholder require build maintain significant sir andrew witty x holding share gsk time executive director x base salary require continue satisfy shareholding requirement simon dingemans x minimum month follow retirement x base salary company cet member require build share dr moncef slaoui x ownership requirement sor x base salary x base salary current shareholding compare sor illustrate x x x x x x x sor shareholding chart opposite f ollowe appointment ceo sor emma walmsley increase x base salary sor dr patrick vallance x base salary level ownership march x x base salary ceo president rd respectively gsk annual report annual report remuneration continue total remuneration audit value earn annual total salary benefit pension lti bonus remuneration award fix pay b pay performance total remuneration executive director set table dr moncef slaoui chairman sir andrew witty ceo simon dingemans cfo global vaccine fix pay salary benefit pension total fix pay b pay performance annual bonus page lti awards matching award dabp psp total pay performance ab total remuneration note detail respect vest psp dabp award provide page committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect executive director deferral annual bonus number share number share number ad bonus defer number share ad purchase gsk annual report strategic report governance remuneration financial statement investor information total remuneration audit continue follow section provide detail element total global pharmaceutical comparator group remuneration include committee implement basis tsr comparator group feature longterm approve remuneration policy incentive award comparator group pay tsr follow review pay comparator group year committee pay comparator group role comparator remove group consider executive pay primary group bbvie amgen include remuneration benchmarke executive director follow include tsr comparator group uk crossindustry global pharmaceutical reviewing ceo remuneration committee comparator group comparator group reference pay group lead european company sir andrew witty dr moncef slaoui selection base size complexity simon dingemans anglo american france sanofi astrazeneca switzerland novartis bg group roche holdings bhp billiton uk astrazeneca bp abbvie british american tobacco amgen diageo bristolmyers squibb reckitt benckiser eli lilly rio tinto johnson johnson royal dutch shell merck co sab miller pfizer tesco unilever vodafone fix pay audit salary benefit comprise expense incur ordinary course table set base salary executive director business deem taxable benefit individual year disclose year salary increase include table align provide wide workforce detail salary level provide benefit benefit sir andrew witty base salary employee benefit change travel sir andrew witty benefits simon dingemans total dr moncef slaoui simon dingemans benefit employee benefit follow table show breakdown gross cash value travel benefit receive executive director benefit employee benefit include employee share plan healthcare total car allowance personal financial advice life assurancedeath dr moncef slaoui service cover employee benefit travel expense include car travel spousepartn cost travel associate accompany executive director gsk benefit business deem taxable benefit individual total dr moncef slaoui benefit include uk accommodation gsk annual report annual report remuneration continue fix pay audit continued pension executive director pension plan type member sir andrew witty uk define benefit simon dingemans cash payment lieu pension dr moncef slaoui belgian plan sir andrews maximum pension entitlement twothird final salary april pensionable salary increase limited pa member plan close new entrant member sir andrew build pensionable service different tier glaxo wellcome pension plan current pension entitlement product service progression gsk simon dingemans receive cash payment lieu pension base salary line gsk define contribution pension plan rate follow table show breakdown pension value set sir andrew witty simon dingemans dr moncef slaoui pension remuneration value uk define benefit define benefit belgian define benefit employer cash contribution member contribution define benefit plan total pension remuneration value pension remuneration figure calculate accordance methodology set large mediumsize company group account report amendment regulation remuneration regulation calculate define benefit pension value difference accrue pension december accrue pension december increase inflation uk define benefit define benefit belgian define benefit multiply mount translate euro dollar exchange rate sir andrew dr moncef slaoui detail pension value set table accrue pension december pension remuneration sir andrew witty pa pa value uk fund uk unfunded total accrue pension december pension remuneration dr moncef slaoui pa pa value fund unfunded belgium fund k essp total member plan dr moncef slaoui build pensionable service belgian plan cash balance supplemental pension plan annual employer cash contribution k plan executive supplemental saving plan essp current pension entitlement product service progression gsk mount translate euro dollar exchange rate gsk annual report strategic report governance remuneration financial statement investor information pay performance audit annual bonus annual bonus opportunity base formal review performance stretch financial target outcome adjust reflect individual performance apply individual performance multipli ipm ipm set committee take account performance individual objective multipli set performance target financial measure weighting follow weight performance performance positioning measure sir andrew witty simon dingemans dr moncef slaoui target outcome target core group operating profit core group pbit vaccine performance threshold maximum performance target set target respectively core group operating profit core group pbit target outcome purpose annual bonus differ core group operating profit pbit disclose annual report primarily target outcome number calculate apply gsk budget exchange rate actual exchange rate follow table show actual bonus earn compare opportunity bonus opportunity bonus outcome financial performance base salary target maximum outcome total total bonus salary salary salary ipm salary sir andrew witty simon dingemans dr moncef slaoui table set matter committee consider respect financial measure weighting set executive director financial performance core group operating group turnover increase cer report basis billion cer proforma basis profit core group core group operating profit increase cer report basis cer proforma basis core group pbit pbit grow cer report basis ahead target performance maximum target core operate margin percentage point high percentage point high cer term proforma basis reflect improved operating leverage drive sale growth favourable mix business delivery restructuring integration benefit tight control ongoing cost partly offset continued price pressure particularly respiratory supply chain rd investment vaccine performance vaccine sale increase cer report basis million cer proforma basis overall result benefit strong performance bexsero high demand fluarixflulaval international menveo international growth drive synflorix market expansion international tender award europe boostrix grow europe international vaccine core operating profit increase cer term operate profit margin percentage point high cer term proforma basis result drive primarily improve product mix enhance operating leverage strong sale growth integration restructuring benefit cost sale sga rd high royalty income gsk annual report annual report remuneration continue pay performance audit continue determine appropriate individual performance multipli ipm apply annual bonus outcome executive director committee take account performance number key strategic objective set individual start year summary principal achievement executive respect objective provide table personal performance achievement sir andrew witty deliver key financial objective ahead financial plan achieve strong progress integration novartis business consumer vaccine new product sale double billion strong return rd investment year approval submission target late stage asset exceed deliver sustained pipeline progress asset file h shingrix close triple benlysta sc sirukumab key phase iii start q asset hiv respiratory anaemia deliver continue improvement quality risk profile business fully implement new commercial business model maintain progress deliver responsible business commitment eg topping access medicine index th consecutive year embed number critical simplification change programme realise benefit global platform provide effective leadership group year significant change successfully transition new ceo simon dingemans deliver strong financial leadership group continue progress cost saving total annual cost saving billion include currency benefit billion group remain track deliver target annual saving billion cer continue successful implementation new business operating system bison ipt successfully go live legacy system decommission cerp accounting system successfully deploy market merps system deploy site exit novartis transaction relate service agreement complete core commercial cycle integrate financial planning process dr moncef slaoui lead highly successful year vaccine business overall effectively manage vaccine leadership succession transition new head vaccine luc debruyne finalise successful creation galvani bioelectronic joint venture verily life science significant opportunity create value shareholder work creation coalition epidemic preparedness innovation support biopreparedness establish gsk place found board major vaccine organisation support gsk external reputation build global public health arena work directly barda wellcome trust unga amr malus clawback policy company policy malus clawback set company remuneration policy report available wwwgskcom investors section january respect financial year committee disclose recoupment committee exercise clawback malus disclosure matter subject public report misconduct fully resolve legally permissible disclose unduly prejudice company shareholder line disclosure guideline committee recoupment committee exercise malus clawback gsk annual report strategic report governance remuneration financial statement investor information pay performance audit continue value earn longterm incentive ltis line committee agree principle measure applicable lti awards actual performance target review adjustment appropriate reflect impact novartis transaction business ensure vest outcome reflect genuine underlie business performance committee satisfy adjusted target remain suitably stretch detail adjustment provide time vest award performance period end december committee review performance psp dabp matching award grant executive director target set performance achieve year december vest level set table outcome vest level performance measure relative weighting performance target outcome maximum award rd new product rd new product sale performance measure aggregate threeyear sale new bn performance product launch threeyear performance period precede year rd ie original target adjust target vest maximum bn bn bn bn bn bn threshold bn bn adjust free line company agree principle afcf figure include adjustment bn cash flow afcf number material distort item include legal settlement exchange rate performance movement special pension contribution rd original target adjust target vest maximum bn bn bn bn bn bn threshold bn bn relative tsr rank th tsr ranking comparator group vest performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company total vest respect award gsk annual report annual report remuneration continue pay performance audit continued historical vest gsk ltis year grant performance measure total vest level r dabp matching award onwards dabp match r b award wholly subject tsr performance total vest level award subject r b measure psp vested line figure show chart r b performance measure key r rd new product adjust free cash flow tsr b business diversification lapse update performance ongoing lti awards committee review performance psp dabp matching award grant executive director follow chart provide estimate vest level take account performance december actual vest level determine base performance threeyear performance period indication regard prediction final vest level award performance update award performance update rank rd rank rd bn threshold bn threshold maximum maximum commercially commercially median bn sensitive median bn sensitive threshold threshold tsr adjust free rd new tsr adjust free rd new rd cash flow product rd cash flow product estimate vest level rd rd estimate vest level rd rd threshold performance award vest respect rd new product afcf measure tsr element tsr comparator group remain unchanged show respect award longterm incentive awards level participation dabp respect show table maximum matching award grant respect deferral bonus table show psp award level dabp matching awards psp award total bonus number face value award level number face value defer sharesadss award base salary sharesadss award sir andrew witty shares share simon dingemans share share dr moncef slaoui adss adss face value award calculate base share price share award ad award close price february performance period awards january december dabp matching awards uk executive form nilcost option psp award form conditional share award executive adss form conditional share gsk annual report strategic report governance remuneration financial statement investor information ceo pay comparison ceo total remuneration position historic ceo remuneration single figure remuneration annual bonus award maximum vest lti awards maximum uk global european bonus amount include amount pay operational efficiency crossindustry pharmaceutical crossindustry bonus place year overall maximum bonus receivable subject group group group limit base salary low quartile median upper sir andrew wittys median quartile current position n respect psp award sir andrew outstanding awards share option grant respectively remuneration include salary expect value incentive base lapse include total vest percentage committee agree benchmarke methodology distort effect aggregate conditional share share option percentage change remuneration ceo performance graph sir andrew witty uk employee follow graph set performance company relative ftse index pharmaceutical performance change change comparator group year period december salary index select comparison purpose reflect benefit primary index gsk constituent industry annual bonus operate reflect salary earn benefit receive annual bonus earn respect compare wide uk employee population salary increase include annual salary review additional change year eg promotion increase benefit ceo result change benefit arrangement ceo benefit higher primarily result increase level financial planning fee partially offset low level travel uk employee benefit unchanged previous year change benefit policy level reflect change level benefit individual receive result change role eg promotion uk population consider relevant comparison closely reflect economic environment encounter ceo gsk total return gsk pharma peer ftse total return index total return index index comprise astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holding sanofiaventis gsk annual report annual report remuneration continue additional remuneration disclosure relative importance spend pay shareholder vote remuneration matter table show percentage change total employee pay table provide detail shareholder vote group dividend pay shareholder recent resolution respect annual remuneration report remuneration policy report change vote total employee pay total vote total vote total vote withhold agm cast billion million dividend remuneration report share buyback vote figure table reflect payment total vote total vote total vote withhold year set page dividend agm cast billion million declare respect million remuneration policy million plus special dividend million ie increase exclude special dividend company expect external appointment executive director ordinary share repurchase executive director hold remunerated external appointment total employee pay base employee average payment past director audit number people employ service contract payment loss office audit table set relevant date executive director service contract available review company register office office hour executive director service contract contain month notice period set remuneration policy report date contract effective date expiry date sir andrew witty emma walmsley simon dingemans dr moncef slaoui dr patrick vallance appoint board january remuneration governance role committee membership role committee set company remuneration membership committee appointment policy gsk able recruit retain motivate date set executive committee member committee member remuneration policy regularly review ensure consistent company scale scope operation urs rohner january chairman support business strategy growth plan help drive creation shareholder value vindi banga january term reference dr vivienne cox january committees term reference available judy lewent january company website term reference review dr stephanie burn annually revise january reflect good practice corporate governance development sir deryck maughan july hans wijer october governance board consider members committee committee meeting usually include closed session independent nonexecutive director accordance member committee present individual uk corporate governance code invite attend committee meeting year executive committee attendee involve decision present discussion remuneration detail committee member skill experience give biography board page committee member attendance level gsk annual report strategic report governance remuneration financial statement investor information remuneration governance continue company secretary secretary committee attend deloitte provide independent commentary matter meeting attendee committee include consideration committee update market practice legislative requirement deloitte fee advice provide committee attendee committee fee charge regular attend time material basis deloitte provide consult attendee attendee require tax assurance service gsk year ceo committee satisfy compromise cfo independence advice receive deloitte head human resource follow announcement deloitte replace head reward pricewaterhousecooper llp auditor company committee adviser deloitte llp deloitte long name adviser remuneration committee company currently undergo tender process judy lewent vindi banga member audit risk intention new adviser appoint july remuneration committee provide input audit risk committee review group performance oversight willis tower watson provide additional market datum committee risk factor relevant remuneration decision committee evaluation adviser committee committee annual evaluation internally facilitate committee access external advice require company secretary supplement questionnaire committee carry formal review independent adviser circulate committee member behalf committee committee result review committee chairman conclude committee continue reappointe deloitte llp deloitte provide independent operate effectively term enhancement committee advice executive remuneration committee chairman agree work agree seek gain deep protocol deloitte provide advice understand performance system culture committee satisfy advice receive linkage remuneration arrangement group talent deloitte objective independent deloitte member remuneration consultant group voluntarily operate code conduct relation executive remuneration consulting uk code conduct find wwwremunerationconsultantsgroupcom committee area committee focus item discuss remuneration policy committee set broad structure remuneration policy determine remuneration executive director chairman propose remuneration policy corporate officer board approval engagement shareholder remuneration environment include wide employee trend salary review committee periodically review consider remuneration executive director cet benchmarking competitiveness gsk environment executive director cet approve annual amendment comparator group necessary executive director cet salary recommendation increase ceo executive director cet bonus recommendation annual bonus bonus objective committee responsible set specific performance measure annual bonus rd annual bonus target metric lti plan defer annual bonus plan rule committee responsible approve lti plan rule change grant assessment performance vest lti awards executive lti performance outcome vest lti awards cet directors cet lti grant cet include share value plan awards committee evaluation process shareholder feedback annual investor meeting remuneration report remuneration consideration agm remuneration report feedback external remuneration governance area focus environment performance target disclosure incentive plan committee adhere robust remuneration governance framework ensure alignment internal action external reporting chairman fee compliance requirement remuneration report disclosure gsk annual report annual report remuneration continue nonexecutive director fee chairman nonexecutive director nonexecutive director fee apply set company aim provide chairman nonexecutive table director fee competitive pay annum company equivalent size complexity subject limit standard annual fee contain gsk article association supplemental fee chairman fee chairman audit risk committee chairman philip hampton pay fee annum senior independent director scientificmedical expert elect gsk share chairman remuneration corporate responsibility committee nonexecutive director fee nonexecutive director undertake intercontinental change nonexecutive director fee travel meeting meeting year fee remain level set january nonexecutive director minimum fee deliver share defer nonexecutive director step board table audit set value fee benefit receive nonexecutive director form cash share ad detail nonexecutive director share allocation plan set nonexecutive director fee pay gbp convert average exchange rate review time time nonexecutive director fix fee fix fee emolument audit cash sharesad benefit total pay cash sharesad benefit total pay professor sir roy anderson vindi banga dr vivienne cox lynn elsenhans dr jesse goodman philip hampton judy lewent urs rohner dr stephanie burn stacey cartwright sir deryck maughan dr daniel podolsky hans wijers dr jesse goodman join board january accordance nonexecutive director share allocation plan dr jesse goodmans fee retain reinveste company adss future date mutually agree dr vivienne cox join board july dr stephanie burn sir deryck maughan dr daniel podolsky hans wijer retired board agm stacey cartwright retire board december benefit primarily consist travel subsistence cost incur normal course business relation meeting board committee matter gskhoste event consider taxable overseasbase nonexecutive director include travel meeting uk gsk annual report strategic report governance remuneration financial statement investor information director interest share audit interest director company office december person closely associate pca show table total share plan interest december total director interest sharesad option aunveste unvested aunveste unvested march december january subject subject subject subject vest exercise performance performance performance performance exercise year executive director share sir andrew wittybcdfh simon dingemansbcdfh dr moncef slaouicdeg emma walmsleyk na na na na na na na na dr patrick vallancek na na na na na na na na ad dr moncef slaouicdeg share allocation plan nonexecutive director total director interest number share ad december january march date date idividend december allocate december retirement appointment reinveste pay elect nonexecutive director sharesi professor sir roy anderson vindi banga dr vivienne cox philip hampton urs rohner dr stephanie burnsj stacey cartwrightj hans wijersj adsi lynn elsenhans dr jesse goodmani judy lewent dr stephanie burnsj sir deryck maughanj dr daniel podolskyj u nveste share subject performance sir andrew represent share award end year performance period psp grant subsequent reinveste dividend share subject twoyear vest period sir andrews unvested option subject performance represent bonus deferral share save option unvested option subject performance simon dingemans represent bonus deferral share save option unvested ad subject performance dr moncef slaoui represent bonus deferral deferral psp plan share value plan award pca b otal director interest include share purchase glaxosmithkline share reward plan sir andrew witty simon dingemans award share plan total number share hold plan follow share reward plan share march december january sir andrew witty simon dingemans emma walmsleyk na na dr patrick vallancek na na dr moncef slaoui eligible participate share reward plan open uk employee gsk annual report annual report remuneration continue director interest share audit continue c otal director interest include share ad result deferral bonus subsequent reinvestment dividend dabp total show table include bonus deferral exclude unvested matching award subject ongoing performance criterion amount represent gross share ad balance prior sale share ad satisfy tax liability defer annual bonus plan bonus deferral march december january sir andrew witty shares simon dingemans share dr moncef slaoui ad emma walmsleyk share na na dr patrick vallancek share na na otal director interest march include share ad vest performance meet element dabp psp award sell satisfy tax liability vest amount page detail e f dr moncef slaoui total director interest include ad purchase k plan executive supplemental saving plan essp ad award dr moncef slaouis pca svp relevant balance follow dr moncef slaoui ad march december january retirement saving plan share value plan executive director dr moncef slaoui eligible receive award svp svp award show reflect holding dr slaouis pca employee gsk award subject threeyear vest period vest contingent continue employment gsk gain arise vest include dr moncef slaouis total remuneration figure year pca grant ad september grant price face value dr moncef slaouis total share plan interest include psp award hold pca award subject performance criterion relevant employee cet december pca hold ad psp comprise award ad ad ad amount include dividend reinvestment f share save plan sir andrew witty simon dingemans unvested option subject performance include holding respectively share save plan participate term employee share save option grant sir andrew witty simon dingemans grant option plan november g ad vest unexercised option totalling dr moncef slaoui represent ad option hold pca gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continue h follow table set detail option include nilcost option dabp exercise executive director dr moncef slaoui exercise option year number share market gain exercise type award date grant option date exercise grant price price exercise sir andrew witty dabp deferral dabp match simon dingemans share save dabp deferral dabp match respect option share save plan remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share ad total value share ad vest date executive director choose exercise option vest date subsequent increase decrease realise movement share ad price vest date date exercise increase decrease value result investment decision executive director record remuneration respect nilcost option dabp bonus defer director record remuneration annual bonus year relate gain record exercise nilcost option comprise remuneration total amount receive reinveste dividend prior vest gain loss result movement share price date grant exercise initial bonus defer date dividend reinvestment exercise reinveste dividend matching element dabp remuneration executive director record year performance period end represent number vest share multiply price vest gain record exercise nilcost option comprise total remuneration gain loss result movement share price vest exercise sir andrew witty gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment loss relate movement share price vest exercise date simon dingemans gain result exercise option grant share save plan gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date f nonexecutive director total interest include share ad receive fee nonexecutive director share allocation plan note dividend receive share ad plan january convert share ad february accordance share allocation arrangement nonexecutive director dr jesse goodmans fee retain reinveste company ad future date mutually agree j r stephanie burn sir deryck maughan hans wijer retire board elect receive share ad nonexecutive director share allocation plan immediately retire board dividend entitlement respect q q q dividend pay cash accordance plan rule dr daniel podolsky retire pay gsk ad nonexecutive director share allocation plan elect defer payment q stacey cartwright retire board december elect receive gsk share nonexecutive director share allocation plan immediately follow retirement k e mma walmsley dr patrick vallance appoint board january gsk annual report annual report remuneration continue director interest share audit continue deferred annual bonus plan matching award follow table provide detail executive director office december respect dabp matching awards market price grant vest represent closing share price business day prior date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continue deferred annual bonus plan matching award continue performance period dr moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest ad number ad market price vest gain remuneration remuneration emma walmsley dr patrick vallance appoint board january follow table provide detail dabp matching award grant february grant share emma walmsley dr patrick vallance performance period number share market price grant face value grant unvested march gsk annual report annual report remuneration continue director interest share audit continued performance share plan award follow table provide detail executive director office december respect psp award market price grant vest represent closing share price date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continued performance share plan award continue performance period dr moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest ad number ad market price vest gain remuneration remuneration gsk annual report annual report remuneration continue director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director members cet company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group pca employee gsk award share ad company share plan set table award dividend reinvestment award award share ad share ad defer annual bonus plan performance share plan defer investment awardsa b share value planb march group pcas follow interest share ad company holding issue executive share plan describe note financial statement employee share scheme interest march share ad own unexercised option defer annual bonus plan performance share plan defer investment awardsa b share value planb n otional share ad b executive director eligible receive defer investment award participate share value plan share plan dilution limit allemployee share plan dilution limit executive director participate allemployee share award plan incorporate dilution plan include share save share reward limit consistent guideline publish investment association limit roll year period share save plan hm revenue customs approve plan roll year period executive share plan open uk employee participant save plan estimate dilution exist award month net salary fix term year year december follow end saving period option buy gsk share discount market price set launch saving contract sir andrew witty simon dingemans contribute respectively month gsk employee share plan executive share plan share save plan share reward plan hm revenue customs approve plan open uk employee term participant contribute month gross salary purchase gsk share company match number gsk share buy month arrangement sir andrew witty simon dingemans contribute maximum month buy share share reward plan actual limit gsk annual report strategic report governance remuneration financial statement investor information implementation remuneration policy salary inevitably target link directly financial strategic plan committee determine follow salary increase take commercially sensitive committee consider account average increase wide workforce appropriate disclose annual bonus target year result competitive harm detail performance change target disclose retrospective basis annual wide workforce report sir andrew witty sir andrew dr moncef slaoui cease executive dr moncef slaoui director year accordance remuneration simon dingemans policy receive prorata ontarget bonus payment emma walmsley na committee set role specific objective dr patrick vallance na period individual cease executive director new remuneration policy approve target bonus base average increase budget employee level cet uk opportunitie set policy approve effective appointment role ceo april low shareholder ie salary sir andrew receive sir andrew witty emma walmsley appoint board january ceo designate base salary salary dr moncef slaoui effective appointment board january legacy awards matching award dabp benefit time matching award significant change provision benefit propose dabp award relate bonus outcome detail policy relation benefit refer remuneration policy detail remuneration policy report table provide detail level participation pension dabp respect annual bonus payment associate table provide overview pension arrangement matching award grant executive director sir andrew witty dr moncef slaoui receive match pension contribution award cease executive director sir andrew witty uk define benefit year annual bonus payment subject dr moncef slaoui belgian plan mandatory deferral simon dingemans base salary lieu pension total bonus matching emma walmsley base salary matching contribution defer award number dr patrick vallance base salary lieu pension share share emma walmsley detail provide simon dingemans member define contribution plan eligible receive matching award salary accordance term plan dr patrick vallance ie matching award base bonus earn respect prior appointment annual bonus plan board performance share plan psp award number change operation intend award psp later year annual bonus plan simplify align follow approval psp rule agm executive director award sir andrew witty dr moncef slaoui award remain executive director matching award remove defer follow level annual bonus plan dabp percentage bonus subject mandatory deferral share psp award salary period year increase emma walmsley financial performance measure reference simon dingeman profit relate measure core group pbit dr patrick vallance operating profit remove measure group pbit select profit measure align performance measure shareholder metric psp dabp matching award remain calculation bonus operate additive unchanged award continue base basis removal individual performance multiplier equally weight measure rd new product performance introduction scorecard individual objective adjust free cash flow relative tsr align strategic goal business year tsr continue measure global pharmaceutical peer prior year target rd new product commercially sensitive time grant committee bonus opportunity weighting salary performance measure intend disclose target follow end core scorecard performance period addition committee continue group individual provide shareholder interim performance update target maximum pbit objective element course performance period adjust emma walmsley free cash flow target disclose shareholder simon dingemans prospective basis time grant report dr patrick vallance annual report remuneration gsk annual report annual report remuneration continue implementation remuneration policy continue termination arrangement sir andrew witty nonexecutive director fee dr moncef slaoui nonexecutive director fee review year follow announce sir andrew witty dr moncef increase january slaoui leave board mutual agreement march agree increase fee chairman dr moncef slaoui remain employee group remuneration corporate responsibility committee june chairman new science committee termination payment sir andrew witty receive fee fee remain unchanged dr moncef slaoui define benefit pension arrangement minimum fee continue deliver share outstanding incentive award treat accordance defer nonexecutive director step remuneration policy approve shareholder board disclosure payment cessation include annual report remuneration remuneration element summary treatment annual bonus receive ontarget bonus payment prorate proportion financial year work psp award grant psp award dabp matching award dabp matching award grant respect bonus psp vest normal vesting date subject dabp matching awards achievement performance condition assess end performance period award respect bonus defer defer bonus respect prior year vest normal vesting date addition executive director require maintain shareholde equal respective share ownership requirement month leave company gsk annual report strategic report governance remuneration financial statement remuneration policy summary investor information remuneration policy review remuneration policy approve shareholder addition change policy agm require regulation align remuneration arrangement senior layer shareholder ask approve new remuneration policy organisation agm intend apply financial year deliver appropriately competitive package attract retain motivate executive talent committee review remuneration policy ensure policy continue simplify pay arrangement align good practice committee consult large shareholder respect propose change take shareholder feedback account create shareholder value finalise revise remuneration policy table drive success company delivery provide overview main change propose business strategy respect remuneration policy remuneration policy shareholder ask approve set page remuneration element propose change policy rationale change mandatory deferral annual bonus increase bonus alignment shareholder earn align executive longterm interest shareholder simplification annual bonus simplify align structure executive simplification director consistent approach executive director reduce level payout threshold clearly communicate performance nil pay performance ensure high level bonus payout receive significant performance annual bonus performance share plan provide additional flexibility committee flexibility psp performance measure determine performance measure context appointment new annual basis year life ceo consider appropriate provide remuneration policy sufficient flexibility ensure performance committee consult metric choose year shareholder prior change remain aligned key financial performance measure strategic objective company lti opportunity matching element dabp simplification remove go forward psp longterm incentive plan maximum lti opportunity ceo reduction maximum opportunity reduce total lti opportunity executive director salary reduce award ceo maximum opportunity salary share ownership requirement sor formally include shareholde guideline alignment shareholder remuneration policy provide alignment shareholder increase sor ceo x salary gsk annual report remuneration policy report future policy table subject shareholder approval company agm remuneration policy remuneration element outline table salary material change purpose link strategy opportunity provide core reward role formal maximum limit ordinarily salary increase broadly line average increase wide gsk set level appropriate secure retain high calibre individual workforce need deliver group strategic priority increase higher reflect change scope operation individual role responsibility experience salary individual role experience performance independently adjustment reflect wide market condition source datum relevant comparator group consider geography individual operate determine salary level detail current salary level set annual report salary increase typically effect quarter year remuneration salary normally pay currency executive director performance measure home country overall performance individual key consideration determine salary increase benefit material change purpose link strategy role executive director entitle car travel level set recruit retain high calibre individual execute accompanied spousepartn business trip business strategy benefit include expense incur ordinary course business deem taxable benefit individual operation executive director eligible receive benefit line benefit provision tailor reflect market practice policy employee vary location include geography executive director base different limited car allowance healthcare life assurance policy apply current future executive director base death service provide individual different country pension arrangement personal financial advice contractual opportunity postretirement benefit line policy employee formal maximum limit benefit cost fluctuate executive director eligible receive overseas relocation depend change provider cost individual circumstance allowance international transferrelate benefit require executive director eligible participate allemployee detail current benefit cost set annual report share scheme eg share save share reward plan remuneration subject term employee performance measure order recognise high business travel requirement pension material change purpose link strategy uk pension arrangement provide competitive level retirement salary contribution define contribution plan income match contribution subject relevant cap line implementation principle member plan operation pension arrangement structure accordance plan operate country individual likely retire salary cash payment lieu pension contribution individual choose member pension plan cash lieu relevant pension contribution pay instead eligible benefit senior executive executive director uk entitle join define cash balance pension plan supplemental cash balance contribution pension plan receive cash payment lieu pension plan include executive pension credit provide maximum pension contribution contribution base salary pension plan individual member gsk legacy define benefit gsk k plan retirement saving plan plan define contribution plan alternative pension plan executive supplemental saving plan core contribution arrangement subsequently appoint board salary bonus match contribution remain member plan salary bonus opportunity global policy current executive director new external eligible appropriate equivalent arrangement excess recruit usuk arrangement performance measure gsk annual report strategic report governance remuneration financial statement investor information future policy table continue annual bonus change purpose link strategy committee apply judgement make appropriate incentivise recognise execution business strategy adjustment bonus outcome ensure reflect underlie annual basis business performance reward achievement stretch annual financial clawback andor malus provision apply describe strategic business target delivery personal objective opportunity operation maximum bonus opportunity executive director financial operational business target set start salary threshold performance bonus payout nil year committee bonus level determine target performance bonus payout committee base performance target maximum opportunity individual objective set start year committee performance measure performance objective assess base combination financial target individualstrategic committee performance objective majority bonus assess executive director require defer bonus earn financial measure weight different share ad appropriate year measure determine year accord business priority defer bonus share eligible dividend equivalent date vest detail include measure financial year provide annual report remuneration selection annual bonus measure annual bonus design drive achievement gsk majority annual bonus opportunity base formal annual financial strategic business target delivery review performance stretch financial target personal objective remainder bonus subject balanced scorecard strategic individual target align company key objective financial year performance share plan psp change purpose link strategy clawback andor malus provision apply describe incentivise recognise delivery long term business opportunity prioritie financial growth increase shareholder value normal maximum award limit grant compare pharmaceutical company psp individual year set table addition provide alignment shareholder interest award ceo salary retention element encourage longterm shareholding salary discourage excessive risk take ceo operation cfo conditional award annually vest dependent executive director achievement performance condition year subject additional twoyear hold period performance measure base combination financial share price relate award eligible dividend equivalent date strategic performance condition align vest release company strategic plan awards vest committee adjust formulaic vest outcome threshold performance detail include performance ensure overall outcome reflect underlying target attach psp respect year provide business performance vest period annual report remuneration selection longterm incentive measure committee select performance measure focus major adjustment calculation performance measure executive director longterm remuneration delivery gsk disclose shareholder vest chairman audit key strategic priority long term addition set risk committee member member robust target committee implement number remuneration committee provide input audit risk safeguard ensure target meet sustainable way committee review group performance oversight performance reflect genuine achievement target risk factor relevant remuneration decision represent delivery value shareholder detail rationale performance measure select performance measure impact acquisition calculate set annual report divestment quantify adjust event remuneration gsk annual report remuneration policy report continue future policy table continue legacy arrangement defer annual bonus plan dabp remove onwards purpose performance measure incentivise recognise delivery long term business outstanding matching award subject measure priority provide alignment shareholder interest award psp give year encourage longterm shareholding detail outstanding award provide page operation maximum opportunity annual report remuneration matching award bonus payment include bonus respect dabp respect bonus executive director require defer onwards bonus earn share year voluntarily defer additional bonus earn defer share match maximum subject achievement performance condition year matching award conditional share nilcost option eligible dividend equivalent share ownership requirement increase requirement ceo align interest executive director executive director require continue satisfy shareholder require build maintain significant requirement minimum month follow retirement holding share gsk time requirement company executive director follow salary ceo executive director clawback malus change event trigger event eg significant misconduct way respect financial year remuneration committee violation regulation law significant gsk policy disclose recoupment committee exercise code conduct company ability claw clawback malus disclosure matter year annual defer bonus vest subject public report misconduct fully unvested ltis addition participant new psp resolve legally permissible disclose dabp shareholder ask approve agm unduly prejudice company subject investigation vest award shareholder delay outcome investigation additionally continuity responsibility separate recoupment committee establish initiation adverse event emergence investigate relevant claim misconduct recoupment problem adverse event take account committee exercise authority wide employee base assess annual bonus award lti vest level year comprise senior executive relevant oversight problem identify future period remuneration appropriate experience include senior vice president global committee recoupment committee appropriate ethic compliance senior vice president general adjustment individual annual bonus grant counsel vest level lti awards reflect gsk annual report strategic report governance remuneration financial statement investor information approach recruitment remuneration committee determine remuneration package new committee mindful sensitivity relate recruitment executive director casebycase basis depend package particular buying right relate role market operate experience previous employment seek minimise total remuneration level set reference relevant pay arrangement certain circumstance enable comparator group appropriate allow future recruitment exceptional talent committee determine development role arrangement good interest company shareholder arrangement possible expect new executive director participate short likeforlike basis forfeit remuneration term longterm incentive plan basis exist director arrangement vary depend plan exceptional circumstance committee reserve arrangement place previous employer flexibility set incentive limit new executive director form cash share subject additional exist limit performance condition explanation provide committee retain flexibility recognition high payment compensation previous remuneration level variable pay gsk global pharmaceutical competitor forfeit committee use flexibility remuneration arrangement newly appoint executive consider good interest company director disclose soon practicable investor appointment pension arrangement external recruit executive director set remuneration policy table follow policy principle apply role chairman nonexecutive director benefit provide line policy exist chairman executive director fee set level competitive pay company equivalent size complexity fee require meet business need relocation support pay partly share provide line company policy internal appointment entitlement exist nonexecutive director remuneration element continue include pension fee level new nonexecutive director set entitlement outstanding award basis exist nonexecutive director company case internal appointment require subject local law regulation fee pay partly executive director contractual term include termination share provision event nonexecutive director different role responsibility appoint fee level benchmarke set reference comparable role company equivalent size complexity gsk annual report remuneration policy report continue loss office payment policy company policy fix term contract generally notice period termination employ company contract new appointment expire line applicable executive director calendar month policy retirement age ability impose month noncompete period contract exist executive director expire date show nonsolicitation restriction executive director consider important company ability protect group intellectual property staff light committee believe appropriate provide mitigation contract termination employment event executive director employment company terminate follow policy payment apply element remuneration loss office payment policy termination payment termination notice month annual salary payable termination company prorate notice period work termination payment respect notice period extend contract expiry date bonus element normally include termination payment term contract seek balance commercial imperative good practice redundancy termination notice uk statutory redundancy pay apply general severance policy apply retirement death illhealth injury disability termination payment lti award psp dabp matching awards govern plan rule approve shareholder award prior approval psp dabp rule follow provision normally apply termination notice unvested awards lapse redundancy retirement generally award continue vest original timescale subject original performance condition award month forfeit death illhealth injury disability reason generally performance assess follow end financial year cessation employment occur award vest month follow cessation award prorate time award approve rule psp follow provision normally apply termination notice unvested awards lapse redundancy retirement death illhealth injury disability reason generally award continue vest original timescale subject performance prorate time event change control psp dabp matching awards vest take account performance date normally take account proportion performance period elapse alternatively award exchange new award annual bonus termination notice individual individual serve notice termination date fall december bonus forfeit termination notice company redundancy retirement death illhealth injury disability termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result dabp defer dabp defer bonus award govern plan rule approve shareholder award prior approval bonus award dabp rule follow provision normally apply termination notice award vest date termination original vest date determine date grant redundancy retirement death illhealth injury disability reason generally award vest original vest date award approve rule dabp follow provision normally apply termination gross misconduct generally unvested awards lapse reason generally award vest original vest date event change control awards vest exchange new award benefit generally benefit continue apply termination date committee payment connection exist legal obligation respect claim related cessation employment include fee outplacement assistance legal andor professional advice termination notice company retirement executive line policy applicable senior executive chairman global vaccine eligible future date receive continue medical dental insurance terminationretirement termination mutual agreement certain circumstance good interest company board manage proactively succession planning development senior talent pipeline circumstance board agree executive departure mutual agreement order apply committee need satisfied executive demonstrate performance line expectation require contribute orderly succession complete year service group termination date case executive director treat good leaver purpose gsk longterm incentive plan termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result gsk annual report strategic report governance remuneration financial statement investor information loss office payment policy continue committee anticipate exercise discretion executive director leave company committee provide psp dabp plan rule respect termination carry assessment individual performance payment manner benefit executive director conduct time role determine individual unforeseen circumstance performance conduct contrary legitimate expectation good interest company shareholder company committee reserve right apply necessary exercise discretion explanation provide appropriate mechanism clawback reduction lapse outstanding incentive award malus ensure termination payment good interest company shareholder difference remuneration policy executive director employee set remuneration level executive director salary benefit include pension tailor local committee consider prevail market condition market competitive environment comparison annual bonus plan apply wide employee population remuneration executive company similar size complexity base business individual performance international reach position relativity pay employment condition broad gsk workforce combination performancerelate restricted share plan apply wide employee population particular committee consider range base salary rise workforce part gsk executive allemployee share plan available employee uk director employ consider relevant include hm revenue customs approve uk share save comparison population reflect closely economic share reward plan environment encounter individual employee formally consult respect principle apply remuneration policy executive remuneration policy company conduct regular employee director employee remuneration offer survey include feedback remuneration matter executive director policy strong emphasis wide organisation align performance performancerelate pay offer employee reward system value group performance system formally evaluate employee need senior people disincentivise unethical working practice clawback mechanism allow recover performance relate pay gsk annual report remuneration policy report continue scenario future total remuneration chart opposite provide illustration future total remuneration executive director respect emma walmsley new ceo remuneration opportunity grant policy range potential outcome provide executive director underlie assumption set scenario base salary benefit pension figure cfo ie base actual amount receive respect ongoing policy new ceo president rd role benefit value base value benefit exclude pension provide current ceo cfo respectively amount show value psp award base fix expect maximum relevant multiple include amount respect dividend reinveste factor change share price vest period simon dingemans cfo fix pay performance annual bonus psp payable expect annual bonus assume target performance achieve psp award threshold level vest assume maximum fix expect maximum assume annual bonus payable maximum level award psp vest dr patrick vallance president rd fix expect maximum fix pay annual bonus psp gsk annual report strategic report governance remuneration financial statement investor information nonexecutive director remuneration policy element purpose link strategy operation formal maximum fee review annually set reference review chairman performance independently source market datum committee responsible evaluating make recommendation board fee payable chairman chairman participate discussion provide inclusive flat rate fee respect fee competitive pay fee pay combination cash andor gsk share ad nonexecutive company equivalent size complexity director share allocation plan subject limit contain chairman fee gsk article association chairman fee review annually set reference independently source datum chairman ceo responsible evaluating make recommendation board fee payable company nonexecutive director minimum deliver form gsk share ad nonexecutive director share allocation plan deliver share ad nonexecutive basic fee director follow retirement board compensate nonexecutive director chairman take supplemental additional board responsibilitie additional fee committee chairman senior independent nonexecutive director fee undertake intercontinental travel science medical expert intercontinental travel travel subsistence cost nonexecutive director incur normal course business relation meeting board committee matter gskhoste event overseasbase nonexecutive director include travel meeting uk event necessary business purpose whilst normal practice non executive director accompany spouse partner meeting event cost associate meet company facilitate execution responsibility instance deem taxable treat benefit non benefit duty require role executive director gsk annual report remuneration policy report continue operation scope remuneration policy propose remuneration policy policy set page performance share plan defer annual bonus plan award annual report intend policy subject term relevant plan rule gsk executive nonexecutive director apply award grant committee adjust amend close company annual general meeting award accordance provision plan rule submit committee approval include make adjustment reflect oneoff corporate shareholder event change company capital structure committee write policy principally relation committee minor amendment policy remuneration arrangement executive director whilst take set report regulatory exchange control tax account possible recruitment replacement administrative purpose account change legislation additional executive director operation policy obtain shareholder approval amendment committee intend policy operate period set statement consideration shareholder view entirety consideration seek committee engage regular dialogue shareholder change policy period believe hold annual meeting gsk large investor discuss appropriate longterm success company feedback remuneration policy governance matter consultation shareholder seek shareholder approval general meeting annual meeting hold december urs rohner committee chairman share update remuneration committee reserve right remuneration matter month proposal onwards payment andor payment loss office include exercise shareholder consultation carry february discretion available connection payment march committee chairman propose notwithstanding line policy set remuneration policy committee take account feedback term payment agree shareholder determine policy shareholder agm date company ask approve agm shareholderapprove director remuneration policy come effect ii policy set come effect provide term payment consistent shareholderapprove remuneration policy force time agree iii time relevant individual director company opinion committee payment consideration individual director company purpose payment include committee satisfy awards variable remuneration relation award share ad term payment agree time award grant basis preparation director remuneration report prepare accordance company act large mediumsize company group account report amendment regulation regulation accordance regulation follow part annual report remuneration subject audit total remuneration figure executive director include detail element remuneration salary benefit pension annual bonus longterm incentive awards nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section director remuneration report subject audit page refer audit section director remuneration report approve board director sign behalf urs rohner remuneration committee chairman march gsk annual report strategic report governance remuneration financial statement investor information financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare uk gaap gsk annual report director statement responsibility director responsible prepare annual report strategic report risk section annual report remuneration report group financial statement represent management report include fair review accordance applicable law regulation development performance business position group description principal risk uk company law require director prepare financial uncertainty face statement financial year law director require prepare group financial statement accordance disclosure information auditor international financial reporting standard ifrs adopt director office date annual report european union prepare group financial statement confirm director elect comply ifrs issue far aware relevant audit information international accounting standard board iasb company company auditor unaware law director approve group financial statement satisfied true fair view state take step ought take affair group profit loss period director aware relevant audit information establish company auditor aware prepare financial statement director information require confirmation give interpret accordance select suitable accounting policy apply provision section company act consistently go concern basis judgement accounting estimate page contain information performance reasonable prudent group financial position cash flow net debt position state group financial statement comply ifrs borrowing facility information include treasury risk adopt european union ifrs issue iasb management policy exposure market credit risk subject material departure disclose explain hedging activity give note financial statement group financial statement financial instrument relate disclosure assess principal risk matter consider connection prepare financial statement go concern basis viability statement director consider appropriate adopt inappropriate presume group continue go concern basis accounting prepare financial business statement director responsible keep adequate accounting internal control record sufficient explain companys board audit risk committee review transaction disclose reasonable accuracy time assessment risk internal control framework operate financial position group enable ensure gsk consider effectiveness system group financial statement remuneration report comply internal control operation group year cover company act article ias regulation annual report date approval board responsible safeguarding asset group director take reasonable step prevention detection fraud irregularity uk corporate governance code board consider glaxosmithkline plc apply principle group financial statement year end december complie provision uk corporate governance comprise principal statement support note code maintain financial reporting council describe set financial statement page corporate governance section page board report responsibilitie auditor relation group consider annual report take fair financial statement set independent auditor report balanced understandable provide information page necessary shareholder assess group position group financial statement year end december performance business model strategy include annual report publish require financial conduct authority list rule print form available website director auditor consider director statement compliance responsible maintenance integrity annual report relation point uk corporate governance code website accordance uk legislation govern specified review preparation dissemination financial statement access website available outside uk comparable annual report legislation different annual report year end december comprising report director remuneration report current director name function list financial statement additional information investor corporate governance section annual report approve board director sign behalf confirm good knowledge group financial statement prepare accordance ifrs adopt eu ifrs philip hampton issue iasb true fair view asset chairman liability financial position profit group march gsk annual report strategic report governance remuneration financial statement independent auditor report investor information member glaxosmithkline plc report group financial statement opinion area focus refine reflect development opinion glaxosmithkline plcs group financial statement group business include continue competitive pricing pressure discount resolution true fair view state group affair investigation group commercial practice secdoj december profit cash flow year end overview properly prepare accordance international materiality financial reporting standard ifrss adopt overall group materiality million represent european union profit tax add certain item adjust profit tax million prepare accordance requirement company act article ias regulation audit scope audit include scope audits report component separate opinion relation ifrss issue iasb specific audit procedure perform reporting explain note group financial statement group component addition apply ifrss adopt european union apply ifrss issue international accounting take component audit work standard board iasb perform account consolidated revenue consolidated profit tax adjust profit opinion group financial statement comply ifrss tax cover component individually contribute issue iasb revenue profit tax adjust profit tax audit area focus group financial statement include annual report rebate discount allowance return comprise pharmaceutical vaccine business consolidate balance sheet december carry value goodwill intangible asset consolidate income statement consolidate statement acquisitionrelate liabilities comprehensive income year end uncertain tax position consolidate cash flow statement year end litigation consolidate statement changes equity year end finance transformation note group financial statement include investigation group commercial practice summary significant accounting policy explanatory scope audit area focus information conduct audit accordance international standard certain require disclosure present audit uk ireland isas uk ireland annual report note financial statement design audit determine materiality assess crossreference financial statement risks material misstatement financial statement identify audit particular look director subjective financial reporting framework apply judgements example respect significant accounting preparation group financial statement applicable law estimate involve make assumption consider future ifrss adopt european union applicable law event inherently uncertain audits address risk management override internal control audit approach include evaluate evidence bias context director represent risk material misstatement context audit set group activity fraud risk fraud revenue recognition procedure reduce extent finance transformation design execute address risk include use datum completion threepart transaction novartis enable auditing technique test journal entry postclose group increase pace change number adjustment test evaluate management key accounting market migrate group common enterprisewide estimate reasonableness consistency undertake cutoff resource planning platform erp move financial transaction procedure verify proper cutoff revenue expense process accounting service business process test existence accuracy revenue transaction outsource location bpo inhouse business service addition incorporate element unpredictability centre bsc establish new bpos europe audit work year asia group migrate new consolidation platform risk material misstatement great effect bison implement new system track intercompany audit include allocation resource effort inventory transfer calculate intragroup unrealised profit identify area focus table set inventory ipt result transformation group finance tailor audit address specific area order process include area focus report provide opinion financial statement addition group certain change comment result procedure agreement pfizer shionogi respect noncontrolle read context complete list risk identify interest hold viiv healthcare change audit remeasurement viiv acquisitionrelate liability significant impact correspond accounting valuation judgement include area focus gsk annual report independent auditor report continue report group financial statement continue area focus audit address area focus rebate discount allowance return obtain management calculation accrual applicable pharmaceutical vaccine business scheme validate assumption reference refer note group financial statement group state commercial policy term applicable contract party datum relate patient enrolment group make sale customer fall government fund benefit scheme historical level product certain commercial government mandate contract return reimbursement arrangement significant medicaid medicare group provide right compare assumption contract price historical rebate return customer certain product discount allowance return level relevant current payment trend consider historical accuracy arrangement result deduction gross sale arrive group estimate previous year impact competitive turnover rise obligation group provide pricing pressure great discount market customer rebate discount allowance right generally form independent expectation large return unsettle amount recognise accrual element accrual december party datum focus area rebate discount allowance compare expectation actual accrual recognise return arrangement complex establish group appropriate accrual require significant judgement base procedure perform identify material estimation director judgement particularly complex difference independent expectation accrual healthcare environment competitive pricing pressure product discount grow trend director determine accrual million necessary december december million increase accrual primarily foreign exchange rate impact factor drive increase accrual high sale great discount competitive pressure particularly relation advair carry value goodwill intangible asset deploy valuation specialist obtain group refer note group financial impairment analysis test reasonableness key statement assumption include profit cash flow growth decline terminal value impact expiry patent potential product group billion intangible asset december obsolescence selection discount rate challenge billion comprise significant licence patent management substantiate assumption include compare acquire trademark exclude computer software relevant assumption industry economic forecast addition group billion goodwill december december billion interrogate integrity support calculation corroborate certain information party source include carry value goodwill intangible asset expectation performance certain asset component contingent future cash flow risk asset business obtain evaluated management sensitivity impair cash flow meet group analyse ascertain impact reasonably possible change expectation impairment review perform group key assumption perform independent sensitivity contain number significant judgement estimate calculation quantify downside change management include revenue growth success new product launch model require result impairment genericisation exist product follow patent expiry profit margin cash conversion terminal value discount rate result work determine impairment charge change assumption lead impairment million record intangible asset appropriate carrying value intangible asset goodwill intangible asset include goodwill management determine impairment require find judgement year group change basis aggregating support reasonable assumption require individual cash generating unit cgus goodwill impairment unreasonable downside change additional material testing purpose comprise global pharmaceutical impairment necessary consumer healthcare vaccine exercise undertaken align group operate segment respect aggregation cgus confirm result aggregation pharmaceutical viiv low level management monitor goodwill internal healthcare purpose consistent way group result report board corporate executive team focus intangible asset acquire historical acquisition significant individually aggregate number indefinite life include significant intangible asset acquire novartis group recognise goodwill number acquisition include threepart transaction novartis gsk annual report strategic report governance remuneration financial statement investor information report group financial statement continue area focus audit address area focus acquisitionrelate liability deploy valuation specialist evaluate certain key refer note group financial assumption include growth projection discount rate statement integrity mechanical accuracy management valuation model consider reasonably possible change recent year group complete number significant significant impact value record certain procedure specific transaction include individual liability include follow threepart transaction novartis consumer healthcare option redemption price contractually establishment viiv healthcare base multiple agree gsk novartis acquisition viiv healthcare remain interest consumer healthcare revenue profit compare earning shionogiviiv healthcare forecast approve consumer healthcare board director management model actual earning transaction result recognition understand reason change consider measurement material acquisitionrelate liability appropriateness earning multiple apply forecast necessitate significant management judgement balance assumption option exercise date sheet date viiv healthcare contingent consideration compare projection addition february group waive certain right group dolutegravir product party expectation respect noncontrolle interest hold pfizer shionogi growth consider potential upside downside impact viiv healthcare term arrangement shionogi product launch expect launch group amend december competitor significant acquisitionrelate liability outline viiv healthcare option obtain review write agreement group pfizer shionogi certain consumer healthcare option group record liability assumption relate forecast revenue dolutegravir product present value expect redemption price write valuation liability consistent viiv healthcare option novartis noncontrolle interest consumer contingent consideration component valuation healthcare december liability carry consider appropriateness assumption forecast value million million growth rate margin reference historical performance board approve budgets party forecast datum viiv healthcare contingent consideration acquisition remain interest shionogiviiv healthcare joint venture acquisitionrelate liability subject significant million record contingent consideration estimation uncertainty range possible outcome broad represent fair value expect payment comfortable value liability december shionogi contingent future sale dolutegravir product reasonable reflect management good estimate time liability require remeasure fair value review disclosure acquisitionrelate liability report date initial recognition increase include management commentary estimation uncertainty response actual future sale significantly exceed original range alternative outcome satisfied disclosure expectation include impact change foreign exchange appropriate rate december liability million million viiv healthcare option pfizer shionogi grant write option group enable noncontrolle interest group future include december financial liability record option arrangement contain clause enable group avoid acquire interest certain condition meet february group unilaterally waive certain right result liabilitie aggregate value million recognise december agreement reach shionogi agree forego right exercise write option result group associate liability million de recognise december december liability respect pfizer write option carry value million addition liability group record certain acquisitionrelate liability december include million relation contingent consideration payable acquisition novartis vaccine business focus area carry value financial liability material determined management judgement estimate include projection future sale product potential impact competitor product delivery anticipate synergy addition valuation sensitive change assumption include discount rate tax rate gsk annual report independent auditor report continue report group financial statement continue area focus audit address area focus uncertain tax position conjunction uk international tax transfer pricing refer note group financial statement specialist evaluate challenge management judgement respect estimate tax exposure contingency order group operate complex multinational tax environment assess adequacy group tax provision include open tax transfer pricing matter uk obtain evaluate certain party tax opinion group overseas tax authority addition time time group obtain assess appropriateness assumption enter transaction complicate accounting tax consequence include threepart transaction novartis understanding evaluate management judgement judgement require assess level provision consider status recent current tax authority audit require respect uncertain tax position december enquiry outturn previous claim judgemental position take group record provision million tax return current year estimate development tax respect uncertain tax position million environment note assumption judgement require formulate provision mean range possible outcome broad base evidence obtain consider level provision acceptable context group financial statement take consider management disclosure regard agree management view material change group estimate tax exposure expect month litigation discuss status significant know actual potential refer note group financial litigation inhouse legal counsel obtain substantively statement test evidence support decision rationale provision hold decision record provision include correspondence pharmaceutical industry heavily regulate increase legal counsel monitor consider external inherent litigation risk group engage number legal information source identify potential legal action action include product liability antitrust relate private litigation significant disclose note develop independent expectation litigation provision base product litigation history available evidence challenge valuation completeness provision recognise focused area eventual outcome claim group obtain confirmation external legal counsel uncertain position take director base confirm understand settle outstanding litigation application material judgement estimation accordingly assert claim evaluate significant adjustment legal unexpected adverse outcome significantly impact provision record year determine indicative group report profit balance sheet position management bias december group hold provision million disclose note group financial statement respect legal action december million eventual outcome legal proceeding dependent outcome future event position take group inherently judgemental find context group financial statement take judgement management reasonable disclosure respect provision contingent liability appropriate gsk annual report strategic report governance remuneration financial statement investor information report group financial statement continue area focus audit address area focus finance transformation centrally manage work perform component audit team group continue rationalise simplify finance bpos bsc consist control substantive testing process include rollout enterprisewide resource conduct oversight visit key bsc bpo site group planning system erp migration accounting service audit scope india malaysia romania uk inhouse business service centre bsc party direct work perform business process outsourcing location bpos addition evaluate design test operating effectiveness group migrate new platform consolidation key automate manual control migration track intercompany inventory transfer calculate centralised processing environment include general control intragroup unrealised profit inventory control respect datum migration erp system change represent financial reporting risk migration substantively test accuracy completeness datum happen control process migration new erp control process establish embed number year update note significant exception similar procedure migrate new environment increase risk perform migration consolidation intercompany breakdown internal financial control transition profit tracking system respect increase risk inaccurate incomplete migration financial significance intercompany profit inventory adjustment datum turn increase risk material misstatement perform detailed testing calculation component group group financial statement level support validation key manual control process note significant unresolved exception testing investigation group commercial practice meet director management inhouse legal counsel refer note group financial speak group external advisor assess risk statement occurrence inappropriate activity status ongoing investigation potential fine penalty secdoj investigation group commercial practice include understand evaluate group internal conclude september result group pay investigation process assess risk allegation report penalty million group remain subject ongoe channel include whistleblowe hotline investigation sfo uk december evaluate ongoing enhancement change group conclude sufficient clarity control process business practice recent year likely time completion investigation able sufficiently reliable estimate fine penalty deploy forensic specialist assess scope finding sfo impose group completion investigative work perform group risk investigation result group state note assessment exercise management perform party unable recognise provision estimate interaction engagement broadly output eventual outcome assessment instruct component team include certain market include group audit scope undertake riskfocused addition group continue carry investigation audit procedure address audit risk group financial number market ascertain inappropriate statement materially misstate potential financial commercial practice take place implication allege illegal act focus follow risk material respect secdoj investigation verify settlement impact group financial statement agreement payment respect sfo investigation fine penalty forthcoming respect independently circularise external legal counsel engage group ongoing investigation group commercial practice obtain view status investigation ascertain sfo rise need material reasonableness management assertion respect likely provision outcome inappropriate activity occur base procedure satisfied group rise material fine penalty result asset provisioning decision december adequacy impairment disclosure give status investigation gsk annual report independent auditor report continue report group financial statement continue tailor audit scope specific audit procedure central function group tailor scope audit ensure perform consolidation area significant judgement include taxation work able opinion financial statement goodwill intangible asset treasury postretirement benefit take account geographic structure elimination unrealise intercompany profit inventory group accounting process control industry directly lead group audit team group operate take territory function perform group financial statement consolidation audit work account consolidated revenue reporting component identify reporting component consolidated profit tax adjust profit tax view require audit complete financial information consider contribution audit evidence size risk characteristic exclude central perform audit work divisional group level adjustment entity audit group level specific audit include test monitor control disaggregate analytical procedure significant balance transaction review procedure cover significant portion group perform report component appropriate small low risk component directly include coverage material balance report group audit scope addition obtain indirect audit component support share financial service centre evidence certain outofscope component centre include group audit scope procedure undertake group share service centre report component include group audit scope encompass bpos bsc centralise individually contribute consolidated revenue infrastructure process standardise profit tax adjust profit tax work perform component auditor determine level involvement need audit work report component unit result overseas component visit senior member group audit team include group financially significant component visit annually belgium japan china switzerland germany ireland italy addition visit overseas share service centre support reporting component group audit scope component group audit scope site visit undertaken involvement include regular dialogue component team review component auditor work paper participation certain component audit clearance meeting gsk annual report strategic report governance remuneration financial statement investor information report group financial statement continue materiality scope audit influence application materiality set certain quantitative threshold materiality qualitative consideration help determine scope audit nature timing extent audit procedure individual financial statement line item disclosure evaluate effect misstatement individually financial statement base professional judgement determine materiality financial statement follow overall group materiality million million determined profit tax add certain item include remeasurement charge shionogiviiv healthcare contingent consideration million vaccine contingent consideration million remeasurement charge consumer healthcare million viiv healthcare million option major restructuring cost million legal cost million impairment intangible asset million deduct net income relate gain disposal asset million rationale benchmark apply group principal measure earning comprise core result add statutory result number item income expenditure include detailed management use measure believe eliminate volatility inherent oneoff item take measure account determine materiality adjust profit tax add amortisation intangible asset certain small noncore item view recur item introduce volatility group earning agree audit risk committee report misstatement identify audit million million misstatement view warrant reporting qualitative reason go concern note director statement director conclude list rule require review director appropriate adopt go concern basis prepare statement set relation going concern group financial statement go concern basis presume report perform review group adequate resource remain operation director intend year date isas uk ireland require report group financial statement sign audit material add draw attention relation conclude director use go concern basis director statement consider appropriate appropriate adopt go concern basis prepare group financial statement material add draw attention future event condition predict statement guarantee group ability continue go concern gsk annual report independent auditor report continue require reporting consistency information compliance strategic report director report applicable requirement prepare accordance applicable legal requirement company act report addition light knowledge understanding group opinion base work undertake course environment obtain course audit audit require report identify material misstatement information give strategic report director strategic report director report report financial year financial statement report respect prepare consistent financial statement isas uk ireland report isas uk ireland require report opinion information annual report exception materially inconsistent information audit group financial statement report apparently materially incorrect base materially inconsistent knowledge group acquire course perform audit misleading statement give director accordance provision c uk corporate governance exception code code consider annual report take fair balanced understandable report provide information necessary member assess group position performance business model strategy materially inconsistent knowledge group acquire course perform audit section annual report require provision c code describe work audit exception committee appropriately address matter communicate audit committee report director assessment prospect group principal risk threaten solvency liquidity group isas uk ireland require report material add draw attention relation director confirmation annual report accordance provision c code material carry robust assessment principal risk face group include threaten business add draw attention model future performance solvency liquidity disclosure annual report describe risk explain manage mitigate material add draw attention director explanation annual report accordance provision c code material assess prospect group period consider period add draw attention appropriate statement reasonable expectation group able continue operation meet liability fall period assessment include related disclosure draw attention necessary qualification assumption list rule require review director statement carry robust assessment principal risk face group director statement relation longerterm viability group review substantially scope audit consist make enquiry consider director process support statement check statement alignment relevant provision code consider statement consistent knowledge acquire course perform audit report perform review adequacy information explanation receive corporate governance statement company act require report list rule require review opinion receive information corporate governance statement relate provision explanation require audit exception uk corporate governance code report report arise responsibility perform review director remuneration company act require report opinion certain disclosure director remuneration specify law exception report arise responsibility gsk annual report strategic report governance remuneration financial statement investor information responsibilitie financial statement audit responsibility director reasonableness significant accounting estimate explain fully director statement responsibility director set director responsible preparation overall presentation financial statement group financial statement satisfy true fair view primarily focus work area assess director judgement available evidence form responsibility audit express opinion financial judgement evaluate disclosure financial statement accordance applicable law isa uk statement ireland standard require comply auditing practice board ethical standard auditor test examine information sampling auditing technique extent consider necessary provide report include opinion prepare reasonable basis draw conclusion obtain audit company member body accordance chapter evidence testing effectiveness control substantive company act purpose procedure combination give opinion accept assume responsibility purpose person report addition read financial nonfinancial information show hand come save expressly annual report identify material inconsistency agree prior consent writing audit financial statement identify information apparently materially incorrect base materially inconsistent audit financial statement involve knowledge acquire course perform audit involve obtain evidence amount audit aware apparent material misstatement disclosure financial statement sufficient reasonable inconsistency consider implication report assurance financial statement free material respect strategic report director report consider misstatement cause fraud error include report include disclosure require applicable assessment legal requirement accounting policy appropriate group circumstance consistently apply adequately disclose matter report separately parent company financial note statement glaxosmithkline plc year end december maintenance integrity glaxosmithkline plc website responsibility director work carry parent company pass resolution accordance auditor involve consideration matter section company act senior statutory accordingly auditor accept responsibility auditor state change occur financial statement initially present website b l egislation united kingdom govern preparation dissemination financial statement differ legislation pricewaterhousecooper llp jurisdiction charter accountant statutory auditor london march gsk annual report consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profitloss attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p consolidate statement comprehensive income year end december profit year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary defer tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement share comprehensive expenseincome associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement lossesgain define benefit plan tax remeasurement define benefit plan comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report strategic report governance remuneration financial statement consolidate balance sheet investor information december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board march sign behalf philip hampton chairman gsk annual report consolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity january profit year comprehensive expenseincome year total comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profitloss year comprehensive expenseincome year total comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder gain transfer net asset consumer healthcare joint venture consumer healthcare joint venture option change noncontrolle interest loss transfer equity investment investment associate ordinary share issue ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive income year total comprehensive income year distribution noncontrolle interest dividend shareholder recognition liability noncontrolle interest derecognition liability noncontrolle interest change noncontrolle interest ordinary share issue ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report strategic report governance remuneration financial statement consolidate cash flow statement investor information year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment contingent consideration pay purchase business net cash acquire disposal business investment associate joint venture proceeds disposal subsidiary interest associate increasedecrease liquid investment interest receive dividend associate joint venture equity investment net cash outflowinflow investing activity cash flow financing activity share acquire esop trust issue share capital purchase share cancellation hold treasury share purchase noncontrolle interest increase longterm loan increase shortterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest finance cash flow net cash outflow financing activity decreaseincrease cash bank overdraft cash bank overdraft begin year exchange adjustment decreaseincrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft comparative figure restate detail gsk annual report note financial statement presentation financial statement description business accounting principle policy gsk major global healthcare group engage financial statement prepare historical creation discovery development manufacture marketing cost convention modify revaluation certain item pharmaceutical product include vaccine overthecounter otc state accounting policy go concern basis medicine healthrelate consumer product gsk principal financial statement prepare accordance pharmaceutical product include medicine follow group accounting policy approve board therapeutic area respiratory antiviral central nervous system describe note accounting principle policy cardiovascular urogenital metabolic antibacterial information application accounting policy dermatology rare disease immunoinflammation vaccine include area estimation judgement given note hiv key accounting judgement estimate compliance applicable law ifrs preparation financial statement conformity financial statement prepare accordance generally accept accounting principle require management company act article ias regulation estimate assumption affect report international accounting standard ias international financial amount asset liability disclosure contingent reporting standard ifrs relate interpretation adopt asset liability date financial statement european union report amount revenue expense report financial statement compliance ifrs issue period actual result differ estimate international accounting standard board implementation new accounting standard composition financial statement follow agenda decision ifrs interpretation committee consolidated financial statement draw sterling offset cash pooling arrangement group functional currency glaxosmithkline plc accordance revise disclosure cash pool arrangement ifrs accounting presentation financial statement change result cash flow year december comprise impact balance sheet december impact january increase cash consolidated income statement cash equivalent shortterm borrowing million consolidate statement comprehensive income amendment ifrs joint arrangement consolidated balance sheet implement january revision consolidate statement change equity material impact result financial position group financial period consolidated cash flow statement financial statement cover financial year january note financial statement december comparative figure financial year composition group january december appropriate list subsidiary associate undertakings january december opinion director principally affect profit parent company financial statement net asset group give note principal financial statement parent company glaxosmithkline plc group company prepare accordance uk gaap uk accounting presentation company balance sheet present accounting policy give accounting principle policy consolidation group ability exercise joint control consolidated financial statement include right net asset entity entity account joint venture group ability exercise joint asset liability result cash flow control arrangement right specify asset company subsidiary include esop trust obligation specify liability arrangement group share result net asset associate arrangement account joint operation group joint venture ability exercise significant influence entity group share asset liability revenue expense account associate result asset liability joint operation associate joint venture incorporate consolidated financial statement equity method account financial statement entity consolidate group right asset liability revenue expense joint december year operation include consolidated financial statement entity group power direct relevant accordance right obligation activity affect return group generally interest acquire entity consolidated date control financial operating policy account group acquire control interest sell deconsolidate subsidiary date control cease gsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue transaction balance subsidiary eliminate revenue profit tax take sale subsidiary revenue recognise income statement good product sell customer outside group relevant service supply available external customer proportion profit transaction joint venture joint order receive title risk loss pass customer operation associate defer product reliable estimate relevant deduction relevant sell party transaction noncontrolle interest obligation fulfil earning process record directly equity defer tax relief unrealise intra regard complete group profit account extent consider turnover represent net invoice value deduction recoverable discount allowance give accrual estimate future goodwill capitalise separate item case subsidiary rebate return methodology assumption cost investment case joint venture estimate rebate return monitor adjust regularly associate goodwill denominate currency operation light contractual legal obligation historical trend past acquire experience project market condition market condition evaluate wholesaler thirdparty analysis market cost acquisition fair value net asset research datum internally generate information value add tax acquire difference recognise directly income sale taxis exclude revenue statement group copromote product counterparty business combination record sale group records share revenue co business combination account acquisition promotion income turnover nature copromotion accounting method identifiable asset liabilitie contingent activity group record cost sale liability acquire measure fair value acquisition date pharmaceutical turnover include copromotion revenue consideration transfer measure fair value million million million addition include fair value contingent consideration initial eventbase milestone income exclude royalty income consideration transfer noncontrolle interest arise development marketing collaboration group exceed fair value net asset liability contingent compound product party recognise turnover liability acquire excess record goodwill cost milestone income nil include turnover nil acquisition charge income statement period million incur royalty income recognise accrual basis accordance equity subsidiary acquire non term relevant licensing agreement control interest recognise fair value non control interest share net asset subsidiary expenditure casebycase basis change group ownership percentage expenditure recognise respect good service receive subsidiary account equity supply accordance contractual term provision obligation exist future liability respect foreign currency translation past event obligation reliably foreign currency transaction book functional currency estimate manufacturing startup cost validation group company exchange rate ruling date achievement normal production expense incur transaction foreign currency monetary asset liability advertising promotion expenditure charge income retranslate functional currency rate exchange rule statement incur shipment cost intercompany transfer balance sheet date exchange difference include charge cost sale distribution cost sale customer income statement include sell general administrative expenditure consolidation asset liability include related goodwill restructuring cost recognise provide overseas subsidiary associate joint venture translate appropriate respect direct expenditure business sterling rate exchange rule balance sheet date reorganisation plan sufficiently detail result cash flow overseas subsidiary associate advance appropriate communication affect joint venture translate sterling average rate undertake exchange exchange adjustment arise open net asset profit year retain overseas subsidiary associate joint venture translate sterling exchange difference arise related foreign currency borrowing hedge group net investment operation take separate component equity translating sterling asset liability result cash flow overseas subsidiary associate joint venture report currency hyperinflationary economy adjustment material reflect current price level loss net monetary asset charge consolidated income statement gsk annual report note financial statement continue accounting principle policy continue research development employee share plan research development expenditure charge income incentive form share provide employee statement period incur development share option share award scheme expenditure capitalise criterion recognise asset fair value option award calculate meet usually regulatory filing major grant date blackschole option pricing model charge market approval consider highly probable property plant income statement relevant vest period equipment research development capitalise depreciated accordance group policy group provide finance esop trust purchase company share meet obligation provide share employee environmental expenditure exercise option award costs run esop trust environmental expenditure relate exist condition result charge income statement share hold esop past current operation current future trust deduct reserve transfer benefit discernible charge income statement group reserve retain earning vest period recognise liability sitebysite basis reliably relate share option award reflect ultimate proceed estimate liability include group portion total cost receivable employee exercise portion potentially responsible party cost probable able satisfy respective property plant equipment share cleanup obligation recovery reimbursement property plant equipment ppe state cost record asset virtually certain purchase construction provision depreciation impairment financing cost capitalise cost legal dispute qualify asset construction provision anticipate settlement cost legal dispute group outflow resource depreciation calculate write cost residual value consider probable reliable estimate likely ppe exclude freehold land straightline basis outcome addition provision legal expense expect useful life residual value life review arise claim receive dispute respect product appropriate adjust annually normal expect useful liability claim relate certain product sufficient history live major category ppe claim settlement enable management reliable estimate provision require cover unasserted claim freehold building year certain case incur report ibnr actuarial leasehold land building lease term year technique determine estimate plant machinery year group involved legal proceeding respect equipment vehicle year possible reliable estimate expect financial effect result ultimate resolution disposal ppe cost relate accumulate depreciation proceeding case appropriate disclosure impairment remove financial statement case include provision cost net proceed take income statement associate claim group party lease charge income statement incur leasing agreement transfer group substantially pension postemployment benefit benefit risk ownership asset treat finance cost provide pension define benefit scheme lease asset purchase outright asset calculate project unit credit method spread include ppe computer software capital element period benefit expect derive leasing commitment show obligation finance employee service consistent advice qualified actuary lease asset hold finance lease depreciate basis pension obligation measure present value estimate consistent similar own asset lease term short future cash flow discount rate reflect yield high interest element lease rental include income quality corporate bond pension scheme asset measure statement lease operating lease rental cost fair value balance sheet date charge income statement straightline basis lease term cost postemployment liability calculate similar way define benefit pension scheme spread goodwill period benefit expect derive goodwill state cost impairment goodwill deem employee service accordance advice qualified indefinite useful life test impairment actuary annually actuarial gain loss effect change actuarial fair value interest acquire entitys asset assumption recognise statement comprehensive liability contingent liability exceed consideration pay income year arise excess recognise immediately gain income statement group contribution define contribution plan charge income statement incur gsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue intangible asset availableforsale investment intangible asset state cost provision amortisation liquid investment investment classify available impairment forsale investment initially record fair value plus transaction cost remeasure subsequent reporting licence patent knowhow marketing right separately date fair value unrealised gain loss availableforsale acquire acquire business combination investment recognise directly comprehensive income amortise estimate useful life generally exceed impairment arise significant prolong decline fair year straightline basis time available value equity investment reduce carrying asset use estimate useful life determine amortisation directly charge income statement charge account patent live applicable value obtain period nonexclusivity asset live disposal impairment investment gain review appropriate adjust annually contingent loss defer comprehensive income milestone payment recognise point contingent reclassify income statement dividend equity event probable development cost incur investment recognise income statement group associate acquire licence patent knowhow group right receive payment establish equity investment marketing right write income statement record noncurrent asset expect incur criterion recognition internally generate sell year intangible asset meet usually regulatory filing purchase sale equity investment account major market approval consider highly probable trade date purchase sale availableforsale acquire brand value independently fair value investment account settlement date business acquire party brand value inventory substantial long term brand inventory include financial statement low contractual legal nature sell separately rest cost include raw material direct labour direct cost business acquire brand amortise related production overhead net realisable value cost estimate useful life year consider generally determine basis prelaunch inventory useful economic life indefinite hold asset high probability regulatory cost acquire develop computer software internal approval product point provision use internet site external use capitalise intangible carrying value recoverable provision fix asset software site support significant reverse point high probability regulatory business system expenditure lead creation approval determine durable asset erp system software amortise seven trade receivable year computer software year trade receivables carry original invoice impairment noncurrent asset provision doubtful debt provision carry value noncurrent asset review evidence risk nonpayment take account age impairment standalone basis large cash previous experience general economic condition trade generating unit indication asset receivable determine uncollectable write firstly impair additionally goodwill intangible asset indefinite provision available income statement useful live intangible asset available use subsequent recovery amount previously provide test impairment annually provision impairment credit income statement longterm receivables charge income statement year concern discount effect material impairment goodwill reverse impairment loss borrowings noncurrent asset reverse change borrowing initially record proceed estimate determine recoverable amount receive net transaction cost borrowing subsequently extent revise recoverable amount exceed carry amortise cost difference proceed carry value exist net depreciation net transaction cost redemption amortisation impairment recognise recognise charge income statement period investment associate joint venture joint operation relevant borrowing investment associate joint venture carry consolidated balance sheet group share net asset date acquisition postacquisition retain profit loss goodwill arise acquisition group recognise right asset liability revenue expense joint operation gsk annual report note financial statement continue accounting principle policy continue taxation derivative financial instrument classify heldfortrade current tax provide amount expect pay apply carry balance sheet fair value derivative tax rate enact substantively enact designate hedge instrument classify inception balance sheet date cash flow hedge net investment hedge fair value hedge defer tax provide temporary difference arise change fair value derivative designate cash flow tax basis asset liability carry hedge recognise comprehensive income amount financial statement defer tax asset extent hedge effective ineffective portion recognise extent probable future taxable profit recognise profit loss immediately amount deferred available temporary difference comprehensive income reclassify income utilise defer tax provide temporary difference arise statement hedge item affect profit loss investment subsidiary associate joint venture net investment hedge account similar way cash timing reversal temporary difference flow hedge control probable temporary difference reverse foreseeable future defer tax provide rate change fair value derivative designate fair value tax enact substantively enact hedge record income statement balance sheet date change fair value hedge asset liability derivative financial instrument hedge change fair value derivative instrument derivative financial instrument manage exposure qualify hedge accounting recognise immediately market risk principal derivative instrument gsk income statement foreign currency swap interest rate swap foreign exchange discount forward contract option group hold issue time value money material balance derivative financial instrument trading speculative discount current value appropriate discount rate purpose unwind discount record finance income finance expense key accounting judgement estimate prepare financial statement management require taxation estimate assumption affect amount tax charge year million million asset liability revenue expense report financial december current tax payable million statement actual amount result differ million current tax recoverable million estimate follow consider key accounting million defer tax liability million judgement estimate million defer tax asset million million turnover group turnover million current tax provide amount expect pay million defer tax provide temporary difference tax basis asset liability carry amount rate revenue recognise title risk loss passed enact substantively enact balance customer reliable estimate relevant deduction sheet date relevant obligation fulfil earning process regard complete defer tax asset recognise extent probable future taxable profit available gross turnover reduce rebate discount allowance temporary difference utilise base management product return give expect give vary product assumption relate amount time future taxable arrangement buy group arrangement profit factor affect tax charge future year set purchasing organisation dependent submission note taxation change group effective tax rate claim time initial recognition sale accrual change total tax charge year time sale estimate rebate discount approximately million allowance payable return base available market information historical experience group open tax issue number revenue authority outflow fund believe probable reliable amount estimate fully reflect estimate outcome dispute management final outcome amount subject change dependent provide good estimate liability calculate thing type buy group product liability gsk apply risk base approach take account sale mix appropriate probability group able obtain level accrual rebate return review adjust compensatory adjustment international tax treaty regularly light contractual legal obligation historical estimate account specific circumstance trend past experience project market condition market dispute relevant external advice inherently judgemental condition evaluate wholesaler thirdparty change substantially time new fact emerge analysis market research datum internally generate information dispute progress future event cause assumption accrual base change affect future result group gsk annual report strategic report governance remuneration financial statement investor information key accounting judgement estimate continue gsk continue believe adequate provision assumption relate future cash flow estimate useful liability likely arise open assessment december live discount rate base business forecast group recognise provision million inherently judgemental future event cause respect uncertain tax position million assumption impairment test change open issue exist ultimate liability matter vary consequent adverse effect future result group amount provide dependent outcome contingent consideration option liability negotiation relevant tax authority necessary income statement charge contingent consideration litigation proceeding option liability million million legal dispute december liability contingent consideration legal cost year million million amount million million december provision legal dispute million million relate acquisition amount million million shionogiviiv healthcare joint venture group provide anticipate settlement cost million million relate acquisition outflow resource consider probable reliable estimate vaccine business novartis likely outcome dispute legal contingent consideration include consideration payable expense arise claim group estimate business combination record fair value date account specific circumstance dispute acquisition fair value generally base riskadjuste relevant external advice inherently judgemental change future cash flow discount appropriate posttax discount substantially time new fact emerge dispute rate fair value review regular basis progress detail status uncertainty involve annually change reflect income statement significant unresolved dispute set note legal note contingent consideration liability proceeding group grant option novartis respect company director take legal advice novartis shareholde consumer healthcare joint venture establish provision take account relevant fact certain circumstance novartis right require gsk circumstance matter accordance accounting acquire shareholde consumer healthcare joint requirement respect product liability claim relate certain venture marketbase valuation right exercisable product sufficient history claim settlement certain window exercise enable management reliable estimate provision respect novartis entire shareholding instalment require cover unasserted claim group involved gsk recognise financial liability million legal proceeding respect possible noncurrent liability december million reliable estimate expect financial effect result represent present value estimate redemption value ultimate resolution proceeding case gsk event exercise right novartis appropriate disclosure case include calculate apply relevant public company multiple provision contingent liability quantify premium discount forecast future profit accordance ultimate liability legal claim vary amount shareholder agreement sensitivity analysis give note provide dependent outcome litigation noncurrent liability proceeding investigation possible settlement negotiation pfizer request ipo viiv healthcare time position change time gsk consent ipo offering complete assurance loss result outcome legal month pfizer require gsk acquire proceeding exceed provision report shareholde liability option recognise group financial statement material group balance sheet initial value goodwill intangible asset impairment million gsk recognise liability future preferential december goodwill million dividend anticipate payable pfizer shionogi million intangible asset million group balance sheet liability pfizer million option million december recognise trade payable sensitivity analysis give note goodwill deem indefinite life amortise trade payable annual impairment test cash generating unit goodwill allocate performed impairment test base shionogi hold option shareholding viiv establish market multiple riskadjuste future cash flow healthcare gsk recognise liability discount appropriate discount rate assumption option group balance sheet initial value impairment test set note goodwill million q shionogi irrevocably agree waive option result gsk derecognise liability case valuation indicate sufficient headroom option group balance sheet directly equity value reasonably possible change key assumption unlikely result liability million derecognised impairment relate goodwill noncontrolle interest viiv healthcare impairment test intangible asset undertake event detail option occur question carry value asset assumption relate future cash flow discount rate brand intangible asset available base business forecast inherently use amortise subject annual impairment judgemental future event cause assumption underlie test valuation impairment test base establish projection marketbase multiple market multiple riskadjuste future cash flow estimate value liability contingent consideration option useful life asset limit discount appropriate change consequent adverse effect future result discount rate set note intangible asset group gsk annual report note financial statement continue key accounting judgement estimate continue pension postemployment benefit expect longterm rate return bond determine cost provide pension postemployment benefit base portfolio mix indexlinke government corporate charge income statement accordance ias bond equity risk premium add equity employee benefit period benefit derive discount rate derive aa rate corporate bond yield employee service cost assess basis country deep market corporate assumption select management assumption bond government bond yield sensitivity analysis include future earning pension increase discount rate provide note pension postemployment expect longterm rate return asset mortality rate benefit reduction discount rate lead disclose note pension postemployment increase net pension deficit approximately million benefit surplus define benefit scheme arises increase annual pension cost approximately million potential surplus arise commit future selection different assumption affect future result contribution right trustee prevent group group obtain refund surplus future consider determine necessary restrict surplus recognise new accounting requirement follow new amend accounting standard ifrs financial instrument issue final form july issue iasb likely affect future annual report implement group january standard replace majority ia cover ifrs revenue contract customer issue classification measurement de recognition financial asset implement group january financial liabilities impairment financial asset provide standard provide single principlesbased approach new hedge accounting model recognition revenue contract customer focus identification performance obligation contract group currently assess new ifrs expect require revenue recognise performance able quantify impact potential change later obligation satisfied group currently assess new ifrs expect ifrs lease issue january able quantify impact potential change later implement group january standard replace ias lease require lease liability right use asset recognise balance sheet lease group early stage assess potential impact new ifrs exchange rate group use average exchange rate prevail period translate result cash flow overseas average rate subsidiary joint venture associate sterling period end rate translate net asset entity currency euro influence translation relevant exchange rate follow yen period end rate euro yen gsk annual report strategic report governance remuneration financial statement investor information segment information operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet completion novartis transaction march change balance group gsk change segment reporting reflect effect january gsk report result segment pharmaceutical include hiv pharmaceutical rd vaccine consumer healthcare individual member cet responsible segment comparative information restate accordingly group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis pharmaceutical rd segment responsibility president pharmaceutical rd report separate segment corporate unallocated turnover cost include result vaccine consumer healthcare product hold sale number market order meet antitrust approval requirement cost corporate function restate restate turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover restate restate pharmaceutical turnover therapeutic area respiratory cardiovascular metabolic urology immunoinflammation pharmaceutical establish product hiv operation pharmaceutical vaccine business sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler restate restate consumer healthcare turnover category wellness oral care nutrition skin health gsk annual report note financial statement continue segment information continue restate restate segment profit pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring charge legal charge expense settlement litigation government investigation disposal business product associate certain item relate major acquisition disposal activity restate restate depreciation amortisation segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statement investor information segment information continued restate restate ppe intangible asset goodwill impairment segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment restate restate ppe intangible asset impairment reversal segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal restate net asset segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset pharmaceutical segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million nil consumer healthcare segment include option liability million million gsk annual report note financial statement continue segment information continue geographical information uk regard group country domicile restate turnover location customer uk international external turnover turnover location subsidiary uk international turnover include intersegment turnover uk international intersegment turnover uk international external turnover operate profit location subsidiary uk international total operating profit noncurrent asset location subsidiary uk international noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables gsk annual report strategic report governance remuneration financial statement investor information operating incomeexpense impairment equity investment disposal equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend remeasurement consumer healthcare option liability fair value adjustment derivative financial instrument incomeexpense disposal business asset include milestone income million relation divestment ofatumumab number small divestment include disposal oncology business novartis million initial million divestment ofatumumab fair value remeasurement contingent consideration recognise business combination comprise million related acquisition shionogiviiv healthcare joint venture million relate contingent consideration payable novartis relate vaccine acquisition partially offset hedging gain small item fair value adjustment derivative financial instrument arise foreign exchange forward contract option take hedge foreign currency movement sale purchase denominate foreign currency note financial instrument relate disclosure include unrealised loss million arise number forward exchange contract enter follow announcement propose novartis transaction protect sterling value net dollar proceed group completion transaction operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset net reversal net foreign exchange lossesgain inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration include operate profit major restructuring charge million million million note major restructuring cost gsk annual report note financial statement continue operating profit continue restate fee payable company auditor associate audit parent company consolidated financial statement audit company subsidiary attestation sarbanesoxley act audit auditrelated service taxation compliance taxation advice assurance service service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement service provide auditor primarily relate advisory service year end december addition fee pay respect gsk pension scheme audit service employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan plan gsk annual report strategic report governance remuneration financial statement investor information employee cost continue average monthly number person employ group include director year number number number manufacturing sell general administration research development average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record monthly average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan major restructuring cost major restructuring cost charge arrive operating profit include restructure cost arise major change programme initiate pharmaceutical restructuring programme announce october follow novartis transaction complete combine programme total restructuring cost million incur follow area restructure rd organisation predominantly unite kingdom north america japan project simplify eliminate process lead staff reduction support function restructuring pharmaceutical business emerge market europe lead staff reduction sale force administration transformation manufacture vaccine business deliver step change quality cost productivity continue integration enhance vaccine business consumer healthcare joint venture analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost provision reversal million million million reflect release legacy support function novartis integration provision asset impairment million million nil noncash charge total million million million noncash item principally fix asset write down support function manufacturing research facility accelerate depreciation asset live rd manufacturing shorten result major restructure programme charge settle cash include termination lease site closure cost consultancy project management fee gsk annual report note financial statement continue finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables fair value adjustment derivative fair value profit loss derivative account fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia finance expense interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value movement derivative designate hedge instrument fair value adjustment hedge item fair value movement derivative fair value profit loss reclassification cash flow hedge comprehensive income unwind discount provision finance expense derivative account fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest expense arise derivative fair value profit loss relate swap interest expense gsk annual report strategic report governance remuneration financial statement investor information associate joint venture group share tax profit loss associate joint venture set share tax profit associate share tax loss joint venture december group hold significant associate innoviva inc summarise income statement information respect innoviva set periods group account investment innoviva associate group share tax profit associate comprehensive income include profit million comprehensive income nil respect innoviva september turnover profit taxation comprehensive income total comprehensive income result innoviva include summarise income statement information represent estimate earning innoviva relevant period innovivas turnover royalty income gsk relation relvarbreo ellipta anoro ellipta sale march group divest half shareholde aspen pharmacare holding limit cease account remain investment associate aspen group significant associate summarise income statement information respect aspen set period group account investment aspen associate march turnover profit taxation comprehensive income total comprehensive income result aspen include summarise income statement information represent estimate earning aspen group relevant period adjust transaction gsk aspen aggregate financial information respect gsk share associate undertaking joint venture set share turnover share tax lossesprofit share comprehensive income share total comprehensive incomeexpense group sale associate joint venture million million million gsk annual report note financial statement continue taxation taxation charge base profit year uk current year charge rest world current year charge credit respect prior period total current taxation total defer taxation gsk payment million uk corporation tax hmrc january gsk payment million relation uk corporation tax amount corporation tax include business taxis bear gsk year significant component defer tax credit prior period arise respect remeasurement contingent consideration relation shionogiviiv healthcare joint venture credit include unwind defer tax liability disposal group oncology business novartis follow table reconcile tax charge calculate uk statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax uk statutory rate taxation difference overseas taxation rate benefit intellectual property incentive rd credit remeasurement nontaxable option liability loss recognisedpreviously unrecognise loss permanent difference disposal acquisition permanent difference reassessment prior year estimate respect current defer taxis tax unremitted earning tax chargetax rate gsk substantial business presence country world impact difference overseas taxation rate arise profit earn country tax rate high uk statutory rate significant france india partly offset increase benefit intellectual property incentive uk patent box belgian patent income deduction regime regime provide reduce rate corporate income tax profit earn qualifying patent group incur material nondeductible charge follow revaluation liability viiv healthcare consumer healthcare joint venture option impact high overseas tax rate reduce permanent difference arise disposal group overall effective tax rate influence significant transactionrelated remeasurement charge arise viiv healthcare contingent consideration liability consumer healthcare joint venture viiv healthcare option liability remeasurement liability give rise charge profit tax million relate tax credit million exclude item effective tax rate year detail consumer healthcare joint venture option set note noncurrent liability viiv healthcare arrangement future tax charge effective tax rate affect factor acquisition disposal restructure location research development activity tax regime reform resolution open matter continue bring tax affair date world tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan defer taxation sharebase payment define benefit plan exchange movement fair value movement cash flow hedge fair value movement availableforsale investment total creditcharge equity statement comprehensive income item charge statement comprehensive income tax share base payment gsk annual report strategic report governance remuneration financial statement investor information taxation continue issue relate taxation group tax charge sum total current defer tax expense calculation group total tax charge necessarily involve degree estimation judgement respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group hold provision million respect uncertain tax position million increase recognise provision primarily drive foreign exchange impact revalue overseas exposure ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue believe appropriate provision period open agree tax authority integrate nature group worldwide operation involve significant investment research strategic manufacturing limited number location consequential crossborder supply route numerous endmarket gsk big risk respect taxation despite adherence oecds establish arm length principle different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation gsk apply riskbased approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction group consider major source estimation uncertainty end reporting period significant risk result material adjustment carry amount taxrelated asset liability financial year continue significant international focus tax reform include oecds bep project european commission initiative include increase use fiscal state aid investigation domestic initiative world result significant change establish tax principle increase tax authority dispute turn adversely affect effective tax rate result high cash tax liability aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax repatriation uk legislation relate company distribution provide exemption tax overseas profit subject certain exception provision defer tax liability million million respect withholding tax arise distribution profit certain overseas subsidiary remainder unremitte profit defer tax provide billion december billion defer tax distribution remain profit provide ground group able control timing reversal remain temporary difference probable reverse foreseeable future movement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total assetliability january exchange adjustment credit income statement credit statement comprehensive income assetliability december defer tax credit income statement million include million rd incentive recognise operate profit taxation charge income statement defer tax liability provide relation intangible asset predominately relate temporary difference arise asset liability acquire historic business combination group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany stock eliminate consolidated account intragroup profit eliminate individual entity tax return temporary difference arise reverse point time stock sell externally defer tax asset recognise tax loss comprise million million asset relate trading loss million nil asset relate capital loss net temporary difference include accrue expense tax deduction available pay basis offset defer tax asset liability appropriate territory net defer tax asset comprise defer tax asset defer tax liability gsk annual report note financial statement continue taxation continue restate unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss december defer tax asset recognise probable future taxable profit available utilise loss unrecognised trading loss revise follow reassessment available loss defer tax recognise earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total special dividend april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend special dividend declare second interim dividend amount recognise year follow dividend shareholder gsk annual report strategic report governance remuneration financial statement investor information property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december depreciation january exchange adjustment charge year disposal writeoff transfer fromto asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business gsk annual report note financial statement continue propertyplant equipment continue net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment million nil net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million impairment nil nil net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost disposal value use fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk value use calculation impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million rd million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale carrying value december asset impairment charge reverse year million million million million computer software reclassify asset construction intangible asset ready use goodwill cost january exchange adjustment addition business combination note transfer asset hold sale cost december net book value january net book value december gsk acquire hiv rd preclinical discovery stage portfolio bristol myers squibb goodwill million arise acquisition allocate pharmaceutical goodwill allocate group segment follow allocation revise reflect current segment structure pharmaceutical vaccine consumer healthcare net book value december gsk annual report strategic report governance remuneration financial statement investor information goodwill continue recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical pa vaccines pa consumer healthcare pa terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill goodwill monitor segmental level pharmaceutical cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset gsk annual report note financial statement continue intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise development cost capitalise borrowing cost addition business combination addition reclassification disposal asset writeoff transfer asset hold sale cost december exchange adjustment capitalise development cost capitalise borrowing cost addition business combination addition disposal asset writeoff transfer asset hold sale reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff transfer asset hold sale impairment december exchange adjustment impairment loss disposal asset writeoff transfer asset hold sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost charge impairment year include impairment oncome ansolar maxinutrition carry value december intangible asset impairment charge reversed year follow impairment reversal million million patent expiry date group significant asset relevant set page gsk annual report strategic report governance remuneration financial statement investor information intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow dolutegravir benlysta menveo bexsero man abcwy fluarixflulaval hiv asset acquire bms selzentry okairos technology platform indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade excedrin physiogel polident brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise increase carry value year primarily reflect impact exchange rate movement brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate country currency specific risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction exchange rate assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply nil management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset gsk annual report note financial statement continue investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal transfer investment distribution receive movement lossprofit tax recognise consolidated income statement comprehensive income recognise consolidated statement comprehensive income december group hold significant associate december innoviva inc december group own million share innoviva biopharmaceutical company list nasdaq company partner gsk development long act beta agonist vilanterol currently receive royalty income sale product contain component relvarbreo ellipta anoro ellipta retain economic interest future royalty pay gsk sale close triple approve commercialise remain economic interest royalty theravance biopharma inc company spin innoviva group hold common stock investment innoviva market value million december million summarise balance sheet information base result information respect innoviva set december december noncurrent asset current asset current liability noncurrent liability net liability interest associate undertake goodwill fair value adjustment carry value december gsk annual report strategic report governance remuneration financial statement investor information investment january exchange adjustment addition fair value gain reclassification investment associate net fair value movement impairment loss transfer investment associate joint venture disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset investment include list investment million million decrease carry value year primarily sale group remain stake aspen pharmacare holding limited book value december million significant investment hold december theravance biopharma inc group hold common stock investment fair value december million million investment include equity stake company gsk research collaboration provide access biotechnology development potential interest interest company arise business divestment disposal investment fair value movement reclassify equity income statement base average cost share acquire different time impairment loss record recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement carry value december investment impaired follow original cost cumulative impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables gsk annual report note financial statement continue inventory raw material consumable work progress finish good trade receivable trade receivables net provision bad doubtful debt accrue income prepayment interest receivable employee loan advance receivables trade receivable include million million associate joint venture receivables include million nil associate joint venture bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit asset hold sale property plant equipment goodwill intangible inventory noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell include asset hold sale asset write fair value cost sell million million valuation methodology use significant input base observable market datum valuation classify level fair value hierarchy gsk annual report strategic report governance remuneration financial statement investor information trade payable trade payable wage salary social security viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include million million associate joint venture customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine fully describe group financial review accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group pfizer option shareholding viiv healthcare recognise currently exercisable table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set pension postemployment benefit restate restate pension postemployment cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk annual report note financial statement continue pension postemployment benefit continue gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive aa rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt uk mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate rp white collar table adjust reflect recent experience rate project scale bbd allow future improvement life expectancy average life expectancy assume individual age project apply individual age follow uk male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment group review investment strategy uk plan asset allocation uk plan adjust approximately return seek asset liability match asset target asset allocation plan update return seek asset liability match asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix return seek asset generate future return liability match asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property bank counterparty risk plan liability series future cash flow relatively long duration ias r basis cash flow sensitive change expect longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liability uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle join define contribution scheme glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal group apply follow financial assumption assess define benefit liability uk rest world pa pa pa pa pa pa pa pa pa rate increase future earning discount rate expect pension increase na na na cash balance creditconversion rate na na na inflation rate gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service cost net interest cost gain settlement expense remeasurement record statement comprehensive income postretirement pension benefit uk group restate rest world restate group amount charge operating profit current service cost past service costcredit net interest cost gain settlement expense remeasurement record statement comprehensive income postretirement pension benefit uk group restate rest world restate group amount charge operating profit current service cost past service costcredit net interest creditcost gain settlement expense remeasurement record statement comprehensive income amount include past service cost include million million million augmentation cost million arise major restructuring programme note provision gsk annual report note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit fair value asset liability uk define benefit pension scheme aggregate datum define benefit pension scheme group follow uk rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset indexlinke gilt hold uk repo programme include government bond relate loan include asset value million million million uk group restate rest world restate december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue uk group restate rest world restate december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit uk group restate rest world restate group movement fair value asset asset january exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december addition asset asset hold uk define contribution plan amount million december million million previously include figure prior year figure restate reflect change group special funding contribution uk pension scheme total million million million nil million nil scheme gsk reach agreement trustee uk pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation base funding agreement follow valuation additional contribution eliminate pension deficit expect million contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report note financial statement continue pension postemployment benefit continue postretirement pension benefit uk group restate rest world restate group movement define benefit obligation obligation january exchange adjustment service cost past service cost interest cost settlement curtailment movement remeasurement scheme participant contribution benefit pay obligation december exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december addition obligation obligation uk define contribution plan amount million december million million previously include figure prior year figure restate reflect change define benefit pension obligation analyse follows restate restate fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million post retirement benefit unfunded gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue movement net define benefit liability follows restate restate january exchange adjustment addition business combination service cost past service cost interest costincome settlement curtailment remeasurement return plan asset exclude amount include interest gainloss change demographic assumption lossgain change financial assumption experience lossesgain employer contribution expensesother movement december remeasurement include postretirement benefit detailed gain change demographic assumption lossgain change financial assumption experience gainslosse gsk annual report note financial statement continue pension postemployment benefit continue define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statement investor information provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute major restructuring programme group involve substantial number legal group initiate major change restructure dispute include notification possible claim set programme focus opportunity simplify supply chain note legal proceeding provision legal dispute process build group capability manufacturing include amount relate product liability antitrust government rd restructure european pharmaceutical business investigation principally relate sfo relate investigation pharmaceutical restructuring programme announce contract termination self insurance environmental cleanup october focus rescale commercial charge year million net reversal operation global support function certain rdmanufacturing estimate insurance recovery primarily relate provision operation pharmaceutical addition integration product liability case paxil product restructuring programme initiated follow commercial dispute government investigation completion novartis transaction restructure integration programme report combined discount provision increase million major restructure programme decrease million high discount rate compare discount calculate provision staff severance payment management riskadjuste project cash flow riskfree rate return formal decision eliminate certain position communicate group employee affect respect product liability claim relate certain product appropriate consultation procedure complete appropriate sufficient history claim settlement enable provision staff severance payment management reliable estimate provision required immediately cover unasserted claim ultimate liability matter vary amount provide dependent outcome pension augmentation arise staff redundancie litigation proceeding investigation possible settlement million million charge negotiation year transfer pension obligation provision show note pension postemployment benefit nature group business number asset writedown recognise impairment matter subject negotiation litigation property plant equipment note property plant year litigation proceeding include appeal equipment majority amount provide expect procedure year reach resolution utilise year outofcourt settlement discussion protract employee relate provision group potential settlement discussion number employee relate provision include obligation certain medical dispute amount provide base benefit disabled employee spouse current assessment progress dispute december provision benefit amount estimate million provide december million million employee benefit reflect settle year december variety provision severance cost jubilee awards expect nil nil provision legal longservice benefit dispute reimburse party insurer discussion legal issue note legal proceeding provision include provision insurance provision million million onerous property lease provision million million number provision include vehicle insurance regulatory matter gsk annual report note financial statement continue noncurrent liability accrual defer income consumer healthcare option liability payable consumer healthcare option liability relate ability novartis share consumer healthcare joint venture gsk certain point future commencing liability record present value estimate redemption value apply discount rate expect redemption calculate average relevant public company multiple approach premium discount base forecast revenue earning consumer healthcare joint venture form gsk consumer healthcare segment remeasurement charge year million million note operate incomeexpense table show indicative basis income statement balance sheet sensitivity reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast sale multiple apply decrease sale forecast sale multiple apply cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft obligation finance lease medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange longterm borrowing medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange obligation finance lease net debt gsk annual report strategic report governance remuneration financial statement investor information net debt continue current asset liquid investment classify availableforsale investment december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate nil million effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate million million respectively million nil gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme billion billion issue december issuance gsk billion year commit facility billion billion day commit facility fiveyear commit facility agree september extend year september day commit facility agree september liquid investment cash cash equivalent show table weight average interest rate commercial paper borrowing december issuance weight average interest rate current bank loan overdraft december average effective preswap interest rate note classify short term december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision addition million million asset include note noncurrent asset form net debt pledge collateral future rental payment operate lease arrangement enter human genome sciences inc prior acquisition group finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december million nil financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant tax legal dispute group party set note taxation note legal proceeding gsk annual report note financial statement continue share capital share premium account share ordinary share p premium number share capital authorise december december december share capital issue fully pay january issue employee share scheme december issue employee share scheme december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme gsk annual report strategic report governance remuneration financial statement investor information movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december exchange movement overseas net asset december exchange movement overseas net asset december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive income year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive expenseincome year gsk annual report note financial statement continue movement equity continue non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary defer tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement loss define benefit plan defer tax remeasurement loss define benefit plan comprehensive expenseincome year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal net fair value movement year ordinary share acquire esop trust writedown share hold esop trust forward contract noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report strategic report governance remuneration financial statement investor information relate party transaction december gsk own million share innoviva inc biopharmaceutical company list nasdaq gsk begin recognise innoviva associate september royalty gsk innoviva year million million september december december balance payable gsk innoviva million december gsk hold interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccine japan gsk sell million million vaccine product joint venture december trading balance gsk jvc million balance payable gsk jvc nil loan million jvc million medicxi venture lp million index venture life vi jersey lp remain gsk december aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment change work capital decreaseincrease inventory increasedecrease trade receivables increase trade payable decreaseincrease receivables contingent consideration pay note noncash increase contingent consideration liability increase payable decreaseincrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report note financial statement continue reconciliation net cash flow movement net debt net debt begin year increasedecrease cash bank overdraft decreaseincrease liquid investment net increase longterm loan net increase inrepayment shortterm loan net repayment obligation finance lease exchange adjustment noncash movement movement net debt net debt end year january reclass december exchange ification acquisition cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper european medium term note debt year european medium term note net debt information significant change net debt note net debt gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give acquisition gsk complete small business acquisition cash consideration million pay year acquire hiv rd preclinical discovery stage portfolio bristol myers squibb consideration contingent commercial milestone future sale performance initial estimate million recognise contingent consideration intangible asset acquire value million goodwill million recognise gsk form galvani bioelectronic limited year acquire intangible asset million cash cash equivalent million verily life sciences llc return shareholding galvani bioelectronic fair value shareholde million gsk recognise credit million noncontrolling interest represent verilys share net asset contribute business disposal gsk number small business disposal period net cash consideration million addition defer consideration receivable million recognise cash flow business business acquisition disposal cash consideration paidreceive purchase adjustment cash cash equivalent acquire cash inflow addition gsk cash investment million associate joint venture acquisition novartis consumer healthcare vaccine business threepart interconditional transaction novartis ag involve consumer healthcare vaccine oncology business complete march gsk novartis contribute respective consumer healthcare business consumer healthcare joint venture noncash transaction gsk equity interest majority control joint venture addition gsk acquire novartis global vaccine business exclude influenza vaccine initial cash consideration billion billion contingent consideration represent subsequent potential milestone payment billion billion arise achievement specify development target ongoing royalty base future sale performance certain product total payable unlimited milestone million million pay march business acquisition addition gsk complete small vaccine business acquisition cash consideration million net cash acquire fair value exist investment million represent goodwill million intangible asset million net liability million gsk annual report note financial statement continue acquisition disposal continue fair value asset acquire business combination include goodwill set table novartis consumer novartis healthcare vaccine business business net asset acquire intangible asset property plant equipment inventory trade receivables asset include cash cash equivalent trade payable defer tax liability liability noncontrolle interest goodwill consideration settle share gsk consumer healthcare holding cash consideration pay purchase adjustment fair value equity investment disposal contingent consideration defer tax contingent consideration loss settlement preexist relationship total consideration noncontrolle interest consumer healthcare joint venture calculate apply goodwill method represent novartis share net asset contribute joint venture attributable goodwill goodwill business acquire represent potential synergy arise combine acquire business gsk exist business value workforce acquire majority goodwill recognise expect deductible tax purpose total transaction cost recognise acquisition novartis amount million march december turnover million arise novartis consumer healthcare vaccine business include group turnover business acquire beginning year estimate group turnover approximately million high business integrate group exist activity practical identify impact group profit period disposal oncology gsk divest market oncology business relate rd activity right akt inhibitor grant commercialisation partner right future oncology product novartis consideration billion million purchase adjustment business disposal gsk number small business disposal period net cash consideration million profit disposal business determine follow oncology cash consideration include currency forward purchase adjustment net asset sell goodwill intangible asset property plant equipment inventory cash net asset loss currency forwards book disposal cost profit disposal gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue investment associate joint venture march gsk sell half shareholding aspen represent issue share capital company million cash result sale group long consider ability exert significant influence aspen group remain investment transfer investment associate investment cash consideration net book value share reclassification exchange comprehensive income transaction fee item profit disposal business business associate acquisition disposal jv disposal total cash flow cash consideration paidreceive purchase adjustment cash cash equivalent acquireddiveste defer cash proceed contingent consideration pay transaction cost cash outflowinflow addition gsk cash investment million associate joint venture acquisition acquisition acquisition integration cost million arise propose threepart interconditional transaction novartis ag expense million pay cash year disposal year million receive deferred consideration sale anticoagulant business complete million disposal associate gsk cash investment million associate business acquisition associate disposal joint venture total cash flow cash consideration pay transaction cost pay purchase business associate net cash proceed disposals gsk annual report note financial statement continue contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare vaccine total january remeasurement goodwill remeasurement income statement cash payment operate cash flow cash payment purchase business movement december addition business combination remeasurement income statement cash payment operate cash flow cash payment purchase business movement december addition business combination remeasurement income statement cash payment operate cash flow cash payment purchase business movement december addition year represent recognition preferential dividend payable shionogi million contingent consideration liability acquisition hiv business bms million contingent consideration payable december million million expect pay year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccine business expect pay number year result total estimate liability discount present value show shionogi viiv healthcare contingent consideration liability discount novartis vaccine contingent consideration liability discount partly partly shionogiviiv healthcare contingent consideration liability calculate base forecast sale performance specify product principally dolutegravir life product table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogi novartis viiv healthcare vaccine increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statement investor information noncontrolle interest group subgroup material noncontrolle interest viiv healthcare limited subsidiary gsk consumer healthcare holding limit subsidiary summarise financial information respect viiv healthcare group gsk consumer healthcare joint venture set viiv healthcare turnover loss taxation comprehensive income total comprehensive expense noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increase cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend loss taxation million loss taxation million loss taxation million state charge preferential dividend payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year follow amount attributable viiv healthcare group include gsk consolidate statement comprehensive income consolidate statement change equity consolidate balance sheet total comprehensive expense year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report note financial statement continue noncontrolle interest continue consumer healthcare joint venture turnover profitloss taxation comprehensive income total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net asset net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity decrease cash bank overdraft year financial information relate consumer healthcare joint venture standalone basis formation march impact grouprelate adjustment major restructuring charge follow amount attributable consumer healthcare joint venture include gsk consolidate statement comprehensive income consolidate statement change equity consolidate balance sheet total comprehensive income year attributable noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report strategic report governance remuneration financial statement investor information commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount number commitment licensing agreement include arrangement janssen sciences ireland uc miltenyi biotec gmbh new arrangement offset reduced commitment prior year transaction include amendment agreement oncome pharmaceuticals inc prime therapeutics inc gsk reach agreement trustee uk pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million subsequent year include table include commitment exclude normal ongoing annual funding requirement uk approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease disclose million million provide commitment group balance sheet commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease gsk annual report note financial statement continue financial instrument relate disclosure gsk use variety financial instrument finance operation market risk derivative financial instrument manage market risk interest rate risk management operation derivative principally comprise interest gsk objective minimise effective net interest cost rate swap foreign exchange forward contract swap balance mix debt fix float interest rate swap borrowing liquid asset currency require time policy interest rate risk management limit group purpose manage exposure financial risk float interest payment prescribe percentage change foreign exchange rate interest rate operating profit gsk hold issue derivative speculative purpose foreign exchange risk management treasury policy specifically prohibit activity foreign currency transaction exposure arise external trade transaction financial instrument undertake manage flow normally hedge foreign currency transaction risk arise underlie business activity exposure arise internal trade flow selectively hedge capital management group objective minimise exposure overseas operating gsk financial strategy support group strategic priority subsidiary transaction risk match local currency income regularly review board gsk manage capital local currency cost possible gsk internal trading structure group appropriate mix debt equity transaction match centrally intercompany payment term manage reduce foreign currency risk foreign currency cash capital structure group consist net debt flow hedge selectively include hedge foreign billion note net debt shareholder equity exchange risk arise acquisition disposal asset billion consolidated statement change equity possible gsk manage cash surplus borrow total capital include provide noncontrolle requirement subsidiary company centrally forward interest billion contract hedge future repayment originate longterm credit rating standard poor stable currency outlook moodys investor service moodys order reduce foreign currency translation exposure group negative outlook group shortterm credit rating seek denominate borrowing currency principal p standard poor moodys respectively asset cash flow primarily denominate liquidity risk management dollar euro sterling borrowing swap gsk policy borrow centrally order meet anticipate currency require funding requirement strategy diversify liquidity source borrowing denominate swap foreign currency range facility maintain broad access financial match investment overseas group asset treat market hedge relevant asset forward contract major december gsk billion borrowing currency reduce exposure group repayable year hold billion cash cash investment overseas asset net investment hedge equivalent liquid investment billion hold section note detail centrally gsk access shortterm finance billion billion commercial paper programme billion billion issue december issuance gsk billion year commit facility billion billion day commit facility fiveyear commit facility agree september extend year september day commit facility agree september facility undrawn december gsk consider level committed facility adequate give current liquidity requirement gsk billion european medium term note programme december billion note issue programme group billion billion note issue december shelf registration gsk currently process renew shelf registration statement order maintain access debt market gsk borrowing mature date option own minority interest partner viiv healthcare consumer healthcare jv business exercisable immediately respectively review liquidity requirement gsk consider sufficient financing option available option exercise gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue credit risk december million cash categorise hold group consider maximum credit risk december unrated subinvestment grade rate counterpartie low million december million bbbbaa million cash transit total group financial asset exception remain exposure concentrate overseas bank local investment comprise equity investment bear cash management investment purpose include million equity risk credit risk detail nigeria hold united bank africa zenith bank stanbic group total financial asset december gsk ibtc bank million btv austria million great concentration credit risk billion citibank islandsbanki iceland million produbanco ecuador aa billion citibank aa million bank balance deposit hold bbb treasuryrelate credit risk baa rate counterpartie million hold bbbbaa gsk set global counterparty limit gsk banking rate counterpartie include balance deposit million investment counterpartie base longterm credit rating state bank india million hdfc bank india moodys standard poor usage limit monitor bank local cash management local daily investment purpose gsk actively manage exposure credit risk reduce surplus cash balance possible gsk strategy regionalise cash management concentrate cash centrally possible table set credit exposure counterpartie rate liquid investment cash cash equivalent derivative gross asset position derivative contract consider purpose table isda agreement risk net position counterparty table e set group financial asset liability offset basis bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security rd party financial derivative total bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security rd party financial derivative total credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table gsk annual report note financial statement continue financial instrument relate disclosure continue gsk centrally manage cash reserve amount billion follow method assumption estimate december available month include fair value billion centrally manage cash hold viiv healthcare cash cash equivalent approximate carry own subsidiary group invest centrally manage liquid asset bank deposit aaaaaa rate treasury treasury liquid investment base quote market price calculate repo money market fund aaaaaa rate liquidity fund base observable input case marketable security base principal amount case nonmarketable wholesale retail credit risk security short repricing period outside customer account investment equity investment trade active market group trade receivable balance determine reference relevant stock exchange quote bid line pharmaceutical company group price equity investment determine reference sell product small number wholesaler addition current market value similar instrument reference hospital pharmacie physician group sale discount cash flow underlie net asset large wholesaler amount approximately shortterm loan overdraft commercial paper sale pharmaceutical vaccine business approximate carry short maturity december group trade receivable instrument wholesaler total million million group expose concentration credit risk longterm loan base quote market price case respect wholesaler european medium term note fix rate encounter financial difficulty materially adversely borrowing level fair value measurement approximate affect group financial result carry case float rate bank loan loan group credit risk monitoring activity relate wholesaler include review quarterly financial information contingent consideration business acquisition base standard poor credit rating development gsk internal present value expect future cash flow risk rating establishment periodic review credit limit interest rate swap foreign exchange forward contract swap group believe credit risk provision option base present value contractual cash require excess normal provision bad doubtful debt flow option valuation model market source datum note trade receivable exchange rate interest rate balance sheet date fair value financial asset liability receivables payable include option approximate table present carry amount fair carrying value group financial asset liability december december companyowne life insurance policy base cash surrender value fair value financial asset liability include price receive sell asset pay transfer lease obligation approximate carry liability orderly transaction market participant fair value investment gsk share measurement date december employee share ownership plan esop trust hold gsk share carry value million million fair value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue carry fair carry fair value value value value note availableforsale investment liquid investment government bond investment loan receivables cash cash equivalent e trade receivables certain noncurrent asset scope ia b financial asset fair value profit loss noncurrent asset scope ia b derivative designate fair value profit loss e derivative classify hold trading ia e total financial asset financial liability measure amortise cost borrowing exclude obligation finance lease bond designate hedge relationship bond bank loan overdraft e commercial paper total borrowing exclude obligation finance lease f obligation finance lease total borrowing trade payable provision certain noncurrent liability scope ias c financial liability fair value profit loss contingent consideration liability c derivative designate fair value profit loss e derivative classify hold trading ia e total financial liability net financial asset financial liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability contingent consideration liability reconcile relevant note page gsk annual report note financial statement continue financial instrument relate disclosure continue financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss contingent consideration liability derivative designate fair value profit loss derivative classify held trading ias level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss contingent consideration liability derivative designate fair value profit loss derivative classify hold trading ia movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income contingent consideration liability business acquire year payment contingent consideration liability addition disposal transfer level exchange december gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue net loss million million attributable level financial instrument recognise income statement attributable financial instrument hold end year net loss report operate income million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million million arise remeasurement contingent consideration payable acquisition novartis vaccine business net gain million million attributable level equity investment report comprehensive income fair value movement availableforsale investment include net gain million net loss million respect equity investment hold end year financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency include million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency sensitivity analysis balance provide note contingent consideration liability b trade receivables noncurrent asset scope ias follow table reconcile financial instrument trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ias fair value non fair value non loan financial financial loan financial financial profit loss receivables instrument instrument total profit loss receivables instrument instrument total trade receivable note noncurrent asset note follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day gsk annual report note financial statement continue financial instrument relate disclosure continue c trade payable provision noncurrent liability contingent consideration liability scope ias follow table reconcile financial instrument trade payable provision noncurrent liability contingent consideration liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ia fair value fair value financial nonfinancial financial nonfinancial profit loss liability instrument instrument total profit loss liability instrument instrument total trade payable note provision note noncurrent liability note contingent consideration liability note derivative financial instrument hedge programme follow table set fair value derivative hold gsk derivative maturity year fair value fair value asset liability asset liabilitie net investment hedge foreign exchange contract principal million million cash flow hedge foreign exchange contract principal million million derivative designate fair value profit loss foreign exchange contract principal million million embed derivative derivative classify hold trading ia total derivative instrument foreign exchange contract classify held trading ia principal foreign exchange contract absolute total outstanding position balance sheet date group foreign exchange contract period month december group hold outstanding foreign exchange contract net asset fair value million million asset million liability december fair value million net asset million asset million liability overall decrease net asset fair value weaken sterle major currency particular impacting hedging euro dollar denominate intercompany loan balance designate accounting hedge fair value movement take income statement period offset exchange gain loss relate intercompany loan balance gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue fair value hedge december group designate fair value hedge net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro foreign operation show table hedge relate japanese yen foreign operation close year carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge hedge foreign exchange exposure arise euro dollar denominate coupon payment relate group european medium term note number highly probable forecast transaction denominate dollar addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year balance reclassify finance cost life bond e offset financial asset liability follow table set financial asset financial liability subject offset enforceable master netting arrangement similar agreement amount set financial asset liability group balance sheet set trade receivables trade payable derivative financial asset derivative financial liability amount offset balance sheet offset certain circumstance set net financial gross gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft net financial gross gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft gross financial asset liability set balance sheet primarily relate cash pooling arrangement bank amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party gsk annual report note financial statement continue financial instrument relate disclosure continue f debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bear g sensitivity analysis foreign exchange interest rate sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation december financial instrument affect market risk include cash cash equivalent borrowing trade receivables payable derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change foreign exchange interest rate foreign exchange sensitivity foreign currency exposure arise translation financial asset liability functional currency entity hold cash cash equivalent bank loan overdraft intercompany loan deposit receivables payable trade receivables payable derivative financial instrument hedge legal provision activity arise acquisition disposal asset group primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen base group net financial asset liability december weaken sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro yen appreciation yen equivalent depreciation currency cause follow increasedecrease income million million million million million million dollar euro yen exchange rate respectively gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro dollar denominate coupon payment relate group european medium term note number highly probable forecast transaction denominate dollar increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro yen appreciation yen equivalent depreciation currency cause follow decreaseincrease equity million million nil nil million million dollar euro yen exchange rate respectively table present group sensitivity foreign exchange rate base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation euro yen appreciation yen equivalent depreciation currency follow impact net debt million million million dollar euro yen exchange rate respectively million million million interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro variable rate financial asset liabilitie interest rate applicable float rate financial asset liability increase basis point assume variable remain constant estimate group finance income increase approximately million million increase basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate gsk annual report note financial statement continue financial instrument relate disclosure continue h contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis group use interest rate swap manage interest rate risk purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december contractual cash flow respect operating lease vacant space provision exclude table include commitment noncancellable operating lease table note commitment obligation finance charge trade payable interest finance obligation liability debt debt lease finance lease net debt total december year year year year year year great year gross contractual cash flow finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow increase contractual cash flow nonderivative financial liability billion year result partially initial recognition viiv healthcare option liability billion addition increase billion forecast future cash flow respect contingent consideration payable acquisition shionogiviiv healthcare joint venture acquisition novartis vaccine business anticipate contractual cash flow repayment debt debt interest increase billion year principally retranslation dollar denominate debt adversely impact weaken sterling volatility market compound political economic event table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument amount receivable payable year increase compare december result hedge commercial paper programme increase hedge euro receivables receivables payable receivables payable year year gross contractual cash flow gsk annual report strategic report governance remuneration financial statement investor information employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share glaxosmithkline plc discount price grant restrict share award normally exercisable end year vest performance period award normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance uk practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail glaxosmithkline share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant director member cet performance condition base equally weight measure year performance period adjust free cash flow tsr rd new product performance award eligible employee performance condition base gsk ep growth compare increase uk retail price index year measurement period adjust free cash flow addition business element award base strategic operational business measure year measurement period specific employee business area fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million ad share option savingsrelate option purpose value savingsrelated option arrive share base payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount gsk annual report note financial statement continue employee share scheme continue share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year year year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable share option ad option currently exercisable expire exercise july change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution treasury share carry value million purchase uk esop trust satisfy future award cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value post balance sheet event february gsk complete sale anaesthesia portfolio aspen exclude canada market million milestone million gsk annual report strategic report governance remuneration financial statement investor information principal group company follow represent principal subsidiary country incorporation group december equity share capital entity wholly own group percentage interest show company incorporate principal country operation state england glaxo group limited block drug company inc glaxo operation uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare lp glaxosmithkline consumer healthcare uk trading limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited novartis consumer health inc glaxosmithkline research development limit stiefel laboratories inc glaxosmithkline service unlimited viiv healthcare company glaxosmithkline uk limited setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare uk limited europe glaxosmithkline biological sa belgium glaxosmithkline argentina sa argentina glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline biological sas france glaxosmithkline consumer healthcare australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline brasil limitada brazil laboratoire glaxosmithkline france glaxosmithkline consumer healthcare inc canada viiv healthcare sas france glaxosmithkline inc canada glaxosmithkline consumer healthcare gmbh co kg d biomedical corporation quebec canada germany glaxosmithkline limited china hong kong glaxosmithkline gmbh co kg germany sinoamerican tianjin smith kline french laboratories ltd china gsk vaccines gmbh germany glaxosmithkline consumer healthcare limited india glaxosmithkline consumer healthcare spa italy glaxosmithkline pharmaceuticals limited india glaxosmithkline spa italy glaxosmithkline consumer healthcare japan kk japan gsk vaccines srl italy glaxosmithkline kk japan glaxosmithkline bv netherlands viiv healthcare kabushiki kaisha japan glaxosmithkline pharmaceuticals sa poland glaxosmithkline pakistan limited pakistan gsk service sp z oo poland glaxo wellcome manufacturing pte ltd singapore glaxosmithkline trading services limited republic ireland glaxosmithkline korea limited republic korea glaxosmithkline sa spain glaxosmithkline llaclari sanayi ticaret turkey laboratorios viiv healthcare sl spain novartis consumer health sa switzerland e xempt provision section company act ireland accordance exemption note section act subsidiary disclose page exempt provision consolidate group financial statement directly hold wholly own subsidiary glaxosmithkline plc subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc page complete list subsidiary undertaking associate joint venture form financial statement gsk annual report note financial statement continue legal proceeding group involve significant legal administrative advair hfa flovent hfa ventolin hfa proceeding principally product liability intellectual property tax september mylan pharmaceuticals mylan file antitrust governmental investigation relate private petition inter part review ipr united states patent litigation significant matter tax trademark office uspto seek invalidate patent matter describe group make provision patent patent patent claim method proceeding regular basis summarise note treatment formulation contain active medication accounting principle policy note provision propellant know substantially free surfactant use group involved significant legal proceeding hydrofluoroalkane hfa meter dose inhaler advair respect possible reliable estimate flovent ventolin group exclusively license patent expect financial effect result ultimate right enforce defend patent resolution proceeding case appropriate expire december list orange book disclosure case include note november group enter settlement agreement provision case mylan resolve ipr term settlement agreement confidential patent subject ipr respect legal proceeding describe settlement number patent cover advair flovent provision group ventolin use hfa meter dose inhaler unable reliable estimate expect financial effect stage group believe information february group receive paragraph iv seek plaintiff know meaningful certification teva flovent hfa paragraph iv respect legal proceeding number certification group receive generic pharmaceutical factor include limited stage proceeding company seek ab rate version flovent hfa entitlement party appeal decision clarity theory patent issue teva allege generic version flovent liability damage govern law infringe patent direct actuation indicator list orange book teva allege patent legal expense incur provision relate legal claim subject mylan ipr proceeding settle charge sell general administration cost provision november valid group evaluate tevas take appropriate legal specialist advice paragraph iv certification deadline filing patent outflow resource consider probable reliable infringement suit trigger month stay statutory estimate likely outcome dispute certain preclusion anda approval generic product month product liability claim group provision date group receipt notice paragraph iv sufficient history claim settlement enable certification hatchwaxman act april management reliable estimate provision require cover unasserted claim december group bexseromen b vaccine aggregate provision legal dispute include tax follow acquisition novartis vaccine business matter describe note taxation million group take litigation originally file novartis ultimate liability legal claim vary amount provide pfizer inc pfizer uk italy united states relate dependent outcome litigation proceeding meningococcal b man b vaccine february novartis investigation possible settlement negotiation file suit pfizer uk high court patent court group position change time declaration european patent own pfizer infringe assurance loss result outcome bexsero invalid pfizer file statement defence legal proceeding exceed material counterclaim infringement trial hold provision report group financial march judge rule pfizer statement happen material adverse patent valid infringe bexsero product group impact result operation group reporting appeal decision appeal hearing expect period judgement incur settlement hear week december enter february novartis file suit pfizer court intellectual property rome declaration european patent own pfizer intellectual property claim include challenge validity infringe bexsero invalid group assume enforceability group patent product responsibility matter group prosecute lawsuit process assertion noninfringement pfizer originally file novartis declaration patent loss case result loss patent european patent issue pfizer relate meningitis b vaccines protection product issue consequence infringe bexsero pfizer counterclaim seek loss significant decrease sale product declaration bexsero infringe patent order materially affect future result operation group damage group actively pursue action gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue february novartis file suit pfizer coreg cr district court district new jersey patent infringement mylan send paragraph iv certification date august complaint assert patent pfizer allege pfizer group flamel ireland ltd flamel state submit sale trumenba infringe patent april abbreviate new drug application anda food group file amend complaint pfizer reassert drug administration fda seek approval generic version patent originally assert novartis assert coreg cr notice assert patent list orange additional recentlygranted patent group file second book coreg cr invalid infringe mylan amend complaint march assert additional product october flamel file civil complaint patent cover trumenba pfizer date set district court northern district west virginia allege summary judgement motion trial mylan product infringe flamel orange bookliste extend release formulation patent expire march july pfizer file suit uk high court group exclusive licensee patent coreg cr mylan group novartis craig venter institute seeking answer december assert flamel patent invalidate uk patent own group relevance invalid infringe mylan file party complaint pfizer trumenba patent own novartis group request declaration group patent oppose european patent office epo carvedilol phosphate hemihydrate invalid infringe pfizer patent revoke epo opposition december party settle matter term division september patent confidential uphold epo board appeal uphold epo opposition division group believe trumenba kivexa infringe patent trial set cover patent covering combination lamivudine abacavir patent issue trial date january second kivexa corresponding supplementary protection certificate trial date february spc challenge independently teva mylan october group file suit seek injunctive relief major european market challenge withdraw pfizer ireland claim infringement group patent pursuant confidential settlement agreement teva date include group patent uphold epo board appeal confidential settlement agreement mylan september patent maintain date instance virtue manufacture trumenba propose q challenge validity spc combination commercialisation ireland group application enter patent kivexa bring germany betapharm dr commercial division irish high court order expedite reddys hexal sandoz hormosan lupin viiv healthcare case successful hearing likely schedule commenced proceeding injunctive relief q company viiv healthcare application injunctive relief october day group file suit hexal deny october confidential settlement pfizer uk ireland group file suit austria seek agreement reach dr reddys cover number injunctive relief boehringer ingelheim bi pfizer contract european market pursuant agreement german action manufacturer antigen trumenba claim infringement involve betapharm withdraw trial date group patent uphold epo board appeal september set hexal hormosan action bi file response complaint trial likely sandoz file nullity action austria germany spain schedule time sweden september october allege november pfizer file suit canadian federal kivexa spc invalid underlying patent cover court group infringement pfizer canadian patent combination lamivudine abacavir invalid sandoz cover trumenba pfizer seek damage seek launch abacavirlamivudine product austria spain injunction trial likely occur sweden viiv healthcare commence proceeding injunctive relief austria sweden decision injunctive relief expect half viiv healthcare counterclaim infringement nullity action spain trial date set jurisdiction gsk annual report note financial statement continue legal proceeding continue doc generici file action september court avandia rome seek declaration italian spc cover kivexa group name product liability lawsuit behalf invalid base invalid combination patent individual assert personal injury claim arise use company eurogeneric join action trial date avandia economic loss action file seek set restitution penaltie consumer protection law federal case file group multidistrict portugal viiv healthcare initiate arbitration proceeding litigation proceed pende district court eastern lupin vale pharmaceutical zentiva patent cover district pennsylvania mdl court case combination lamivudine abacavir company file number state court addition county santa file marketing approval generic version kivexa sandoz clara california bring action behalf california join proceeding future holder lupin marketing resident pende mdl court allege violation approval arbitration date schedule california false advertising act seek restitution damage action civil penalty december accord healthcare ltd accord file february group reach agreement settle revocation action spc uk action substantial majority federal state case pende resolve confidential settlement accord group february kyowa pharmaceutical file nullity action purport class action seek economic relate kivexa japan viiv healthcare evaluate option damage behalf party payer tpps assert claim regard action arise state federal law include racketeer influence corrupt organization act rico state unfair trade lexiva practice andor consumer protection law mdl court february lupin file petition patent consolidate action pretrial proceeding trademark office uspto seek challenge validity appoint plaintiff steer committee group patent claim cover lexiva inter parte review ipr successful obtaining initial case management order second petition ipr lupin file patent require name plaintiff produce documentation relate early petition uspto institute ipr broad claim merit claim name plaintiff patent deny institute challenge specific claim file motion dismiss voluntarily claim group lexiva challenge patent expire opposed order require plaintiff comply june august uspto grant petition discovery obligation group file motion summary institute trial remain claim lexiva patent oral judgement basis preemption tpp action oral hearing schedule april relevant rule argument motion hear february uspto issue decision ipr august court take matter advisement additionally february lupin send viiv healthcare santa clara county action group pende motion paragraph iv certification hatchwaxman act allege summary judgement basis preemption patent cover lexiva valid patent expire seek partial summary judgement county restitution claim december pediatric exclusivity extend june decision expect mdl court dispose viiv healthcare evaluate certification santa claras motion dismiss base lack federal product liability jurisdiction oral argument hear november preclinical clinical trial conduct development santa claras motion dismiss lack jurisdiction court potential product determine safety efficacy product issue decision use human follow approval regulatory body class action canada active notwithstanding effort drug vaccine active case class certification hearing hold introduce marketplace unanticipated safety issue december court issue decision certify nationwide claim evident group class user avandia group file notice intent currently defendant number product liability lawsuit relate appeal group pharmaceutical vaccine consumer healthcare product group able reliable estimate expect financial effect matter discuss category include provision appropriate matter provision legal dispute matter group provision note note provision gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue seroxatpaxil paxil cr canada bartram action certify national group receive numerous lawsuit claim allege class action british columbia settle december use paxil paroxetine cause variety injury eliminate need trial singh action alberta lawsuit contain follow allegation propose national class action seeks certify class relate use paxil pregnancy cause congenital malformation birth defect generally hear motion certify class persistent pulmonary hypertension ii paxil treatment cause previously schedule early adjourn plaintiff patient commit suicidal violent act iii group request additional evidence file revise hearing fail warn patient experience certain symptom date set likely mid discontinue paxil treatment inactive propose national class action british columbia wakeman new class action jensen allege paxil pregnancy ssri use autism file saskatchewan january group reach agreement settle majority claim relate use paxil pregnancy february act violence number claim relate use pregnancy february pende claim case pende court matter concern allegation patient take paroxetine paxil dismiss payment commit attempt commit suicide act violence claim case case canada trial case pende philadelphia pennsylvania mass case dolin begin march federal court tort program mtp rader v gsk go trial march chicago illinois april judge preside trial grant group motion nonsuit end trial group favour discontinuation rule plaintiff fail introduce necessary uk case remain evidence procee june court deny plaintiff subject hearing hold december judgement motion posttrial relief seek new trial plaintiff appeal hearing publish february allow docketed july proceed remain claim continue court management case management conference hold july follow loss rader plaintiff counsel ask mtp february new timetable order proceeding court stay remain case issue rader address pennsylvania appellate court group zofran oppose request april mtp court grant plaintiff allege child suffer birth defect result plaintiff counsel request enter order stay mother ingestion zofran andor generic ondansetron case resolution rader appeal group pregnancyrelate nausea vomit plaintiff assert move lift order grant stay argue host group sell zofran know unsafe pregnant woman fail dispositive issue case depend outcome warn risk illegally market zofran offlabel use rader appeal court deny group motion pregnant woman february group defendant july personal injury lawsuit case pende single california state court case multidistrict litigation proceeding mdl pursuant coordination order motion quash personal district massachusetts mdl case discovery jurisdiction forum non convenien deny december january mdl court issue order deny group file writ seek review california court group motion dismiss claim ground appeal court issue rule preempt federal law group renew motion later date mdl continue monthly status conference fourteen case file state court st louis missouri issues sufficiency pleading scope group remove case federal court discovery address group continue seek eastern district missouri concurrently file motion dismissal individual case appropriate dismiss lack personal jurisdiction alternative transfer federal court plaintiff respective home state significant activity state court february fourteen case dismiss case locate california group defendant propose class action canada october party agree settlement significant activity canadian class plaintiff case state court st louis missouri meyers action denial group motion dismiss personal jurisdiction ground affirm illinois appellate court elmassri connecticut federal court grant group motion summary judgement february kiker case set trial january settled gsk annual report note financial statement continue legal proceeding continue sale marketing regulation average wholesale price group marketing promotion pharmaceutical attorney general illinois file suit group vaccine product subject certain governmental number pharmaceutical company claim damage investigation private lawsuit bring litigant restitution average wholesale price awp andor wholesale theory law group able reliable estimate acquisition cost wac price report pharmaceutical product expect financial effect matter discuss covered state medicaid programme case allege category include provision matter group report caused report false awp wac provision legal dispute note price turn allegedly cause state medicaid agency matter group provision note reimburse provider money cover medicine note provision agency intend state seek recovery behalf payer behalf instate patient consumer case secdoj sfo anticorruption enquiry ongoing trial date set september group reach global resolution securities exchange commission sec cidra thirdparty payer litigation secs investigation foreign corrupt practice act july number major healthcare insurer file suit fcpa group commercial practice country outside group philadelphia pennsylvania county court resolution group agree pay civil common plea seek compensation reimbursement penalty million government department medicine manufacture group cidra plant justice doj confirm conclude investigation puerto rico insurer claim group knowingly group commercial practice action illegally market sell adulterate drug manufacture group sec doj investigation initiate condition noncompliant cgmp current good manufacturing industrywide inquiry pharmaceutical practice thirdparty insurer unlawfully company violate fcpa group agree induce pay suit allege federal resolution admit deny sec allegation state law cause action court deny group motion dismiss discovery schedule complete uk fraud office sfo begin formal trial expect schedule criminal investigation group commercial operation number country include china sfo request antitrustcompetition information group commercial operation certain governmental action private lawsuit bring country group respond sfos request group allege violation competition antitrust law group unable reliable estimate expect financial group able reliable estimate expect effect investigation provision financial effect matter discuss category include provision matter provision legal dispute note matter group vaccines subpoena provision note note provision february group receive subpoena attorney office southern district new york request uk competition market authority investigation document relate group vaccine business group february uk competition market authority respond subpoena group unable reliable cma issue decision fine group estimate expect financial effect matter pharmaceutical company infringement competition act provision cma impose fine million group fine total million company relate subpoena relate imitrex amerge agreement settle patent dispute group march group receive subpoena potential supplier generic paroxetine formulation enter attorney office southern district new york request group terminate agreement document relate group contract imitrex issue group believe strong ground appeal amerge group respond subpoena group cmas find competition appeal tribunal cat unable reliable estimate expect financial effect fine overturn substantially reduce appeal matter provision cat commence march provision matter avandia group defend action county santa clara california bring californias consumer protection law seek civil penalty restitution result group marketing avandia group file number dispositive motion pende mdl court county santa clara recently file motion dismiss action federal court lack federal jurisdiction motion brief argue party gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue lamictal securitieserisa class action stiefel purport class direct indirect purchaser file suit currently outstanding private lawsuit bring district court district new jersey allege stiefel laboratories inc stiefel employee allege group teva pharmaceuticals unlawfully conspire delay stiefel officer director violate employee generic competition lamictal result overcharge retirement income security act erisa federal state purchaser enter allegedly anticompetitive reverse security law induce stiefel employee sell share payment settlement resolve patent infringement litigation employee stock plan stiefel greatly undervalue price separate count accuse group monopolising market disclose employee stiefel sell june court appeal reverse trial court group decision dismiss case remand action fried case currently appeal court appeal trial court october trial court deny group eleventh circuit oral argument take place motion stay set schedule early dispositive motion february stiefel complete defence verdict matter discovery group file petition certiorari jury trial federal court florida october supreme court february november plaintiff appeal trial second florida case stay supreme court deny group petition certiorari pende resolution fry matter discovery continue trial court march group motion judgement case pende new york federal court pleading grant large dismiss statute limitation ground claim allege purport addition private litigant suit december indirect purchaser class trial court deny securities exchange commission sec file formal complaint indirect purchaser class plaintiff motion reconsideration stiefel charles stiefel district court result indirect purchaser class representative agree district florida allege stiefel principal violate settlement exit case resolve remain claim term federal security law induce stiefel employee sell settlement confidential case continue share employee stock plan company greatly forward document production witness deposition undervalue price disclose employee regard claim direct purchaser company sell case stay return active status early summer wellbutrin xl party engage discovery rebriefe summary plaintiff claim antitrust injury relate allegedly sham patent judgement motion court request briefing litigation file biovail generic company pursue anda motion complete july court generic wellbutrin xl group initially name party rule motion plaintiff patent infringement action later withdraw environmental matter matter group party remain group notify potential responsibility relate patent infringement action relate wellbutrin xl plaintiff past operation past waste disposal practice certain allege conspiracy delay generic approval exist site primarily matter subject biovail group court grant summary judgement litigation include proceeding initiate federal state favour group claim sole remain claim government waste disposal site remediation cost tort matter relate plaintiff allegation group enter action bring private party anticompetitive reverse payment settlement resolve patent infringement litigation district court grant summary group advise responsible party judgement favour group claim matter approximately site appear national priority currently pende appeal court appeal list create comprehensive environmental response circuit court compensation liability act superfund proceeding seek require operator hazardous waste facility commercial corporate transporter waste site generator hazardous waste group defendant certain case allege violation dispose site clean site reimburse federal security erisa law group able government cleanup cost instance group reliable estimate expect financial effect involve allege generator hazardous waste matter discuss category include provision matter provision legal dispute superfund provide defendant jointly note matter group provision severally liable cleanup cost proceeding frequently note note provision resolve basis nature quantity waste dispose generator site group proportionate liability cleanup cost substantially determine site refer group potential liability vary greatly site site cost investigation study remediation site time significant group routinely accrue amount relate share liability matter gsk annual report financial statement glaxosmithkline plc prepare uk gaap include frs reduce disclosure framework director statement responsibility relation company financial statement director responsible prepare parent company disclosure information auditor glaxosmithkline plc financial statement remuneration director office date annual report report accordance applicable law regulation confirm uk company law require director prepare financial far aware relevant audit information statement financial year law director company auditor unaware elect prepare parent company financial statement take step ought take accordance united kingdom accounting standard director aware relevant audit applicable law united kingdom generally accept accounting information establish company auditor aware practice company law director approve information parent company financial statement satisfied true fair view state affair parent confirmation give interpret accordance company profit loss period provision section company act prepare financial statement director require go concern basis assess principal risk matter consider select suitable accounting policy apply connection viability statement director consider consistently appropriate adopt go concern basis accounting judgement accounting estimate reasonable prepare financial statement prudent uk corporate governance code state regard parent company financial statement board consider glaxosmithkline plc apply principle applicable uk accounting standard follow subject complie provision uk corporate governance material departure disclose explain parent code maintain financial reporting council describe company financial statement corporate governance section page board consider annual report take fair prepare financial statement go concern basis balanced understandable provide information inappropriate presume parent company necessary shareholder assess group position continue business performance business model strategy director responsible keep adequate accounting require financial conduct authority list rule record sufficient explain companys auditor consider director statement compliance transaction disclose reasonable accuracy time relation point uk corporate governance code financial position company enable ensure specified review parent company financial statement remuneration report page comply company act responsible safeguarding asset company take reasonable step prevention detection fraud irregularity philip hampton parent company financial statement year end chairman december comprise balance sheet year end december support note set page march report responsibilitie auditor relation parent company financial statement set independent auditor report page financial statement year end december include annual report publish print form available website director responsible maintenance integrity annual report website accordance uk legislation govern preparation dissemination financial statement access website available outside uk comparable legislation different strategic report risk section annual report represent management report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report strategic report governance remuneration financial statement independent auditor report investor information member glaxosmithkline plc report parent company financial statement opinion isas uk ireland report opinion glaxosmithkline plcs parent company financial international standard audit uk ireland isas statement financial statement uk ireland require report opinion information annual report true fair view state parent company affair materially inconsistent information audit financial statement december apparently materially incorrect base materially inconsistent properly prepared accordance united kingdom knowledge company acquire course generally accept accounting practice perform audit prepare accordance requirement mislead company act exception report arise responsibility audit financial statement include annual report adequacy accounting record information comprise explanation receive company act require report company balance sheet december opinion company statement change equity year receive information explanation end require audit note financial statement include summary adequate accounting record keep parent significant accounting policy explanatory information company return adequate audit receive certain require disclosure present branch visit annual report note financial statement financial statement director crossreference financial statement remuneration report audit agreement identify audit financial reporting framework accounting record return apply preparation financial statement applicable law united kingdom accounting standard united kingdom exception report arise responsibility generally accept accounting practice include frs director remuneration reduce disclosure framework company act require report require reporting opinion certain disclosure director remuneration specify law exception report consistency information arise responsibility company act opinion opinion base work undertake course director remuneration report company act opinion audit opinion director remuneration report audit properly prepare accordance information give strategic report director company act report financial year financial statement prepare consistent financial statement company act report company act require report strategic report director report opinion certain disclosure director remuneration prepare accordance applicable legal requirement specify law exception report addition light knowledge understanding group arise responsibility environment obtain course audit require report identify material misstatement strategic report director report report respect gsk annual report independent auditor report members glaxosmithkline plc continue report parent company financial statement continue responsibility financial statement audit addition read financial nonfinancial information responsibility director annual report identify material inconsistency explain fully director statement audit financial statement identify information responsibility set director responsible apparently materially incorrect base materially inconsistent preparation financial statement satisfied knowledge acquire course perform true fair view audit aware apparent material misstatement inconsistency consider implication report responsibility audit express opinion financial respect strategic report director report consider statement accordance applicable law isa uk report include disclosure require applicable ireland standard require comply auditing legal requirement practice board ethical standard auditor matter report include opinion prepare report separately group financial statement companys member body accordance chapter glaxosmithkline plc year end december company act purpose information director remuneration report give opinion accept assume responsibility describe audit purpose person report show hand come save expressly company pass resolution accordance section agree prior consent writing company act senior statutory auditor audit financial statement involve state conduct audit accordance isas uk ireland audit involve obtain evidence amount disclosure pricewaterhousecooper llp financial statement sufficient reasonable assurance charter accountant statutory auditor financial statement free material misstatement london cause fraud error include assessment accounting policy appropriate parent march company circumstance consistently apply adequately disclose reasonableness significant accounting estimate director overall presentation financial statement primarily focus work area assess director judgement available evidence form judgement evaluate disclosure financial statement test examine information sampling auditing technique extent consider necessary provide reasonable basis draw conclusion obtain audit evidence testing effectiveness control substantive procedure combination gsk annual report strategic report governance remuneration financial statement company balance sheet uk gaap investor information include frs reduce disclosure framework december note fix asset investment f current asset trade receivable g cash bank total current asset bank overdraft trade payable h total current liability net current asset total asset current liability provision noncurrent liabilitie j net asset capital reserve call share capital k share premium account k reserve retain earning january lossprofit year change retain earning l equity shareholder fund financial statement page approve board march sign behalf philip hampton chairman glaxosmithkline plc register number company statement change equity year end december share share premium retain capital account reserve earning total january profit attributable shareholder dividend shareholder share issue employee share scheme december loss attributable shareholder dividend shareholder share issue employee share scheme treasury share transfer esop trust december gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework presentation financial statement b accounting policy description business foreign currency transaction glaxosmithkline plc parent company gsk major global foreign currency transaction record exchange rate healthcare group engage creation discovery ruling date transaction foreign currency asset development manufacture marketing pharmaceutical liability translate rate exchange rule balance product include vaccine overthecounter otc medicine sheet date healthrelate consumer product dividend pay receive preparation financial statement dividend pay receive include financial statement financial statement prepare historical period relate dividend actually pay cost convention modify include revaluation certain receive financial instrument go concern basis prepare expenditure accordance financial reporting standard reduce expenditure recognise respect good service receive disclosure framework uk accounting presentation supply accordance contractual term provision company act december comparative obligation exist future liability respect figure december past event obligation reliably permit section company act estimate income statement company present annual report investment subsidiary company investment subsidiary company hold cost company include group financial statement provision impairment adjust movement glaxosmithkline plc publicly available contingent consideration follow exemption requirement ifrs apply preparation financial statement impairment investment accordance frs carrying value investment review impairment indication investment impaired paragraph b ifrs sharebase payment provision result impairment review charge ifrs financial instrument disclosure income statement year concern paragraph ifrs fair value measurement share base payment paragraph ias presentation financial statement issuance company subsidiary grant comparative information requirement respect company share represent additional capital contribution paragraph iv ias company subsidiary additional investment paragraph f b subsidiary result correspond increase shareholder ia presentation financial statement equity additional capital contribution base fair value ias statement cash flow grant issue allocate underlying grant vest period paragraph ias accounting policy change accounting estimate error taxation current tax provide amount expect pay apply paragraph ias relate party disclosure tax rate enact substantively enact requirement ia disclose related party transaction balance sheet date enter member group defer tax provide liability method temporary difference arise tax basis asset accounting convention standard liability carry amount financial statement balance sheet prepare historical defer tax asset recognise extent cost convention complie applicable uk accounting consider recoverable future taxable profit standard defer tax measure average tax rate expect accounting principle policy apply period temporary difference preparation balance sheet conformity generally expect realise settle defer tax liability asset accept accounting principle require management discount estimate assumption affect report amount asset liability disclosure contingent asset financial guarantee liabilitie date balance sheet actual amount liability relate guarantee issue company behalf differ estimate subsidiary initially recognise fair value amortise life guarantee balance sheet prepare accordance company accounting policy approve board legal dispute describe note b policy consistently apply company provide anticipate settlement cost state outflow resource consider probable reliable estimate likely outcome dispute legal expense arise claim company december provision legal dispute amount million million gsk annual report strategic report governance remuneration financial statement investor information c key accounting judgement estimate ultimate liability legal claim vary amount legal dispute provide dependent outcome litigation company provide anticipate settlement cost proceeding investigation possible settlement negotiation outflow resource consider probable reliable position change time estimate likely outcome dispute assurance loss result outcome legal legal expense arise claim company proceeding exceed provision report estimate account specific circumstance company financial statement material dispute relevant external advice inherently perate profit judgemental change substantially time new fee relate audit fact emerge dispute progress company charge operate profit company director take legal advice e dividend establish provision take account relevant fact circumstance matter accordance accounting director declare interim dividend result dividend requirement december provision legal year penny line dividend dispute amount million million detail note group financial statement dividend f fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment contribution relate contingent consideration g trade receivables amount year uk corporation tax recoverable receivables amount owe group undertaking amount year amount owe group undertaking gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework continue h trade payable amount year creditor contingent consideration payable amount owe group undertaking company guarantee debt issue subsidiary company receive annual fee aggregate company outstanding guarantee billion debt instrument amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note g provision january exchange adjustment charge year utilise december provision relate number legal dispute company currently involve j noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable k call share capital share premium account share premium ordinary share p account number share capital authorise december december share capital issue fully pay january issue employee share scheme december issue employee share scheme treasury share transfer esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme l reserve loss glaxosmithkline plc year million million profit dividend million million give retain loss million million loss treasury share purchase year nil effect million treasury share transfer subsidiary company nil retain earning december stand million million million unrealised million group company page complete list subsidiary associate joint venture form financial statement gsk annual report strategic report governance remuneration financial statement investor information investor information section quarterly trend pharmaceutical vaccine turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital share price dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term gsk annual report financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month q q q q report report report report report proforma proforma cer cer cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating income operate profitloss net finance cost share tax profitslosse associate joint venture profitloss taxation taxation tax rate profitloss taxation period profitloss attributable noncontrolle interest profitloss attributable shareholder basic earningsloss share penny p p p p p dilute earningsloss share penny p p p p p income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny p p p p p calculation core result describe gsk annual report strategic report governance remuneration financial statement investor information quarterly trend continue unaudite analysis group result provide quarter sterle financial year income statement total month q q q q report report report report report proforma proforma cer cer cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating income operate profitloss net finance cost share tax profitslosse associate joint venture profitloss taxation taxation tax rate profitloss taxation period profitloss attributable noncontrolle interest profitloss attributable shareholder basic earningsloss share penny p p p p p dilute earningsloss share penny p p p p p income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny p p p p p calculation core result describe gsk annual report financial record continue pharmaceutical turnover therapeutic area total europe international restate growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta arnuity ellipta avamysveramyst flixotideflovent incruse ellipta nucala relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart eperzantanzeum immunoinflammation benlysta pharmaceutical dermatology augmentin antibacterial rare disease oncology establish product coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix hiv combivir epzicomkivexa lexivatelzir selzentry tivicay triumeq trizivir pharmaceutical vaccine turnover total europe international restate growth growth growth growth major product cer cer cer cer rotarix synflorix fluarix flulaval bexsero menveo boostrix infanrix pediarix hepatitis priorix priorix tetra varilrix cervarix vaccine cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical turnover therapeutic area total europe international restate restate growth growth restate growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart immunoinflammation benlysta pharmaceutical dermatology augmentin antibacterial rare disease oncology establish product coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix hiv combivir epzicomkivexa lexivatelzir selzentry tivicay triumeq trizivir pharmaceutical vaccine turnover total europe international restate growth growth growth restate growth major product cer cer cer cer rotarix synflorix fluarix flulaval bexsero menveo boostrix infanrix pediarix hepatitis rabipurrabavert cervarix vaccine cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board effect january gsk report turnover segment pharmaceutical include hiv vaccine consumer healthcare comparative turnover information year restate accordingly comparative information restate reflect current breakdown group geographic region comparative information report include effect divestment complete restate restate restate restate group turnover geographic region europe international divestment total turnover include divestment group turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover divestment complete pharmaceutical turnover therapeutic area respiratory cardiovascular metabolic urogenital immunoinflammation pharmaceutical establish product hiv pharmaceutical vaccine turnover consumer healthcare turnover wellness oral care nutrition skin health gsk annual report strategic report governance remuneration financial statement investor information year record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share million million million million million weight average number share issue basic diluted financial result core turnover operate profit profit taxation profit taxation pence pence pence pence pence core earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report financial record continue year record continue restate restate restate balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england pm buy rate average purpose table average rate year calculate average pm buy rate day year mar feb jan dec nov oct sep high low pm buying rate march gsk annual report strategic report governance remuneration financial statement pipeline product competition investor information pharmaceutical vaccine product development pipeline key inlicence alliance relationship party month submission v iiv healthcare global specialist hiv company bla biological licence application gsk pfizer inc shionogi limited shareholders maa marketing authorisation application europe responsible developing deliver hiv medicine nda new drug application lso develop indication phase e valuation clinical pharmacology usually conduct therapeutic area volunteer optionbase alliance ionis pharmaceuticals phase ii etermination dose initial evaluation efficacy optionbase alliance adaptimmune ltd conduct small number patient optionbase alliance oncome pharmaceutical phase iii l arge comparative study compound versus placebo ptionbased alliance telethon ospedale andor establish treatment patient establish san raffaele clinical benefit safety optionbase alliance valneva maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla hiv infectious disease dolutegravir hiv integrase inhibitor nonnucleoside hiv infection drug maintenance regiman iii rilpivirine reverse transcriptase inhibitor nnrti dolutegravir hiv integrase inhibitor nucleoside reverse hiv infection iii lamivudine transcriptase inhibitor nrti hiv attachment inhibitor hiv infection iii cabotegravir hiv integrase inhibitor longacting parenteral hiv preexposure prophylaxis iii formulation cabotegravir hiv integrase inhibitor nonnucleoside hiv infection iii rilpivirine reverse transcriptase inhibitor nnrti longacte parenteral formulation tafenoquine aminoquinoline plasmodium vivax malaria iii relenza iv neuraminidase inhibitor iv influenza iii gepotidacin type topoisomerase inhibitor bacterial infection ii danirixin iv chemokine cxc motif receptor influenza ii cxcr antagonist rg nonstructural protein b nsb polymerase hepatitis c ii inhibitor antimir antisense oligonucleotide antibacterial cephalosporin bacterial infection hiv maturation inhibitor hiv infection hbv antisense oligonucleotide hepatitis b hbv lica antisense oligonucleotide hepatitis b respiratory fluticasone furoate glucocorticoid agonist longacting beta chronic obstructive pulmonary disease copd submit dec nov vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin il monoclonal antibody copd iii fluticasone furoate glucocorticoid agonist longacte beta asthma iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium muscarinic acetylcholine antagonist beta copd ii agonist maba muscarinic acetylcholine antagonist beta copd ii fluticasone furoate agonist maba glucocorticoid agonist danirixin chemokine cxc motif receptor cxcr copd ii antagonist oral phosphatidylinositol kinase delta pik copd acute chronic ii inhibitor recombinant human angiotensin convert acute lung injury ii enzyme rhace tumour necrosis factor receptor tnfr acute lung injury ii domain antibody mepolizumab interleukin il monoclonal antibody hypereosinophilic syndrome ii mepolizumab interleukin il monoclonal antibody nasal polyposis ii tolllike receptor tlr agonist asthma ii sirukumab interleukin il human monoclonal antibody sc severe asthma ii gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla respiratory continue phosphatidylinositol kinase delta activate pik delta syndrome pik inhibitor interleukin r ilr monoclonal severe asthma antibody recombinant human angiotensin pulmonary arterial hypertension convert enzyme rhace alpha v beta integrin antagonist idiopathic pulmonary fibrosis phosphatidylinositol kinase bronchietasis delta pik inhibitor oncology nyeso autologous engineer sarcoma multiple myeloma nonsmall cell lung ii tcrt cell engineer tcr cancer melanoma ovarian cancer tarextumab notch monoclonal antibody small cell lung cancer ii ox agonist monoclonal antibody solid tumour haematological malignancy enhancer zeste homologue solid tumour haematological malignancy ezh inhibitor bet family bromodomain inhibitor solid tumour haematological malignancy lysinespecific demethylase lsd acute myeloid leukemia small cell lung cancer inhibitor bcell maturation antigen antibody multiple myeloma drug conjugate protein arginine methyltransferase cancer prmt inhibitor induce tcell costimulator icos cancer agonist antibody tolllike receptor tlr agonist cancer phosphatidylinositol kinase pik castration resistant prostate cancer beta inhibitor immunoinflammation sirukumab interleukin il human monoclonal rheumatoid arthritis submit sep sep antibody benlysta b lymphocyte stimulator monoclonal systemic lupus erythematosus submit sep sep antibody sc sirukumab interleukin il human monoclonal giant cell arteritis iii antibody granulocyte macrophage colony osteoarthritis ii stimulate factor monoclonal antibody granulocyte macrophage colony rheumatoid arthritis ii stimulate factor monoclonal antibody benlysta rituxan b lymphocyte stimulator monoclonal sjogren syndrome ii antibody sc cluster differentiation cd monoclonal antibody iv receptorinteracte protein rip psoriasis rheumatoid arthritis ii kinase inhibitor macrophage target histone rheumatoid arthritis ii deacetylase inhibitor oncostatin osm monoclonal systemic sclerosis antibody receptorinteracte protein rip ulcerative colitis kinase inhibitor interleukin il receptor monoclonal sjogren syndrome antibody spleen tyrosine kinase syk inhibitor chronic urticaria topical lymphocyte activation gene lag autoimmune disease protein monoclonal antibody chemokine cc motif ligand psoriatic arthritis ccl monoclonal antibody rearrange transfection ret inflammatory disorder bowel kinase inhibitor gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla rare disease strimvelis exvivo stem cell gene therapy adenosine deaminase severe combine immune approve deficiency adascid transthyretin ttr production inhibitor transthyretinmediate amyloidosis iii exvivo stem cell gene therapy metachromatic leukodystrophy iii exvivo stem cell gene therapy wiscottaldrich syndrome iii mepolizumab interleukin il monoclonal antibody eosinophilic granulomatosis polyangiitis iii serum amyloid p component sap amyloidosis ii monoclonal antibody sap depleter cphpc exvivo stem cell gene therapy betathalassemia ii focal adhesion kinase inhibitor pulmonary arterial hypertension pah vaccine shingrix recombinant herpe zoster prophylaxis submit nov oct zoster vaccine mmr live attenuate measle mump rubella prophylaxis iii na ebola recombinant viral vector ebola haemorrhagic fever prophylaxis ii group b conjugate group b streptococcus prophylaxis ii streptococcus maternal immunisation pneumoniae recombinant conjugate streptococcus pneumoniae disease prophylaxis ii generation copd recombinant reduction frequency moderate severe acute ii exacerbation copd patient targette non typeable haemophilus influenzae moraxella catarrhalis hepatitis c recombinant viral vector hepatitis c virus prophylaxis ii malaria generation recombinant malaria prophylaxis plasmodium falciparum ii man abcwy recombinant conjugate meningococcal abcw disease prophylaxis ii adolescent shigella conjugate outer membrane shigella diarrhea prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii rsv recombinant respiratory syncytial virus prophylaxis ii maternal immunisation rsv replicationdefective recombinant respiratory syncytial virus prophylaxis ii viral vector hiv recombinant protein hiv infection prophylaxis ii pharmaceutical metabolic retosiban oxytocin antagonist spontaneous preterm labour iii daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease iii ileal bile acid transport ibat inhibitor cholestatic pruritus ii transient receptor potential cation heart failure ii channel v trpv antagonist interleukin il neutralisation mab delay graft function renal transplantation ii otelixizumab cluster differentiation cd new onset type diabetes ii monoclonal antibody daprodustat prolyl hydroxylase inhibitor topical wound heal diglyceride acyltransferase dgat nonalcoholic steatohepatitis inhibitor selective androgen receptor modulator muscle waste oxytocin inhale oxytocin postpartum hemorrhage dermatology mepolizumab interleukin il monoclonal antibody atopic dermatitis ii nonsteroidal antiinflammatory topical atopic dermatitis ii nonsteroidal antiinflammatory topical psoriasis ii ror gamma inverse agonist topical psoriasis ii neuroscience ionisgskl ocular target lica antisense geographic atrophy agerelate macular disease oligonucleotide brand name appear italic trademark own andor license glaxosmithkline associated company gsk annual report pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand eu respiratory anoro ellipta umeclidinium bromide copd spiriva handihaler vilanterol terfenatate respimat stiolto nce nce spiolto respimat ultibro breezhaler deviceformulation deviceformulation duaklir genuair bevespi aerosphere arnuity ellipta fluticasone furoate asthma qvar pulmicort na asmanex alvesco nce deviceformulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expire expire diskus device diskus device hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce deviceformulation deviceformulation nucala mepolizumab severe eosinophilic asthma xolair cinqair expire relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol terfenatate flutiform dulera nce nce deviceformulation deviceformulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire expire fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil spiriva expire expire handihalerrespimat diskus device diskus device onbrez hfadevice ventolin hfa albuterol sulphate asthmacopd generic company hfadevice hfadevice antiviral valtrex valaciclovir genital herpe coldsore shingle famvir expire expire zeffixepivirhbv lamivudine chronic hepatitis b hepsera expire expire central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression anxiety effexor cymbalta expire expire disorder lexapro cardiovascular urogenital eperzantanzeum albiglutide type diabete victoza byetta bydureon lyxumia trulicity avodart dutasteride benign prostatic hyperplasia proscar flomax expire finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension leave ventricular formulation dysfunction post mi principal risk uncertaintie detail uncertainty time followon competition note financial statement legal proceeding generic competition possible include supplementary protection certificate grant multiple country eu patent term extension grant data exclusivity expire eu generic competition exist market gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand eu antibacterials augmentin amoxicillinclavulanate common bacterial generic product na expire potassium infection rare disease volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta belimumab systemic lupus erythematosus hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla expire descovy genvoya combination odefsey lexivatelzir fosamprenavir hivaids prezista kaletra reyataz selzentrycelsentri maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaid isentress prezista reyataz kaletra triumeq dolutegravir lamivudine hivaids truvada atripla abacavir descovy genvoya odefsey trizivir lamivudine zidovudine hivaids truvada atripla expire expire abacavir descovy genvoya odefsey vaccine product competition intellectual property major patent expiry date product compound indication competitor brand eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxeli cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtype vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtype fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w mencevax menactra conjugate vaccine prophylaxis prepandrix derive split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuate measle mump measle mump rubella mmr ii mmrvaxpro expire varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis medium note financial statement legal proceeding refer priorix priorix tetra patent varilrix expire generic competition commence market relate compoundsindication measle mump rubella vaccineprophylaxis include supplementary protection certificate grant b relate compound varicella vaccine multiple country eu patent term extension grant gsk annual report pipeline product competition continue consumer healthcare product competition brand product application market competition wellness panadol tablets caplet infant paracetamolbase treatment global advil pfizer panadol cold syrup drop headache joint pain fever aspirin bayer flu cold symptom tylenol johnson johnson voltaren topical gel nonsteroidal diclofenac base global advil pfizer antiinflammatory aspirin bayer tylenol johnson johnson otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden ukraine nasivin merck theraflu tablet syrup cold flu relief russia poland ukraine tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief claritin bayer nasacort sanofi flixonase piriton nasal spray tablet allergy relief uk ireland benadryl johnson johnson eno effervescent immediate relief antacid global estomazil hypermarca gelusil pfizer tum chewable tablet immediate relief antacid alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette lozenge gum transdermal treatment nicotine withdrawal global nicorette johnson johnson nicoderm patch aid smoking reduction niquitin perrigo nicotinell cessation ex australia oral health sensodyne toothpaste toothbrushe relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protect colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste medicate help prevent bleed gum germany ireland colgate total gum health corsodyl mouthwash gel spray treat prevent gingivitis italy united kingdom colgatepalmolive yunnan baiyao state enterprise china polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser denture clean denture procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavity global colgate colgatepalmolive mouthwash maintain healthy tooth gum crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicate patch onset cold sore carmex carma labs blistex blistex incorporate retail label nutrition horlick malt drink food nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinz gsk annual report strategic report governance remuneration financial statement principal risk uncertaintie investor information principal risk discuss risk uncertainty similarly business expose litigation government relevant business financial condition result operation investigation include limited product liability litigation affect performance ability achieve objective patent antitrust litigation sale marketing litigation risk believe cause actual litigation government investigation include related provision result differ materially expect historical result unfavourable outcome increase related cost insurance premium materially adversely adapt comply broad range law affect financial result regulation requirement apply research development manufacturing testing approval distribution sale marketing detail status uncertainty involve pharmaceutical vaccine consumer healthcare product significant unresolved dispute potential litigation set affect cost product development time note legal proceeding page require reach market likelihood uk regulation require discussion mitigating activity successfully company take address principal risk uncertainty rule regulation change governmental summary activity group take manage interpretation rule regulation evolve nature principal risk accompany description principal particular risk change change certain regulatory regime risk principal risk uncertainty list substantial change failure comply order significance applicable law regulation materially adversely affect financial result patient safety risk definition individual medical officer pharmaceutical vaccine failure appropriately collect review follow report adverse consumer healthcare business group substantial event potential source act relevant finding safety pharmacovigilance organisation track adverse timely manner issue report product course clinical study group product approve marketing group risk impact extensive postmarkete surveillance signal detection impact risk potentially compromise ability system information possible effect product receive conduct robust safety signal detection interpretation source include unsolicited report health ensure appropriate decision take respect risk professional patient regulatory authority medical benefit profile product include completeness scientific literature medium policy employee accuracy product label pursuit additional study require report immediately issue relate safety analysis appropriate lead potential harm quality product country manager responsible patient reputational damage product liability claim monitor exception tracking training helps assure litigation governmental investigation regulatory action collection safety information report information fine penalty loss product authorisation relevant central safety department accordance group policy context legal requirement preclinical clinical trial conduct development information change riskbenefit profile group investigational pharmaceutical vaccine consumer healthcare product result certain action characterise communicate product determine safety efficacy product use minimise risk propose action discuss human notwithstanding effort determine regulatory authority include modify prescribing safety product appropriate preclinical clinical information communication physicians healthcare trial unanticipate effect evident provider restriction product prescribingavailability help product widely introduce marketplace question assure safe use carry clinical trial safety product raise certain case appropriate stop clinical trial ongoing safety surveillance postmarkete study withdraw medicine market group global safety governmental agency thirdpartie analyse publicly board gsb comprise senior physician representative available clinical trial result support function integral component system group currently defendant number product liability gsb include subsidiary board dedicate consumer lawsuit include class action involve significant claim healthcare product vaccine review safety damage relate product litigation particularly investigational market product group inherently unpredictable class action seek sweep authority stop clinical trial continue conduct trial person product increase potential liability ethically scientifically justify light information claim pain suffer punitive damage frequently emerge start trial assert product liability action allow represent addition medical governance framework group potentially openende exposure materially describe group use mechanism foster adversely affect group financial result early evaluation mitigation resolution dispute mitigate activity arise potential claim arise goal chief medical officer cmo responsible medical programme create culture early identification governance group global policy policy evaluation risk claim actual potential order safeguard human subject clinical trial patient minimise liability litigation product paramount importance cmo authoritative role evaluate addressing matter human safety gsk annual report principal risk uncertainty continue intellectual property risk definition expiration date patent major product failure appropriately secure maintain enforce intellectual affect date generic version product property right introduce set page list annual expiration date mean indicate certainty exclusivity risk impact list product patent design failure obtain subsequent loss patent protection invalidate prior expiration result early entry market include reduce availability scope patent right generic product legal proceeding involve patent challenge compulsory license government force manufacturer set note financial statement legal proceeding license patent specific product competitor materially adversely affect financial result market generic drug manufacturer exhibit readiness absence adequate patent datum exclusivity protection market market generic version important product prior limit opportunity rely market future sale expiration patent effort involve challenge growth product materially adversely validity enforceability patent assertion affect financial result market generic product infringe patent result continue involve legal proceeding involve patent context challenge materially adversely affect financial innovative pharmaceutical vaccine consumer healthcare result common patent product company seek obtain appropriate intellectual infringement action prompt claim antitrust law property protection product ability obtain enforce violate prosecution patent litigation patent proprietary right regard product involve defence patent claim direct critical business strategy success pharmaceutical indirect purchaser payer typically file class product usually protect copied generic action relief seek include treble damage restitution manufacturer period exclusivity provide issue claim similarly antitrust claim bring government patent relate intellectual property right regulatory data entity private party follow settlement patent litigation protection orphan drug status follow expiration certain alleging settlement anticompetitive violation intellectual property right generic manufacturer lawfully antitrust law successful antitrust claim private party produce generic version product government entity materially adversely affect financial operate market intellectual property law patent result office develop government unwilling mitigate activity grant enforce intellectual property right fashion similar global patent group focus secure maintain develop region eu japan enforce patent right global group maintain internal develop country limit threatened limit effective process design seek ensure successful procurement patent protection pharmaceutical product order facilitate enforcement defence patent goal lawfully early competition market generic manufacturer maintain exclusive right market product face competition manufacturer proprietary generic global patent group monitor new development pharmaceutical product major market introduction international patent law seek ensure appropriate protection generic product particularly high asset act trade association work turnover margin typically lead rapid dramatic loss local government seek secure effective balanced sale reduce revenue margin proprietary intellectual property law design meet need patient product abbreviate pathway lead payer support longterm investment innovation substitutable generic vaccine competition market arise brand product generic brand product erosion sale revenue margin dramatic addition proprietary technology manufacture capital investment facility create barrier entry vaccine market depend certain key product significant portion sale product respiratory pharmaceutical product seretideadvair account significant group sale worldwide patent composition contain combination active substance seretideadvair expire generic product contain combination active substance seretideadvair dry powder inhaler meter dose inhaler launch manufacturer number european market new drug application andas file generic competitor seretideadvair diskus date approval uncertain time come early march time anda advair hfa uncertain patent formulation device meter dose inhaler protection afford patent uncertain present similar patent exist ventolin hfa flovent hfa gsk annual report strategic report governance remuneration financial statement investor information product quality risk definition extensive global network quality compliance professional failure comply current good manufacturing practice align business unit provide oversight assist cgmp inadequate control governance quality delivery quality performance operational compliance supply chain cover supplier standard manufacturing site level senior management level management oversight distribution product activity accomplish hierarchy quality council independent chief product quality risk impact officer global product quality office introduce failure ensure product quality far reach revise approach monitor regulate quality gxp implication term patient consumer safety result performance provide corporate executive team product launch delay supply interruption product recall integrate assessment key performance indicator kpi potential damage gsk reputation define kpis cover manufacturing practice clinical practice associate regulatory legal financial consequence pharmacovigilance practice regulatory practice drug safety materially adversely affect company reputation financial assessment animal welfare result implemented riskbase approach assess context manage party supplier provide material patient consumer healthcare professional trust quality finish product contract manufacturer make product product product quality influence factor expect comply gsk standard regularly include product process understand consistency audit provide assurance standard meet manufacture component compliance gmp accuracy labelling reliability external supply chain embodiment staff member regularly train ensure cgmp overarch quality culture internal external standard behaviour base value follow environment continue evolve new product new market additionally advocacy communication programme routinely new legislation introduce increase scrutiny datum deploy ensure consistent message convey integrity supply continuity drug shortage review inspection organisation originate change regulation conduct industry national regulatory authority learning inspection regulatory submission highlight ongoing focus datum integrity continue emphasis value quality performance metric party oversight timely escalation pertinent issue facilitate improvement foster culture right time regulatory authority mitigate activity develop implement single pharmaceutical quality system pqs define quality standard system business associate pharmaceutical vaccine consumer healthcare product clinical trial material system broad scope applicable product lifecycle rd mature commercial supply single external quality standard system govern detailed global regulatory expectation quality medicinal product requirement complex fragmented national regional boundary consequently adopt internationally recognise principle ich q pharmaceutical quality system framework basis gsk pqs industry standard incorporate quality concept product lifecycle gsk pqs augment consolidation numerous regulatory requirement define market world assures gsk pqs meet external expectation product quality market supply pqs regularly update ensure keep pace evolve external regulatory environment new scientific understanding operational improvement incorporate pqs support delivery consistent reliable product gsk annual report principal risk uncertainty continue financial control report risk definition continue significant international focus tax reform failure comply current tax law incur significant loss include oecds base erosion profit shift bep treasury activity failure report accurate financial project european commission initiative increase information compliance accounting standard applicable use fiscal state aid investigation domestic legislation failure maintain adequate governance oversight initiative world result significant change thirdparty relationship establish tax principle increase tax authority dispute regardless merit outcome costly divert risk impact management attention adversely impact reputation noncompliance exist new financial reporting disclosure requirement change recognition income party critical business delivery integral expense expose litigation regulatory action solution improve productivity quality service materially adversely affect financial result change innovation rely party include supplier distributors tax law application respect matter individual contractor license pharmaceutical transfer pricing foreign dividend control company rd tax biotechnology collaboration partner discovery manufacture credit taxation intellectual property restriction tax relief marketing product important business process allow interest intragroup debt impact party business relationship present material risk effective tax rate significant loss arise inconsistent example share critical sensitive information application treasury policy transactional settlement error marketing plan clinical datum employee datum specific counterparty default change substance application party conduct relevant outsourced business govern tax law failure comply tax law operation inadequate protection misuse information significant loss treasury activity materially party significant business impact similarly use adversely affect financial result distributor agent range activity promotion failure adequately manage party relationship result tender inherent risk inappropriate promotion business disruption exposure risk range suboptimal unethical business practice insufficient internal compliance contractual term condition severe business sanction control distributor affect reputation risk significant reputational damage consequence increase complexity work large materially adversely affect business operation financial number party result mitigate activity context group maintain control environment design identify group require law jurisdiction disclose material error financial reporting disclosure design publicly financial result event materially affect operating effectiveness key financial reporting control financial result group regulator routinely review regularly test management independent business financial statement list company compliance new monitoring provide assurance control revise exist accounting regulatory requirement key financial reporting disclosure process operate group believe complie appropriate regulatory effectively requirement concern financial statement disclosure date late development financial material information include transaction relate business reporting requirement work external auditor restructure acquisition divestiture legal advisor subject investigation potential noncompliance accounting disclosure requirement lead shared accountability financial result restatement previously report result significant penalty business financial result review approve regional management review financial controller treasury group deal high value transaction foreign chief financial officer cfo allow financial controller exchange cash management transaction daily basis cfo assess evolution business time transaction involve market volatility counterparty risk evaluate performance plan significant judgement review group effective tax rate reflect rate tax jurisdiction confirm senior management business reorganisation group operate higher low newly acquire activity integrate risk assessment uk rate take account regime encourage innovation appropriate control review apply counterparty exposure investment science provide tax incentive subject define limit approve board credit change affect group tax rate addition worldwide rating individual counterpartie nature operation crossborder supply route result conflict claim tax authority profit tax create finance risk control centre individual country tax charge include financial excellence maintain finance control framework add statement good estimate group tax liability pende resource ensure process control maintain audits tax authority business transformation upgrade financial system process ongoing integration novartis business control reporting framework additional risk mitigation introduce amend programme timeline system upgrade gsk annual report strategic report governance remuneration financial statement investor information financial control report continued group maintains disclosure committee reporting business unit leadership team retain ultimate accountability board review group quarterly result annual manage party interaction risk work report form f determine year party employee expect manage external consultation legal advisor necessary interaction commitment responsibly expectation disclose publicly information group stock embed value code conduct responsibility exchange announcement treasury management group activity perform safely compliance meet regular basis seek ensure liquidity interest applicable law value standard code conduct rate counterparty foreign currency transaction foreign seek guide enforce global principle interaction currency translation risk manage line party place policy framework applicable conservative approach detail associate risk buy good service manage external spend pay strategy policy adopt board work party policy framework apply oversight treasury role manage counterparty risk line employee complementary worker worldwide framework agree policy perform corporate compliance officer complement technical local standard design seek operate independently treasury detail mitigation ensure alignment nature party interaction treasury risk find page note good manufacturing practice adherence local law financial instrument relate disclosure tax risk manage regulation independent business monitor key financial set policy procedure seek ensure consistency operational control place supplement periodic compliance tax legislation seek maintain open check company independent audit assurance function positive relationship government tax authority continuous monitoring performance party enhance worldwide monitor government debate tax policy key party oversight programme manage jurisdiction deal proactively potential future change global ethic compliance organisation global programme tax law engage advisor legal counsel review tax complete deployment latam south east asia legislation implication business relevant country take enterprise wide view party relate active provide relevant business input tax policy maker risk programme strengthen risk assessment significant decision consider agree tax diligence effort party improve overall governance board meet quarterly senior management party risk lifecycle personnel finance group party engagement centralise team dedicate specialist responsible manage transactional tax reporting compliance submit tax return accord statutory time limit engage tax authority seek ensure tax affair current enter arrangement continuous audit programme advance pricing agreement provide longterm certainty tax treatment appropriate exceptional case matter settle agreement tax authority resolve dispute formal appeal proceeding gsk annual report principal risk uncertainty continue antibribery corruption risk definition mitigate activity failure gsk employee consultant party comply code conduct value behaviour commitment antibribery corruption abac principle zero tolerance integral mitigate risk light standard applicable legislation complexity geographic breadth risk constantly evolve oversight activity datum reinforce employee risk impact contractor clear expectation acceptable behaviour failure mitigate risk expose group associate maintain ongoing communication group headquarters person governmental investigation regulatory action civil local market criminal liability group enterprisewide abac programme design addition legal penalty failure prevent bribery ensure compliance group abac policy prevent comply abac legislation regulation risk bribery corruption build value business substantial implication reputation company standard form comprehensive practical approach credibility senior leader erosion investor confidence compliance flexible evolve nature business governance risk management abac programme build good class principle range context feature collectively enable manage risk expose bribery corruption risk global example programme comprise business operation markets government structure toplevel commitment group board director rule law developed bear leadership global risk assessment enable target intervention bribery corruption risk exposure addition global nature compliance monitoring activity programme underpin business healthcare sector highly competitive global abac policy write standard address subject regulation increase instances commercial practice rise abac risk expose activity interaction bribery corruption risk ongoing training communication addition programme group subject number abac inquiry mandate enhanced control interaction government reach resolution authority official business development transaction abac inquiry whilst inquiry uk authority ongoing employee require complete comprehensive abac training investigation discuss note legal dependent role requirement proceeding programme governance provide group abac governance board include representation key functional area business unit dedicate abac team responsible implementation evolution programme response development internal external environment complement independent oversight assurance undertake audit assurance independent business monitoring team continually benchmark abac programme large multinational company use external expertise drive improvement programme gsk annual report strategic report governance remuneration financial statement investor information commercialisation risk definition mitigate activity failure execute business strategy effectively manage strategic objective design ensure group achieve competitive opportunity threat accordance letter mission help people feel well live long spirit legal industry group requirement group continue strive new product launch competitive resource effectively healthy proportion risk impact sale ratio attributable new product innovation sale failure manage risk relate commercialisation materially innovation help group defray effect example adversely affect ability grow diversified global business downward price pressure major market decline emerge deliver product value patient consumer market growth negative foreign exchange impact failure comply applicable law rule regulation result governmental investigation regulatory action legal establish new product price balance expectation proceeding bring group governmental private patient consumer hcp payer shareholder plaintiff failure provide accurate complete information community enable group maintain strong global business relate product result incomplete awareness remain relevant need patient consumer riskbenefit profile product possibly suboptimal treatment value provide guide lead decision patient consumer consequence constantly strive right thing deliver quality product materially adversely affect group seek ensure behaviour reflect value mission company practice find misaligned value result reputational damage dilute trust establish take action level group enhance external stakeholder improve standard procedure promotional interaction base value transparency respect integrity patient context focus policy standard govern promotional operate global basis industry highly activity undertake group behalf competitive highly regulate competitor activity conduct worldwide conform high ethical significant product innovation technical advance regulatory industry standard local standard differ intensify price competition light competitive environment global standard stringent apply continued development commercially viable new product development additional use exist product critical group harmonise policy procedure guide achieve strategic objective pharmaceutical vaccine country commercial practice process clarify consumer company group face downward price applicable standard engage market business pressure major market decline emerge market growth unit group adopt gsk internal control framework negative foreign exchange impact support assessment management risk commercial practice activity appropriate monitoring programme develop new pharmaceutical vaccine consumer healthcare oversight business unit risk management compliance product costly lengthy uncertain process product board country executive board manage risk candidate fail stage include significant group incountry business activity economic human resource invest competitor product pricing strategy failure promotional material activity review develop commercially successful product develop approve accord group policy standard additional use exist product materially adversely conduct accordance local law regulation seek affect ability achieve strategic objective ensure material activity fairly represent product service group necessary commit ethical responsible commercialisation discipline include termination employee product support mission improve quality engage misconduct broaden ability claw human life enable people feel well live long remuneration senior management event misconduct accomplish mission engage healthcare community way provide important information medicine group continue evolve commercial operating model embed industry lead change compensation model promotion approve product seeks ensure healthcare sale professional manager interact hcp professional hcp globally access information need change eliminate reward base sale market share patient consumer access information prescription product individual territorie favour reward product need product prescribe recommend base quality individual interaction hcp manner provide maximum healthcare benefit furthermore begin gsk stop pay patient consumer commit communicate hcp deliver promotional presentation gsk hcp information relate approve product responsible legal sponsor travel medical educational conference ethical manner business unit group confront common type commercialisation risk difference exist type risk present degree risk present business unit consequently risk manage reflect different nature profile business unit group gsk annual report principal risk uncertainty continue research practice risk definition mitigate activity failure adequately conduct ethical sound preclinical establish office animal welfare ethic strategy clinical research addition failure engage scientific activity oawes lead chief animal welfare ethic strategy consistent letter spirit law industry seek ensure humane responsible care animal group requirement increase knowledge application nonanimal alternative group oawes embeds framework animal welfare risk impact governance promote application rs replacement refinement impact risk include harm human subject reputational reduction animal research explore opportunitie damage failure obtain necessary regulatory approval crossindustry datum sharing conduct quality assessment product governmental investigation legal proceeding bring group governmental private plaintiff product information available study include summary liability suit claim damage regulatory action result positive negative gsk fine penalty loss product authorisation company publish clinical study report form basis consequence materially adversely affect financial submission regulatory agency publically post result clinical study report addition study result summarie detailed patientlevel datum context approximately clinical study request research relate animal raise ethical concern access clinicalstudydatarequestcom attempt address proactively animal study remain vital research case method global human biological sample management hbsm investigate effect potential new medicine living governance framework place oversee ethical lawful body test human generally mandate acquisition management human biological sample regulator ethically imperative animal research provide global hbsm network champion hbsm activity provide critical information cause disease experience group support internal sample custodian develop nonetheless continually seek way good practice remain important priority enhance minimise use animal research whilst comply datum integrity control data integrity committee place regulatory requirement year provide oversight datum integrity quality assurance team begin conduct assessment intend clinical trial healthy volunteer patient assess provide independent business monitor internal control demonstrate investigational product efficacy safety rd activity evaluate product approve marketing work human biological sample chief regulatory officer oversee activity sample fundamental discovery development safety regulatory governance board include promote monitor product integrity datum essential compliance regulatory requirement groupwide success stage research datum lifecycle design standard make regulatory service efficient agile generation record management analysis report align regulatory capability international business storage retrieval research datum govern legislation need enterprise local level group strictly prohibit regulatory requirement research datum support promotional practice prior marketing authorisation care document core component stage pipeline take seek ensure se activity promotional progression decisionmake form content specific accountability authorisation se reside regulatory submission poor datum integrity compromise medical governance framework oversee global research effort medical topic board gmtb accountable chief medical innate complexity interdependency require officer gmtb responsible oversight applicable policy regulatory filing particularly give global research seek ensure high level integrity continuous development footprint rapid change submission requirement development se gsk framework seeks ensure develop country continue increase complexity right level accountability clear programme guidance worldwide product registration scientific engagement se define country rd business unit local operating interaction exchange information gsk company external community order advance scientific medical research practice risk align new enterprise understanding include appropriate development use framework seeks ensure strengthen governance product essential scientific discourse rd business pharmaceutical vaccine consumer nonpromotional engagement external stakeholder group healthcare leadership chief research practice vital gsk mission necessary scientific medical officer management risk practical approach advance scope se activity include advisory board information share streamline risk identification escalation scientific consultancy preplanne informal discussion ensure ownership stay business unit level allow healthcare professional hcp share medical information proportional risk treatment plan publication include abstract congresse scientific interaction payer patients government medium support independent medical education se activitie essential present legal regulatory reputational risk sharing datum invite medium coverage payment service provider perceive promotional intent risk particularly high hcp engagement associate financial andor transfer value disclosure require gsk gsk annual report strategic report governance remuneration financial statement investor information environment health safety sustainability risk definition mitigate activity failure manage environment health safety substainability corporate executive team cet responsible ehss ehss risk line objective policy governance group global policy policy relevant law regulation cet seeks ensure control framework place manage risk impact legal compliance issue relate risk impact ehss assign responsibility senior manager failure manage ehss risk lead significant harm provide maintain control individual manager seek people environment community operate fine ensure ehss control framework effective failure meet stakeholder expectation regulatory requirement implement respective business area fully litigation regulatory action damage group reputation compliant applicable law regulation adequately materially adversely affect financial result resource maintain communicate monitor additionally context employee personally responsible ensuring group subject health safety environmental law applicable local standard operating procedure follow jurisdiction law impose duty protect people expect responsibility ehss matter environment community operate riskbase proactive approach articulate refresh potential obligation remediate contaminate site global ehss standard support ehss policy identify potentially responsible party objective discover develop manufacture supply sell comprehensive environmental response compensation product harm people environment addition liability act number site remediation cost relate design provision safe facility plant equipment use ownership site failure manage operate rigorous procedure help eliminate hazard environmental risk properly result litigation regulatory practicable protect employee health wellbee action additional remedial cost materially continue effort improve environmental sustainability adversely affect financial result note financial reduce value chain carbon intensity pack water statement legal proceeding discussion consumption waste generation actively manage environmental relate proceeding involve environmental remediation obligation seek ensure practice routinely accrue amount relate liability environmentally sustainable compliant ehss matter performance result share externally year responsible business supplement information protection risk definition mitigate activity risk gsk business activity information disclose group global information protection policy authorise information system fail support dedicated programme activity increase available corrupt focus information security group establish information protection privacy function provide strategy risk impact direction oversight enhance global information failure adequately protect critical sensitive system security capability information result loss commercial strategic advantage damage reputation litigation business disruption assess change information protection risk environment include regulatory sanction materially adversely briefing government agency subscription affect financial result commercial threat intelligence service knowledge share pharmaceutical crossindustry company context rely critical sensitive system datum corporate aim use industry good practice information strategic plan sensitive personally identifiable information pii security policy process technology invest strategy intellectual property manufacturing system trade secret commensurate change nature security potential computer system information threat landscape privacy centre excellence expose misuse unauthorised disclosure establish ensure compliance prior deadline subject law govern processing pli new general datum protection requirement gdprs employee require complete training appropriate handling maintain pii group bind corporate rule bcrs approve uk information commissioner office human resource research activity datum bcrs recognise european states switzerland allow transfer pii internationally group entity individual privacy agreement european union country approval remain country greece romania expect gsk annual report principal risk uncertainty continue supply continuity crisis management risk definition mitigate activity failure deliver continuous supply compliant finished product supply chain model design ensure supply quality inability respond effectively crisis incident timely manner security product globally far possible closely recover sustain critical operation include key supply monitor supply chain governance committee chain risk previously call crisis continuity inventory status delivery product aim ensure management customer pharmaceutical vaccine consumer healthcare product need risk impact recognise failure supply product adversely improve link commercial forecasting manufacturing impact consumer patient rely material possible core commercial cycle time interruption supply exclusion healthcare programme reduce risk associate demand fluctuation impact expose litigation regulatory action financial ability supply cost writeoff product penalty adversely affect group financial result exceed expiry date node supply chain periodically review ensure adequate safety stock balance work group international operation partner capital endtoend supply chain safety stock backup expose workforce facility operation information supply arrangement medically critical highrevenue product technology potential disruption natural event eg storm place help mitigate risk addition routinely monitor earthquake manmade event eg civil unrest terrorism global compliance manufacture external supplier order emergency eg ebola outbreak flu pandemic important identify manage risk supply base practical gsk robust crisis management recovery plan place minimise dependence single source supply critical manage event item alternative source arrangement possible context inventory strategy aim protect supply chain unanticipated supply chain operation subject review approval disruption regulatory agency effectively provide licence continue implement anticounterfeit system product operate failure manufacture distribution facility serialisation accordance emerge supply chain requirement supplier key service material lead litigation world corporate policy require business unit regulatory action product recall seizure interruption functional area head ensure effective crisis management supply delay approval new product suspension business continuity plan place include authorise manufacturing operation pende resolution manufacturing response recovery strategy key area responsibility logistic issue clear communication route business disruption occur rely material service provide party supplier corporate security support business coordinating crisis product include active pharmaceutical ingredient management business continuity training facilitate simulation api antigen intermediate commodity component exercise assess group preparedness recovery capability manufacture packaging pharmaceutical vaccine provide assurance oversight group central repository consumer healthcare product party service plan support critical business process business procure service provide contract manufacturing unit governance board perform risk oversight clinical research organisation support development key monitoring include identify new emerge threat product important ensure continuous operation group coordinate approach evaluate manage business implication business uks exit undertake business continuity planning single source european union certain component bulk api finish product service activity help ensure appropriate level readiness create supply risk event regulatory noncompliance response capability maintain develop maintain physical disruption manufacturing site logistic system partnership external body like business continuity small number singlesource party supplier institute un international strategy disaster risk service provider use fail fulfil contractual obligation reduction helps improve business continuity initiative timely manner experience regulatory noncompliance physical disasterprone area support development community disruption logistic manufacturing site resilience disaster result delay service interruption use effective crisis management business continuity planning provide health safety people minimise impact group maintain functional operation follow natural manmade disaster public health emergency gsk annual report strategic report governance remuneration financial statement shareholder information investor information share capital control detail issue share capital number share share buyback programme hold treasury december find board authorise issue allot ordinary share note financial statement share capital share article company article association power premium account article authority company purchase share subject shareholder authority ordinary share list london stock exchange seek annual basis annual general meeting agm quote new york stock exchange nyse share purchase company cancel hold form american depositary share ad ad treasury share satisfy share option grant represent ordinary share detail list debt group employee share plan list refer note financial statement net debt programme cover purchase share cancellation hold treasury share accordance authority holder ordinary share ad entitle receive renew shareholder agm dividend declare company annual report attend company authorise purchase maximum speak general meeting company appoint proxy million share detail share purchase cancel exercise voting right hold treasury share subsequently transfer restriction transfer limitation hold treasury satisfy awards group share plan ordinary share ad requirement obtain approval disclose note financial statement share capital prior transfer ordinary share ad carry special share premium account right regard control company determine specific share repurchase level company restriction vote right major shareholder voting consider development free cash flow year give right share shareholder know impact sustain strength sterle free cash flow arrangement financial right hold person company suspend share repurchase programme holder share know agreement share purchase financial year restriction share transfer voting right end share acquire share scheme plan rank equally company confirm currently intend share issue special right market purchase company review trustee employee share ownership plan trust waive potential future share buyback line right dividend share hold trust usual annual cycle subject return rating criterion exchange control limitation affect security holder market capitalisation certain economic sanction force market capitalisation base share issue exclude time time currently applicable law decree treasury share gsk december billion regulation force uk restrict import export date gsk fifth large company market capital affect remittance dividend payment capitalisation ftse index holder company share nonresident uk similarly certain economic sanction share price force time time limitation relate nonresident uk english law company article january association right holder vote respect december company share increasedecrease interest voting right high year state far aware low year person significant direct indirect holding company information provide company pursuant financial table set middle market closing price conduct authoritys fca disclosure transparency rule companys share price increase compare dtrs publish regulatory information service increase ftse index year company website wwwgskcom share price march march company receive notification accordance fca dtrs follow notifiable interest uk voting right company issue share capital percentage issue share capital blackrock inc p ercentage ordinary share issue exclude treasury share acquire disposed interest share period review exception transfer treasury satisfy awards group share plan uk share price uk ad price gsk annual report shareholder information continue share capital control continue nature trading market follow table set period indicate high low middle market closing quotation pence share london stock exchange high low closing price dollar ad nyse ordinary share ad pence share dollar share high low high low march february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december year end december march analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bny mellon depositary company ad list nyse ordinary share represent company adr programme manage depositary register bny nominees limited march bny nominees limit hold ordinary share represent issue share capital exclude treasury share date march number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder gsk annual report strategic report governance remuneration financial statement investor information dividend company pay dividend quarterly continues return cash dividend calendar shareholder dividend policy dividend remain ad exdividend exdividend essential component total shareholder return company quarter date date record date payment date commit increase dividend longterm detail q february february february april dividend declare amount payment date q july give note financial statement dividend q august august august october dividend share q november november november january table set dividend share ad year dividend ad translate dollar applicable exchange rate year dividend pence special q interim ordinary dividend special dividend receivable adr holder calculate base exchange rate april annual fee ad ad quarter charge depository cumulative dividend receivable adr holders q q q special dividend relate return net cash proceed novartis transaction complete march pay fourth quarter ordinary dividend financial calendar result announcement event date result announcement issue london stock exchange quarter result announcement aprilmay available news service send annual general meeting securities exchange commission nyse issue quarter result announcement july media available website quarter result announcement october financial report preliminaryquarter result announcement february company publish annual report available annual report publication februarymarch website date publication shareholder annual report distribution march elect receive annual report contact registrar information company include share price available alternatively shareholder elect receive notification website wwwgskcom information available email publication financial report register website constitute annual report wwwshareviewcouk copy previous financial report available website print copy obtain registrar uk contact detail gsk annual report shareholder information continue annual general meeting pm uk time thursday adr holder wish attend meeting obtain proxy queen elizabeth ii centre broad sanctuary westminster bny mellon depositary notifying request london swp ee enable attend vote business transact adr holder instruct bny mellon way agm company principal forum communication share represent adr vote private shareholder addition formal business complete return voting card provide depositary presentation ceo performance group future development opportunity document display question ask board chairman board articles association company director service committee question relate committee contract applicable letter appointment director company subsidiary investor hold share nominee service arrange letter relate severance term pension arrangement nominee service appoint proxy respect available inspection company register office shareholding order attend vote meeting available inspection agm tax information shareholder summary certain uk tax federal income tax uk tax year onwards dividend tax credit consequence holder share adr citizen long apply uk resident individual entitle instead uk set complete analysis dividend tax allowance possible tax consequence purchase ownership sale dividend receive tax year free tax proposal security intend general guide holder announce march reduce allowance advise consult adviser respect tax tax year onwards dividend excess consequence purchase ownership sale share allowance tax basic rate taxpayer adr consequence state local tax law high rate taxpayer additional rate taxpayer implication current ukus tax convention uk resident shareholder corporation taxpayer note holder adr generally treat owner dividend payable ordinary share generally entitle underlie share purpose current usuk double exemption corporation tax taxation convention relate income gain income tax taxation capital gain convention estate gift taxis estate gift tax convention uk shareholder liable uk tax gain disposal purpose internal revenue code amend share adr different rate apply taxation capital gain code tax year uk shareholder disposal individual uk tax year summary apply uk resident shareholder hold subject availability exemption relief annual share capital asset exempt taxable capital gain accrue disposal taxation dividend share adr tax allowable deduction different regime apply taxation dividend income payable shareholder taxable income tax year exceed basic uk resident individual uk tax year april rate income tax limit case taxable capital gain accrue tax year commence april disposal share adr tax combination rate april rate reduce uk tax year include uk resident respectively shareholder generally subject uk income tax dividend pay gross tax credit corporation taxpayer entitle indexation allowance tax credit set individual income tax liability apply reduce capital gain extent gain respect gross dividend repayable shareholder arise inflation indexation allowance reduce chargeable tax liability associate tax credit extent gain create allowable loss individual income exceed basic rate limit inheritance tax high rate limit upper dividend rate apply set individual ukdomicile shareholder liable gross dividend figure uk inheritance tax transfer share adr tax income exceed high rate limit additional charge value shareholder dividend rate normally apply estate reduce result transfer way lifetime gift disposal market value case bequ death tax charge value share date shareholder death gift disposal subject uk inheritance tax estate gift tax estate gift tax convention generally provide tax pay credit tax payable uk gsk annual report strategic report governance remuneration financial statement investor information tax information shareholder continue stamp duty stamp duty reserve tax dividend qualify subject taxation uk stamp duty andor stamp duty reserve tax sdrt subject federal graduate tax rate maximum rate certain exemption payable transfer share rate type dividend automatically exclude qualified rounded near case stamp duty dividend meet requirement include consideration transfer notwithstanding provide limit instrument execute pursuance agreement give rise capital gain distribution charge sdrt instrument stamp year agreement include stamp exempt dividend bank deposit sdrt charge cancel sdrt ividend hold corporation employee stock ownership pay repay plan esop shareholder dividend pay taxexempt corporation summary apply shareholder citizen resident domestic corporation person state local tax rate qualify nonqualified dividend subject federal income tax net income basis vary assess addition federal tax rate respect share adr hold share adr capital communicate asset resident uk uk tax purpose taxation capital gain hold share purpose trade profession vocation generally holder subject uk capital gain tax carry uk branch agency subject tax capital gain realise sale summary address tax treatment holder disposal share adr gain longterm capital gain subject special tax rule bank taxexempt entity subject reduced rate taxation individual holder insurance company dealer security currency person share adr hold year date hold share adr integrate investment share vestedrelease shortterm capital gain include straddle comprise share adr subject taxation rate longterm capital position person directly indirectly gain subject rate state local tax voting stock company address tax rate capital gain apply treatment applicable result international income information report backup withholding tax treaty dividend payment proceed sale share taxation dividend adr pay certain usrelated financial gross dividend receive treat foreign source intermediary subject information reporting dividend income tax purpose eligible dividend subject backup withholding holder corporation receive deduction allow corporation dividend adr exempt recipient provide taxpayer identification number payable dollar dividend share payable pound certifie loss exemption occur nonus holder sterling dividend pay pound sterling include income generally subject information report backup dollar calculate reference exchange rate withholding require provide certification day dividend receive holder subject nonus status connection payment receive amount certain exception shortterm hedge position individual withhold allow refund credit holder eligible holder subject taxation maximum rate federal income tax liability provide require information respect qualified dividend qualified dividend furnish internal revenue service define internal revenue service dividend meet estate gift taxis follow criterion estate gift tax convention shareholder ust issue corporation corporation incorporate generally subject uk inheritance tax possession corporation eligible stamp duty benefit comprehensive income tax treaty deem uk stamp duty andor sdrt subject certain exemption satisfactory publish irs payable transfer share adr custodian dividend list irs dividend depository rate consideration qualify provide transfer sale value transfer consideration require dividend hold period meet share own day stamp duty sdrt payable transfer hold period define day period agreement transfer adr begin day exdividend date day stock trade dividend price example stock exdividend date october share hold day period august november year order count qualified dividend gsk annual report shareholder information continue shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance bn da wwwshareviewcouk tel uk tel outside uk equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form download drip reinvest dividend buy gsk share wwwshareviewcouk request telephone equiniti dividend payment direct bank account currently receive dividend cheque post dividend bank mandate form bank mandate instead pay directly bank building download wwwshareviewcouk society account quick secure avoid risk request telephone equiniti cheque go astray dividend payment direct bank account instead wait sterling cheque arrive post equiniti detail service cost overseas shareholder convert dividend local currency send direct involve contact equiniti local bank account service available country worldwide electronic communication shareholder elect receive electronic notification company register wwwshareviewcouk communication include annual report dividend payment pay way bank mandate access electronic tax voucher availability online vote general meeting time gsk mail hard copy shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view share register wwwshareviewcouk balance movement update address dividend payment instruction register vote agm duplicate publication mailing receive duplicate copy report mailing contact equiniti contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificated form hold internet transaction log corporate sponsor nominee internet telephone wwwshareviewcoukdealing note market trading hour postal dealing service provide equiniti financial service limit pm uk time telephone transaction monday friday exclude public holiday uk england wale outside uk postal transaction request deal form corporate sponsor nominee account convenient way manage share require application form request share certificate service provide facility hold wwwshareviewcouk share nominee account sponsor company telephone equiniti continue receive dividend payment annual report attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service limit detail available provide gsk corporate isa hold gsk ordinary share wwwshareviewcouk request telephone equiniti line open pm deal pm enquiry monday friday exclude public holiday england wale uk line open pm monday friday exclude public holiday england wale provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information shareholder service contact continue adr depositary contact investor relation adr programme administer bank new york mellon investor relation contact follow uk bny mellon shareowner services great west road po box brentford middlesex tw gs college station tx tel overnight correspondence send bny mellon shareowner services crescent drive quality circle suite philadelphia pa college station tx tel toll free wwwmybnymdrcom tel outside tel toll free gsk response center tel outside tel toll free email shrrelationscpushareownerservicescom share scam alert depositary provide global buydirect direct ad receive unsolicited telephone offering sell buy purchasesale dividend reinvestment plan adr holder share extra care caller highly detail enrol visit wwwmybnymdrcom organise financial scam helpline number obtain enrolment pack uk shareholder contact financial conduct glaxo wellcome smithkline beecham authority information similar activity corporate pep wwwfcaorgukconsumer consumer helpline share centre limited oxford house oxford road aylesbury buck hp sz tel uk tel tel outside uk wwwsharecom line open pm uk time monday friday uk public donating share save child holiday pm saturdays gsk embark ambitious global partnership responsible business supplement save child share expertise resource publish responsible business supplement aim help save live million child online outline gsk approach performance key responsible business area health behaviour shareholder small number share value people planet make uneconomical sell wish consider donate save child donate share aggregate sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale uk share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report statutory disclosure law regulation number provision law regulation apply responsible establish maintain internal company share quote new york stock control financial reporting provide reasonable assurance exchange nyse form adss reliability financial reporting preparation financial statement external purpose accordance nyse rule generally accept accounting principle general nyse rules permit company follow uk corporate governance practice instead apply disclose annual report form f provide explain significant variation explanation change internal control financial reporting contain form f access period cover annual report form f security exchange commission sec edgar database materially affect reasonably likely affect materially website nyse rule come effect require company internal control financial reporting file annual interim write affirmation concern audit disclose base recent evaluation internal control risk committee statement significant difference financial report external auditor arc corporate governance significant deficiency material weakness design operation internal control financial reporting sarbanesoxley act reasonably likely affect adversely company ability record follow number corporate accounting scandal process summarise report financial information fraud congress pass sarbanesoxley act sarbanesoxley regardless materiality involve person significant wideranging piece legislation concern largely financial role company internal control financial reporting report corporate governance group carry evaluation supervision recommend sec company establish participation management include ceo disclosure committee committee report ceo cfo cfo effectiveness design operation group audit risk committee chair company disclosure control procedure december secretary member consist senior manager finance legal corporate communication investor relation inherent limitation effectiveness system disclosure control procedure include possibility external legal counsel external auditor internal expert human error circumvention override control invite attend meeting periodically responsibility procedure accordingly effective disclosure control consider materiality information timely basis procedure provide reasonable assurance achieve determine disclosure information responsibility control objective timely filing report sec formal review annual report form f committee meet ceo cfo expect complete certification time report conclusion effectiveness disclosure control procedure march follow certificate sarbanesoxley require annual report form f file sec group form f contain statement member audit risk committee arc audit committee financial expert define section management annual report internal control sarbanesoxley statement relevant member financial reporting arc judy lewent include audit risk committee report accordance requirement section sarbane biography additional disclosure oxley follow report provide management respect requirement arise section section sarbane company internal control financial reporting define oxley respect disclosure control procedure internal rule af df securities exchange act control financial reporting amend exchange act section corporate responsibility financial report management responsible establish maintaining sarbanesoxley introduce requirement ceo adequate internal control financial reporting group cfo complete formal certification confirm internal control financial reporting design provide reasonable assurance reliability financial reporting review annual report form f preparation financial statement external purpose base knowledge annual report form f accordance ifrs contain material misstatement omission management conduct evaluation effectiveness base knowledge financial statement internal control financial reporting base framework financial information fairly present material respect internal control integrate framework issue financial condition result operation cash flow committee sponsor organisation treadway date period present annual report commission coso form f change group internal control responsible establish maintain disclosure financial reporting materially affected control procedure ensure material information reasonably likely affect materially group internal control known evaluated effectiveness financial reporting control procedure yearend result management assess effectiveness internal control evaluation contain annual report financial reporting december form f conclusion file group form f gsk annual report strategic report governance remuneration financial statement investor information law regulation continue pricewaterhousecooper llp audit consolidated group direct knowledge identity distributor financial statement group year end december downstream customer iran possible assess effectiveness group internal customer include entity governmentowne hospital control financial reporting auditing standard pharmacy own control directly public company accounting oversight board united states indirectly iranian government person entity audit report file group form f sanction connection terrorism proliferation activity group direct knowledge distributor section r exchange act customer establish proportion gross revenue section r exchange act require issuer specific sale potentially attributable entity affiliate iranian disclosure annual report certain type dealing government party sanction disclosable activity iran include transaction dealing governmentowne result group report entire gross revenue million entity dealing entity sanction activity net profit million group sale iran relate terrorism proliferation weapon mass destruction activity prohibit law group aware hospital medical involve person group legal entity base facility lebanon affiliate control hezbollah iran export certain pharmaceutical vaccine product designate united states terrorist organisation iran sale nonus entity privately hold iranian group deal directly facility sell distributor group business nonus entity distributor group unable identify jurisdiction target sanction law include syria certainty degree nature affiliation end customer crimea north korea sudan hezbollah group unable establish proportion gross revenue sale potentially attributable reportable believe group direct dealing iran entity result group report entire gross revenue require specific disclosure requirement group million net profit million group sale limit sale iran north korea syria sudan cuba essential lebanon medicines determine criterion set world health organization donation political organisation political expenditure effect january ensure consistent approach notwithstanding policy company act require political contribution group introduce global company continue obtain shareholder approval policy stop voluntarily corporate political contribution donation eu political organisation incur eu political expenditure intend period january december group donation eu political party organisation political donation eu noneu organisations incur eu political expenditure definition political notwithstanding introduction policy accordance donation political expenditure political organisation federal election campaign act continue legislation wide annually seek shareholder support employeeoperate political action committee pac authorisation inadvertent expenditure particular facilitate voluntary political donation eligible gsk definition eu political organisation extend body employee concerned policy review law reform representation pac control gsk decision amount business community special interest group recipient contribution participate employee concerned environment company exercise legal right pool resource political subsidiary wish support result definition contribution subject strict limitation total cover legitimate business activity ordinary sense donate political consider political donation political expenditure organisation gsk employee pac activity design support political party independent election candidate authority board seek annually precautionary measure ensure company subsidiary inadvertently breach legislation authorisation process expenditure year date agm hold follow introduction political party election referendum act authority renew annually gsk annual report statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold glaxosmithkline plc percentage hold class share state state subsidiary company register office country incorporation subsidiary company resident tax purpose country incorporation state security register address wholly own subsidiary alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limit ordinary great west road brentford middlesex tw gs england adechsa gmbh iv ordinary co prv provide treuhandgesellschaft ag dorfstrasse baar switzerland affymax research institute common corporation service company gateway oak drive suite n sacramento california united states alenfarma especialidades farmaceuticas ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge limitada iv portugal allen hanbury limit iv ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria aner sa iv nonendorsable nominative tucuman piso ciudad autonoma de buenos aire ordinary caaa argentina barrier therapeutics inc common corporation service company centerville road suite wilmington delaware de united states beecham group p l c p share p shares b great west road brentford middlesex tw gs england beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham pharmaceuticals sa iv vi nominative av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador beecham portuguesaproduto farmaceuticos e ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge quimicos lda portugal beecham sa iv ordinary parc de la noire epine rue fleming wavre belgium biddle sawyer limited equity dr annie besant road mumbai india biovesta ilalari ltd sti iv nominative bykdere caddesi levent plaza b blok kat levent istanbul turkey burrough wellcome co australia pty limited liquidation ordinary mountain highway boronia vic australia burrough wellcome co bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh burrough wellcome international limited ordinary great west road brentford middlesex tw gs england cascan gmbh co kg partnership capital industriestrasse bad oldesloe germany castleton investment ltd vi ordinary co dtos ltd th floor standard chart tower cybercity ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited ordinary great west road brentford middlesex tw gs england cellzome therapeutics inc iv ordinary corporation service company centerville road suite wilmington delaware de united states cellzome inc ordinary corporation service company centerville road suite series preferred wilmington delaware de united states series b prefer series c convertible prefer series c convertible prefer charles midgley limit iv ordinary great west road brentford middlesex tw gs england cumulative preference chiron behring vaccine private limited ordinary wing floral deck plaza opp rolta bhavan central midc road mumbai andheri east india clarge pharmaceutical limit ordinary great west road brentford middlesex tw gs england preference colleen corporation common corporation service company centerville road suite wilmington delaware de united states corixa corporation common corporation service company centerville road suite wilmington delaware de united states coulter pharmaceutical inc iv common corporation service company centerville road suite wilmington delaware de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain domantis limit ordinary great west road brentford middlesex tw gs england duncan flockhart australia pty limited iv vi ordinary mountain highway boronia vic australia gsk annual report strategic report governance remuneration financial statement investor information group company continue security register address wholly own subsidiary continue edinburgh pharmaceutical industry limit ordinary preference shewalton road irvine ayrshire ka ap scotland eskaylab limited p ordinary great west road brentford middlesex tw gs england etex farmaceutica ltda social capital avenue andre bello piso las conde santiago cp chile europharm sa ordinary poienelor street brasov romania fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oak drive suite n sacramento california united states glaxo iv ordinary klaus torgrd vei oslo norway glaxo group limit ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha iv ordinary sendagaya shibuyaku tokyo japan glaxo laboratories nigeria limit iv ordinary marine road apapa lagos nigeria glaxo laboratory limit iv ordinary great west road brentford middlesex tw gs england glaxo new zealand pension plan trustee limited ordinary level ii zurich house queen street auckland new zealand glaxo operation uk limit ordinary great west road brentford middlesex tw gs england glaxo property bv ordinary huis ter heideweg lz zeist netherlands glaxo verwaltung gmbh vi ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd iv vi ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome holding limit liquidation ordinary baker street london wu eu england glaxo wellcome international bv v ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary route de versaille marly le roi france glaxo wellcome pst pty ltd liquidation ordinary mountain highway boronia vic australia glaxo wellcome uk limit ordinary great west road brentford middlesex tw gs england glaxo wellcome vidhyasom limit iv ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgo spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limit iv ordinary creek road apapa lago pmb nigeria glaxochem uk unlimite ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxochem pte ltd v ordinary beach road gateway west singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia co ltd ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room building ocean international center mid th east ring road bejing chaoyang district china glaxosmithkline china rd company limited equity building halei road zhang jiang hi tech park pudong new area shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline private limited iv ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quotas estrada de cacuaco bairro petrangol luanda angola glaxosmithkline argentina sa ordinary tucumn piso ciudad autonoma de buenos aires caaa argentina glaxosmithkline ordinary klaus torgrd vei oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological shanghai ltd ordinary niudun road zhangjiang hiteck park shanghai china glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological sa ordinary preference rue de b rixensart belgium glaxosmithkline brasil limitada quotas estrada do banderiante camorim jacarepagua rio de janeiro brazil glaxosmithkline business service sa ordinary metros al este de la rotonda de la betania mercede de montes dissolve january de oca sabanilla montes de oca san jose costa rica glaxosmithkline capital inc ordinary wilmington trust sp services inc north market street suite wilmington delaware de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andrs bello piso las conde santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare investment ordinary cork airport business park kinsale road cork county cork ireland limited ii v ireland glaxosmithkline consumer healthcare ireland ip limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline consumer holding bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline doo quota zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline ehf ordinary thverholt reykjavik iceland glaxosmithkline el salvador sa de cv ordinary avenida el boqueron calle izalco parque industrial el boqueron santa elen antiguo custatlan la libertad el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary novena avenida zona guatemala city guatemala glaxosmithkline hold ordinary klaus torgrd vei oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington delaware de united states glaxosmithkline holdings ireland limited ordinary defer great west road brentford middlesex tw gs england glaxosmithkline holding limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok kat levent istanbul turkey glaxosmithkline inc class common mississauga road north mississauga ln l canada class c preference glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holding limit ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary defer great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limit ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline investment holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline investment service limit ordinary great west road brentford middlesex tw gs england glaxosmithkline investments ireland limited ii v ordinary currabinny carrigaline county cork ireland gsk annual report strategic report governance remuneration financial statement investor information group company continue security register address wholly own subsidiary continue glaxosmithkline investment pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary sendagaya shibuyaku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary dunte iela riga latvia glaxosmithkline lietuva uab ordinary ukmerge st vilnius lt lithuania glaxosmithkline limit ordinary unit f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline llc llc interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline malta limit ordinary floor de la cruz avenue qormi qrm malta glaxosmithkline manufacture spa ordinary alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou ham el glaza casablanca morocco glaxosmithkline medical healthcare product limit ordinary h csorsz utca budapest hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico glaxosmithkline nz limit ordinary level zurich house queen street auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limit ordinary lr th floor icea lion centre riverside park west wing chiromo road westland po box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan semangat petale jaya selangor darul ehsan malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals suzhou limited ordinary su hong xi road suzhou industrial park suzhou china glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercede de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline pharmaceuticals sa ordinary ordinary b ul grunwaldzka poznan poland ordinary c ordinary glaxosmithkline pharmaceutical sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue v kiev ukraine glaxosmithkline pte ltd ordinary beach road gateway west singapore glaxosmithkline puerto rico inc common centro internacional de mercadeo road tower ii suite guaynabo puerto rico glaxosmithkline republica dominicana sa ordinary av lope de vega torre novocentro local santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg vi partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc iv common corporation service company centerville road suite wilmington delaware de united states glaxosmithkline service unlimite ordinary great west road brentford middlesex tw gs england glaxosmithkline sl holdings llc llc interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline sl llc llc interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline sl lp iv partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline superannuation company pty ltd ordinary mountain highway boronia vic australia liquidation glaxosmithkline trading services limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline trading zao ordinary yakimanskaya nab moscow russian federation glaxosmithkline tunisia sarl ordinary immeuble les quatre r rue du lac lochness berge du lac tunis tunisia gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline uk limit ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa register share provisory salto cp montevideo uruguay stock glaxosmithkline venezuela ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company iv vi equity capital metropolitan dong khoi ben nghe ward district ho chi minh city viet nam glycovaxyn ag vi common preferred grabenstrasse schlieren switzerland preferred b preferred c group laboratories south africa pty limited iv vi ordinary flush meadow build campus sloane street bryanston south africa groupe glaxosmithkline sas ordinary route de versaille marly le roi france gsk business service centre sdn bhd ordinary level quill jalan semangat petale jaya selangor darul ehsan malaysia gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk kazakhstan llp partnership interest furmanov street almaty kazakhstan gsk service sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany herbridge unlimited company ii vi ordinary currabinny carrigaline county cork ireland hgs france sarl iv vi ordinary avenue victor hugo boulognebillancourt france horlick limited ordinary great west road brentford middlesex tw gs england human genome sciences pacific pty ltd iv vi ordinary mountain highway boronia vic australia human genome sciences inc common corporation service company centerville road suite wilmington delaware de united states d biomedical corporation quebec common boul du parc technologique qubec gp r canada d biomedical corporation washington iv common corporation service company centerville road suite wilmington delaware de united states instituto luso farmaco limitada iv ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal interpharma dienstleistungen gmbh quota wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc iv llc interest corporation service company bank america th floor east main street richmond virginia va united states laboratoire glaxosmithkline ordinary route de versaille marly le roi france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt iv ordinary route de versaille marly le roi france laboratoire saintgermain iv ordinary route de versaille marly le roi france laboratorios dermatologicos darier sa de cv ordinary calzada mexico xochimilco san lorenzo huipulco district federal mexico mexico laboratorios farmaceuticos stiefel portugal ltda iv ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal laboratorios phoenix sociedad anonima industrial nonendorsable nominative tucuman piso ciudad autonoma de buenos aire caaa comercial financiera ordinary share argentina laboratorios stiefel de chile compaa limitada social capital avenue andrs bello piso las conde santiago cp chile laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem guarulhos sao paulo brazil laboratorios wellcome de portugal limitada iv ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal maxinutrition limited liquidation ordinary baker street london wu eu england mixis genetics limit ordinary great west road brentford middlesex tw gs england ordinary euro montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland montrose pharma company limit ordinary quota h csorsz utca budapest hungary montrose pharma uab liquidation ordinary agostauto vilnius lt lithuania novartis vaccine diagnostic ag liquidation ordinary co obc suisse ag aeschenvorstadt basel switzerland novartis vaccine diagnostic pty ltd iv vi ordinary mountain highway boronia australia gsk annual report strategic report governance remuneration financial statement investor information group company continue security register address wholly own subsidiary continue okairos ag iv vi common prefer co obc suisse ag aeschenvorstadt basel preferred b switzerland penn labs inc iv common corporation service company centerville road suite wilmington delaware de united states sr international bv ordinary huis ter heideweg lz zeist netherlands sr limit unit common corporation service company interstate drive suite harrisburg pennsylvania pa united states setfirst limit ordinary great west road brentford middlesex tw gs england smith kline french laboratory limit ordinary great west road brentford middlesex tw gs england smith kline french portuguesaproduto ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge farmaceuticos lda iv portugal smithkline beecham australia pty ltd liquidation ordinary mountain highway boronia vic australia smithkline beecham bangladesh private limited iv ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham export limit ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinary smithkline beecham investment limit ordinary great west road brentford middlesex tw gs england smithkline beecham manufacturing limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham swg limit ordinary great west road brentford middlesex tw gs england smithkline beecham animal health company liquidation common upper water sreet suite halifax ns bj n canada smithkline beecham biological partnership partnership interest corporation service company centerville road suite wilmington delaware de united states smithkline beecham egypt llc quotas amoun street po box el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham holdings australia pty limited ordinary mountain highway boronia vic australia liquidation smithkline beecham interamerican corporation iv share par value common corporation service company centerville road suite wilmington delaware de united states smithkline beecham limit ordinary p great west road brentford middlesex tw gs england smithkline beecham marketing technical service limit ordinary great west road brentford middlesex tw gs england smithkline beecham nominee limit ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limit ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limit iv ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustee limit iv ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited iv vi ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical co share par value common corporation service company centerville road suite wilmington delaware de united states smithkline beecham port louis limited vi ordinary co cim global business edith cavell street port louis mauritius smithkline beecham retirement plan nominee ordinary mountain highway boronia vic australia pty limited liquidation smithkline beecham senior executive pension plan ordinary great west road brentford middlesex tw gs england trustee limit iv stiefel distributor ireland limited ii iv ordinary finisklin business park sligo ireland stiefel dominicana srl iv vi ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital industriestrasse bad oldesloe germany stiefel india private limited equity wing floral deck plaza opp rolta bhavan central midc road mumbai andheri east india stiefel laboratories ireland limited ii ordinary finisklin business park sligo ireland stiefel laboratory maidenhead ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratory uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratory limit iv ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratory pte limited iv ordinary gul circle singapore stiefel laboratories pty ltd liquidation ordinary mountain highway boronia vic australia gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue stiefel laboratory inc common corporation service company centerville road suite wilmington delaware de united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd vi ordinary mountain highway boronia vic australia stiefel research australia pty ltd vi ordinary mountain highway boronia vic australia stiefel west coast llc llc interest corporation service company centerville road suite wilmington delaware de united states strebor inc common corporation service company centerville road suite wilmington delaware de united states tempero pharmaceuticals inc series preference corporation service company centerville road suite series b preference common wilmington delaware de united states sydney ross co iv ordinary corporation service company bear tavern road west trenton new jersey nj united states wellcome foundation limit ordinary great west road brentford middlesex tw gs england ucb pharma asia pacific sdn bhd iv ordinary level symphony house pusat dagangan dana jalan pju petale jaya selangor darul ehsan malaysia wellcome consumer healthcare limit iv ordinary great west road brentford middlesex tw gs england wellcome consumer product limit iv ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd iv vi ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operation pty ltd iv vi ordinary mountain highway boronia vic australia effective security ownership register address subsidiary effective interest amoun pharmaceutical industry co sae new monetary share el salam city po box cairo egypt beecham enterprises inc iv common corporation service company centerville road suite wilmington delaware de united states block drug company inc common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states block drug corporation iv common par value corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states british pharma group limited capital great west road brentford middlesex tw gs england de micln ordinary priemyselny park gena ul e sachsa levice slovakia duncan consumer healthcare philippines inc common chino roce avenue makati city philippines duncan pharmaceuticals philippines inc common chino roce avenue city makati philippines exlax inc common fgr corporate services inc oriental center suite p munoz rivera avenue san juan puerto rico galvani bioelectronics inc common corporate service company centerville road suite wilmington delaware de united states galvani bioelectronic limit ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limit ordinary po box area warehouse city stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limit ordinary galle road kaldemulla moratuwa sri lanka ordinary b glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline bangladesh limit ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline brasil produtos para consumo e saude ltda quota bl vitor civita street barra tijuca rio de janeiro brazil glaxosmithkline consumer healthcare china co ltd ordinary room b f headquarters building tibet road shanghai china glaxosmithkline consumer healthcare hong kong limit ordinary unit f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limit ordinary great west road brentford middlesex tw gs england gsk annual report strategic report governance remuneration financial statement investor information group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare ip llc llc interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab vii ordinary nykaer dk brondby denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer healthcare colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holding llc llc interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england ordinary b glaxosmithkline consumer healthcare inc common mississauga road th floor mississauga ln l canada glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company ii v glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan co waterford x ry ireland ireland limited ii v glaxosmithkline consumer healthcare japan kk ordinary sendagaya shibuyaku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline consumer healthcare llc llc interest corporation service company interstate drive suite harrisburg pennsylvania pa united states glaxosmithkline consumer healthcare limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand limited ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary klaus torgrd vei oslo norway glaxosmithkline consumer healthcare pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common chino roce avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary beach road gateway west singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare spa ordinary zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu klang industrial estate selangor darul ehsan malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ltd ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline consumer healthcare spzoo common ul rzymowskiego warsaw poland glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline consumer healthcare srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline consumer healthcare lp partnership interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline consumer healthcare produto para ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge saude e higiene lda portugal glaxosmithkline consumer healthcare vietnam charter capital floor metropolitan dong khoi ben nghe ward district company limit ho chi minh city vietnam glaxosmithkline consumer nigeria plc iii ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer trading service limit ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jose este de la rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limited ii ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr munchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline landholding company inc common chino roce avenue city makati philippines glaxosmithkline limited ordinary likoni road po box nairobi kenya glaxosmithkline otc pvt limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline panama sa ordinary panama city republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline philippines inc common chino roce avenue city makati philippines glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary route de versaille marly le roi france glaxosmithkline tuketici sagligi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability company membership h csorsz utca budapest hungary gsk consumer healthcare singapore pte ltd ordinary beach road gateway west singapore gsk ch argentina sa nominative non tucuman piso ciudad autonoma de buenos aire caaa endorseable ordinary argentina share gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company centerville road suite wilmington delaware de united states gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr munchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt novartis consumer health australasia pty ltd iv vi ordinary hughe avenue ermington nsw australia redeemable preference nch nutrition consumer health ltd ordinary hamephalsim st petach tikva israel novartis consumer health gmbh ordinary barthstr mnchen germany novartis consumer health sa ordinary route de prangin switzerland novartis consumer health service sa register share route de prangins switzerland novartis consumer health uk limit ordinary park view riverside way watchmoor park camberley surrey gu yl england novartis consumer health inc common corporation service company centerville road suite wilmington delaware de united states pt smithkline beecham pharmaceuticals share jl pulobuaran raya kav iii dd kawasan industri pulogadung b share jakarta indonesia pt sterling product indonesia share graha paramita build th f jalan denpasar raya blok jakarta b share indonesia panadol gmbh ordinary barthstr mnchen germany phivco jersey ii limit iv v ordinary castle street st helier je ut jersey phivco jersey limit iv v ordinary castle street st helier je ut jersey phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limit ordinary great west road brentford middlesex tw gs england phivco llc llc interest corporation service company centerville road suite wilmington delaware de united states phivco llc llc interest corporation service company centerville road suite wilmington delaware de united states pt glaxo wellcome indonesia share jl pulobuaran raya kav iii dd kawasan industri pulogadung timur b share jakarta indonesia pt gsk consumer healthcare indonesia ordinary graha paramita b floor ji denpasar raya blok kuningan jakarta indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia gsk annual report strategic report governance remuneration financial statement investor information group company continue effective security ownership register address subsidiary effective interest continued shionogiviiv healthcare llc common interest corporation service company centerville road suite wilmington delaware de united states sinoamerican tianjin smith kline french laboratories ltd ordinary cheng lin zhuang industrial zone dong li district tianjin china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limit ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiome ooo participation interest nab kosmodamianskaya building rd floor moscow russian federation staffordmiller ireland limited ii ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limit ordinary great west road brentford middlesex tw gs england noncumulative non redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampangulu klang industrial estate selangor darul ehsan malaysia sterling product international incorporate iv common corporation service company centerville road suite wilmington delaware de united states stiefel consumer healthcare uk limit ordinary great west road brentford middlesex tw gs england stiefel egypt llc iv quota amoun street el salam city cairo egypt stiefel manufacturing ireland limited ii ordinary finisklin business park county sligo ireland viiv healthcare south africa proprietary limited ordinary flush meadow build campus sloane street bryanston south africa viiv healthcare bv ordinary huis ter heideweg lz zeist netherlands viiv healthcare company common corporation service company centerville road suite wilmington delaware de united states viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england viiv healthcare finance limit ordinary redeemable great west road brentford middlesex tw gs england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limit ordinary f tower gateway harbour city canton road tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary sendagaya shibuyaku tokyo japan viiv healthcare limited class share defer great west road brentford middlesex tw gs england class b share class c share class class class e cumulative preference viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interest centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota alessandro fleming verona italy viiv healthcare sas ordinary route de versaille marly le roi france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc participation interest krylatskaya str moscow russian federation viiv healthcare trading service uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit v ordinary castle street st helier je ut jersey viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interest corporation service company centerville road suite wilmington delaware de united states viiv hiv healthcare unipessoal lda quota rua dr antonio loureiro borge arquiparque miraflore alge portugal winster pharmaceutical limit ordinary association avenue ilupeju industrial estate lago po box nigeria zhejiang tianyuan biopharmaceutical co ltd ordinary tian road yuhang economic development zone hangzhou zhejiang province china gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued associate apollo therapeutics llp partnership interest calci medica inc series junior prefer index venture life vi jersey lp partnership interest innoviva inc common japan vaccine distribution co ltd ordinary jcr pharmaceuticals co ltd common kurma biofund ii fcpr partnership interest longwood founder fund lp partnership interest medicxi ventures lp partnership interest river vision development corp series prefer joint ventures chiron panacea vaccines private ltd liquidation th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india japan vaccine co ltd yonbancho chiyodaku tokyo japan qualivax pte limited robinson road singapore qura therapeutics llc corporation service company centerville road suite wilmington delaware de united states key directly own glaxosmithkline plc iv dormant company ii e xempt provision section company act v tax resident uk ireland accordance exemptions note section act vi entity expect dispose remove iii c onsolidated subsidiary accordance section vii incorporate sweden company act ground dominant influence gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc corporate integrity agreement cia company enter settlement federal government relate past sale marketing practice settlement company enter corporate integrity agreement department health human service currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derive value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party novartis transaction threepart interconditional transaction novartis ag involve consumer healthcare vaccine oncology business complete march ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue uk corporate governance code require uk list authority company disclose annual report apply good practice corporate governance provision financial reporting council uk corporate governance code gsk annual report index accountability major restructuring cost accounting principle policy movement equity acquisition disposal net debt adjustment reconcile profit tax operate new accounting requirement cash flow nomination committee report annual general meeting noncontrolle interest approach tax noncontrolle interest viiv healthcare asset hold sale nonexecutive director fee associate joint venture note financial statement audit risk committee report operate profit cash cash equivalent intangible asset ceo statement investment chairmans statement noncurrent asset chairman governance statement noncurrent liability chairman remuneration report statement operating income commitment provision consolidate balance sheet behaviour consolidated cash flow statement board consolidate income statement business model consolidate statement change equity global marketplace consolidate statement comprehensive income integrate approach consumer healthcare people consumer healthcare product competition planet contingent consideration liability strategy priority contingent liability pay performance corporate executive team pension postemployment benefit corporate governance pharmaceutical corporate responsibility committee report pharmaceutical product competition critical accounting policy intellectual property director senior management pipeline director interest share post balance sheet event director statement responsibility presentation financial statement dividend principal group company donation political organisation principal risk uncertaintie political expenditure property plant equipment earning share quarterly trend employee cost reconciliation net cash flow movement net debt employee share scheme registrar exchange rate relate party transaction executive director remuneration relation shareholder finance expense remuneration governance finance income remuneration policy report financial calendar remuneration report financial instrument relate disclosure report framework financial position resource research development financial statement glaxosmithkline plc prepare responsible business uk gaap segment information year record share capital control glossary term share capital share premium account goodwill share price group company shareholder information group financial review shareholder service contact health taxation manage risk tax information shareholder independent auditor report trade payable inventory trade receivables investment associate joint venture law regulation investor relation vaccine key accounting judgement estimate viability statement key performance indicator leadership effectiveness legal proceeding gsk annual report gsk glaxosmithkline plc incorporate brand name brand name appear italic report english public limited company trade mark own andor license gsk associate company exception prolia december form merger own amgen zofran own novartis trumenba own pfizer glaxo wellcome plc smithkline acknowledgement design beecham plc gsk acquire english friend wwwfriendstudiocom printing company december pureprint group iso fsc certify carbon neutral merger arrangement paper annual report print revive silk recycle paper fsc certification share list london stock exchange pulp deinked postconsumer waste elemental chlorine free new york stock exchange manufacturing mill hold iso eu ecolabel certificate environmental management read wwwgskcom download pdfs annual report form f responsible business supplement cautionary statement factor include limit discuss assumption group revenue earning forwardlooke statement principal risk uncertaintie page expectation assume material merger acquisition group report file furnish annual report forwardlooke statement disposal litigation cost share repurchase securities exchange commission sec include behalf group speak date company change group shareholding document write information release oral base knowledge viiv healthcare consumer healthcare assume statement public future behalf information available director date material change macroeconomic healthcare group contain forwardlooke statement annual report environment forwardlooke statement group current number adjust measure report group expectation assume successful delivery expectation forecasts future event investor performance business measure define group integration restructuring plan period identify statement fact relate reconciliation core result material cost investment new product strictly historical current fact use word total result set launch rd factor expectation anticipate estimate expect intend project plan give expectation give constant currency believe word term similar meaning information document constitute basis assume material change group connection discussion future operating offer sell invitation buy share glaxosmithkline effective tax rate financial performance particular include plc invitation inducement engage statement relate future action prospective product investment activity past performance rely notice limitation product approval future performance result guide director liability english law current anticipate product sale effort expense future performance annual report uk company act safe harbour limit outcome contingency legal proceeding construe profit forecast liability director respect statement financial result accordance legal omission director report regulatory obligation include uk list assumption relate outlook strategic report remuneration rule disclosure transparency rule outline expectation fiveyear period report english law director liable financial conduct authority group undertake group certain assumption company party obligation update forwardlooke statement healthcare sector different market report contain error result recklessness result new information future event group operate delivery revenue financial know misstatement dishonest concealment reader consult benefit current portfolio pipeline restructuring material fact liable page additional disclosure group programme inclusive comprise r c loe n aio osa uc c kd tu p il ie om ar gs nrse u e sin r c dw tet au nh tl e oew r mr h e ec ei ov xc c ne p h p tr e r li l acdt ctp ic n eu g ib uole yl nni ds nh w uose ei h ls l r bsa eu en iu ad mr n ato e nr tk ec fi ae e ol n e n nc ds st hw ne h e b aot h fref oe tt rg hhh wi oee v ls e ds n dee rtc sh ta r ell h p egf xao h es cse rr lf k uobih n sreee ier vx og p ian td ye n r f uo c focu ct es rtp oo otf rn thep hr et ee h f g rc e na ki rfi rt eoogdc yu eea pphncll reel ai n r sgo die c sv r ue c mir l un tt set p eh r snae v l nae ep oss rie v tr peo hi eo r f et es os p e mt eo ar e iuv onti r dd e e r l tf na hst esth v f oe ua f ur u rs e e ch n onti er r nge r nlc p ie eet ro g h cem r ts ccs iu oe nr nnr e tp wee r pao dp iat tr hnit n r ya tnt ha n l ar ep cd e w sa c pp eg ao ae r rnr dg es dae p e ns oh c r eo c te h l w sao hit btf ah w l l la tc h bn elu ec ss h si oi inv n uh fe c bra l hec u v jeelo es m dv b tn ep e tic r er eec n tco u h e tm p eo r p rh snre w nne forwardlooke statement subject assumption group expectation billion revenue limitation restriction provide law inherent risk uncertaintie relate annum cer basis product launch website factor group control precise year include contribution current estimate group caution investor number pipeline asset shingrix target expect gsk website wwwgskcom give additional information important factor include document meet year early group expect volume group notwithstanding reference cause actual result differ materially express demand product annual report gsk website imply forwardlooke statement increase particularly emerge market information available website constitute annual report shall deem incorporate reference hereinhead office register office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel register number wwwgskcom search